WO2007099398A2 - procédés et compositions pour le traitement de la peau - Google Patents

procédés et compositions pour le traitement de la peau Download PDF

Info

Publication number
WO2007099398A2
WO2007099398A2 PCT/IB2006/004122 IB2006004122W WO2007099398A2 WO 2007099398 A2 WO2007099398 A2 WO 2007099398A2 IB 2006004122 W IB2006004122 W IB 2006004122W WO 2007099398 A2 WO2007099398 A2 WO 2007099398A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glyconate
acid
sodium
sulfate
Prior art date
Application number
PCT/IB2006/004122
Other languages
English (en)
Other versions
WO2007099398A3 (fr
Inventor
Jan De Rijk
Original Assignee
Naturalite Benelux B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2005/003665 external-priority patent/WO2006035320A2/fr
Application filed by Naturalite Benelux B.V. filed Critical Naturalite Benelux B.V.
Priority to EP06849473.1A priority Critical patent/EP1948236B1/fr
Priority to EP21160312.1A priority patent/EP3871693A1/fr
Priority to US11/912,839 priority patent/US9499419B2/en
Publication of WO2007099398A2 publication Critical patent/WO2007099398A2/fr
Publication of WO2007099398A3 publication Critical patent/WO2007099398A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/008—Preparations for oily skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
    • A61Q1/02—Preparations containing skin colorants, e.g. pigments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the present invention relates to compositions and methods for the treatment of human skin, particularly facial skin, to alleviate the symptoms of cosmetic or determatologic skin conditions and to improve the appearance and the feel of skin.
  • the invention relates to compositions for treating and ameliorating skin conditions including acne, rosacea and wrinkling caused by photodamage, aging, hormonal imbalances, hyper-pigmentation, melasma, keratosis or the like.
  • the invention also relates to a methods of treating the hair or scalp.
  • the invention may further be used to remove biofilms from contact lenses.
  • Acne vulgaris is an inflammatory dermatological disorder that occurs frequently in adolescence and with some regularity in older adults.
  • the condition can include skin lesions ranging from the comedo in a pilosepaceous follicle, to more severe symptoms such as pustules, papules, cysts and nodules.
  • the condition can be uncomfortable and embarrassing, and can result in scarring and facial disfigurement.
  • the pathology is believed to involve a number of factors. The first is formation of comedones (more commonly referred to as whiteheads) and blackheads, made up of solid homy masses that plug follicles and are associated with increased production of sebum. As keratinized cells continue to accumulate, pressure builds up within the follicles and eventually rupture. Horny material, sebum and bacteria are dumped into the skin, provoking inflammatory responses which take the form of pustules or cystic nodules.
  • Rosacea is a common chronic skin condition characterized by a spectrum of clinical indications including flushing episodes, erythema, telangiectasia, inflammatory papulopustular eruptions resembling acne, and ocular symptoms. See U.S. Patent No. 6,723,755, Chomczynski, et al. The etiology of rosacea is unknown, but it is presumed to be a genetically determined anomalous vascular response that develops in the third to sixth decades of life. The hypothesis that the basic pathogenesis of the disease is a flushing disorder is based on several findings.
  • rosacea may represent a type of hypersensitivity reaction disease in which vascular sensitivity is a central mechanism in its etiology.
  • the correlation between sensitive blood vessels and sensitive skin has, however, not yet been determined.
  • Epidemiological studies suggest that the regulatory mechanism of blood vessels maybe of importance in the onset and development of rosacea. Studies show that 27% of rosacea patients were found to suffer from migraine and 42% from a tendency to flush, both of which represent about twice the level that would typically be found in a control group.
  • Psoriasis is a chronic, widespread skin disorder afflicting millions of humans and even domesticated animals. The disorder is characterized by recurrent, elevated red lesions, plaques or rarely pustules on the skin. These plaques are the results of an excessively rapid growth and shedding of epidermal (skin) cells. The cause of psoriasis is unknown.
  • Eczema (including but not limited to atopic, nummular and hand types) often has similar overlapping features with psoriasis. See, e.g., H. Roenigk, Jr. et al., "Psoriasis", ⁇ 1991, Marcel Dekker, Inc., Chapter 2. For instance, it is often difficult to distinguish based on clinical appearance. They can coexist, or the disease can begin as eczema and over time turn to psoriasis. Again, treatments are similar with corticosteroids and preparations commonly employed for both of these conditions.
  • seborrheic dermatitis Another skin condition commonly confined to the scalp is seborrheic dermatitis (seborrhea).
  • Inflammatory skin diseases refer to diseases that are accompanied by a series of clinical signs and symptoms, such as itch, edema, erythema and abrasion are induced by various stimulative factors that cause a series of inflammatory reactions in the skin epithelium.
  • Seborrheic dermatitis is a dermatitis that frequently occurs on areas with a high sebum secretion, such as the scalp, the forehead and the armpit, and is also called seborrheic eczema. It causes much erythema and fine scale(dandruff) and often appears in persons in the 20-40 age group. Unlike common eczema, it is a disease resulting from abnormal constitution or sebum secretion, and is characterized in that it causes the skin to be sensitive to sunlight or heat, grows worse mainly in spring and autumn and tends to recur.
  • aging of the skin is a complex phenomenon that can result in skin changes that may take a variety of different forms.
  • Skin aging can result from cigarette smoke, chemicals, ultraviolet radiation, hi particular, UV radiation has led to increased prevalence of photoaging. Photoaging can be prevented by sun avoidance and proper skin protection.
  • Skin conditions that may occur as skin ages include dry skin, zerosis, ichthyosis, brownish spots, keratoses, melasma, lentigines, age spots, liver spots, pigmentied spots, wrinkles, skin lines, fine lines, oily akin, warts, eczema, pruritic skin, psoriasis, inflammatory dermatoses, or disturbed keratinization.
  • the present invention relates to cosmetic methods of improving skin appearance and/or condition by topical application of the subject compositions.
  • the present invention also relates to a composition that may be used in hair color and bleaching products, shampoos, conditioners, lotions, bath oils and salts, bar soaps, facial cleansers, and foot treatments.
  • the present invention relates to oral care compositions, including therapeutic rinses, especially mouthrinses and methods of use to provide significantly enhanced antimicrobial activity, thereby reducing oral bacteria and promoting overall oral health.
  • Microbial populations such as Streptococcus sanguis, Streptococcus mutans, and Streptococcus sobrinus are pioneer species, the first microbial to absorb, multiply and form micro-colonies; and reduction of these species are correlated to disruption of plaque biofilm. (P. Marsh & M. Martin, Oral Microbiology, 3 rd Edition, London, Chapman & Hall Publishers, 1996).
  • the compositions described herein can be used to treat conditions in the oral cavity.
  • the present invention provides topical oral care compositions, including therapeutic rinses, especially mouth rinses, toothpastes, tooth gels, tooth powders, subgingival gels, chewing gums, mouth sprays, and lozenges (including breath mints), comprising an effective amount of the present composition for treating or preventing conditions of the oral cavity.
  • therapeutic rinses especially mouth rinses, toothpastes, tooth gels, tooth powders, subgingival gels, chewing gums, mouth sprays, and lozenges (including breath mints)
  • the present invention addresses the need to remove bacteria and biofilm accumulation in the oral cavity.
  • the present invention also relates to compositions that can be used for the effective cleaning and disinfection of contact lenses.
  • Deposits such as protein derived from tears or lipid derived from discharge can adhere to the surfaces of contact lenses when the lenses are worn. These deposits must be removed from the lenses prior to subsequent use.
  • the present invention addresses the need for novel contact lens cleaners.
  • the present invention relates to methods and compositions for the treatment of human skin, particularly facial skin and the scalp.
  • the invention also relates to compositions and methods for removing biofilms in the oral cavity and from contact lenses.
  • the compositions are useful for imparting a visual improvement in skin appearance, for alleviating the symptoms of cosmetic or dermatologic skin conditions, or for alleviating conditions of the scalp such as dandruff.
  • the present invention is directed to a composition
  • a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate, in a topical carrier.
  • the composition may also contain (e) salts, e.g., sea salts and/or other additives.
  • a composition and method for improving the appearance or condition of skin wherein an effective amount of the composition described herein in a pharmaceutically or cosmetically-acceptable topical carrier is applied to the surface of the skin or to the scalp using a hair care product.
  • the present invention is directed to a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate, in a topical carrier.
  • the composition may also contain (e) salts, e.g., sea salts and/or other additives.
  • a composition and method for improving the appearance or condition of teeth or the oral cavity wherein an effective amount of the composition described herein in an acceptable carrier is applied to the oral cavity. Similar to the composition described above, such the composition comprises (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate, in a carrier that can be delivered orally.
  • a composition and method for disinfecting and cleaning contact lenses is provided.
  • composition and method employs a composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate, in a carrier that can be delivered orally.
  • the one or more metasilicate is an alkali metal silicate selected from the group consisting of sodium or potassium metasilicate, sodium or potassium orthosilicate and mixtures thereof.
  • the one or more carbonate is selected from the group consisting of sodium carbonate, sodium sesquicarbonate, sodium sulfate, sodium bicarbonate and mixtures thereof.
  • the glyconate is selected from the group consisting of ammonium glyconate, lithium glyconate, sodium glyconate, sodium starch glyconate, potassium glyconate, ammonium acid glyconate, sodium acid glyconate, lithium acid glyconate, potassium acid glyconate, ammonium D-glyconate, lithium D-glyconate, sodium D-glyconate, potassium D-glyconate, glyconic acid, glyconic D acid, glyconic L acid, ammonium L-glyconate, lithium L-glyconate, sodium L-glyconate, potassium L-glyconate, magnesium glyconate, magnesium acid glyconate, magnesium D- glyconate, magnesium L-glyconate, calcium glyconate, calcium acid glyconate, calcium D-glyconate, calcium L-glyconate and mixtures thereof.
  • the one or more sulfate is selected from the group consisting of potassium aluminum sulfate, sulfuric acid, sodium sulfate, potassium sulfate, lithium sulfate, ammonium sulfate, magnesium sulfate, strontium sulfate, aluminum sulfate, and mixtures thereof.
  • Topical carriers include powders, lotions, gels, sprays, sticks, creams, ointments, liquids, emulsions, foams and aerosols.
  • compositions may also be used in combination with a fragrance, an anti-microbial such as a bactericide or fungicide, acne medications, wart remover such as salicylic acid with or without other hydroxy! acids, a reductant to bleach skin spots such as hydroxyquinone, a nutrient such as vitamin A or other vitamins and sunscreens.
  • a fragrance an anti-microbial such as a bactericide or fungicide
  • acne medications wart remover such as salicylic acid with or without other hydroxy! acids
  • a reductant to bleach skin spots such as hydroxyquinone
  • a nutrient such as vitamin A or other vitamins and sunscreens.
  • the composition may also be incorporated into a cosmetic, night cream, or skin ointment. Further, the composition may be used with Hp balm, hand creams or lotions, bath salts or other bath additives, and treatments for hands, feet, nails, lips or the skin surrounding the eye area.
  • the composition further comprises another cosmetically active agent
  • a cosmetically active agent is a compound that has a cosmetic or therapeutic effect on the skin, e.g., agents to treat wrinkles, acne, or to lighten the skin.
  • the agent is selected, but not limited to, from the group consisting of hydroxy acids, benzoyl peroxide, sulfur resorcinol, ascorbic acid, D-panthenol, hydroquinone, sunscreen agents, anti-inflammatory agents, skin lightening agents, antimicrobial and antifungal agents, estrogens, 2-dimethylaminoethanol, lipoic acid, amino acids such a proline and tyrosine, lactobionic acid, acetyl- coenzyme A, niacin, riboflavin, thiamin, ribose, electron transporters such as NADH and FADH2, botanical extracts such as aloe vera and soy, and derivatives and mixtures thereof.
  • the cosmetically active agent will typically be present in the composition of the invention in an amount of from about 0.001% to about 20% by weight of the composition, e.g., about 0.01% to about 10%, e.g., about 0.1% to about 5%.
  • hydroxy acids include, but are not limited, to (i) alpha-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid, and tartaric acid; (ii) beta-hydroxy acids such as salicylic acid; and/or (iii) polyhydroxy acids. See, e.g., European Patent Application No. 273,202.
  • Examples of derivatives of ascorbic acid include, but are not limited to, ascorbyl palmitate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, zinc ascorbyl phosphate, ascorbyl glucoside, sodium ascorbate, and ascorbyl polypeptide.
  • An example of a derivative of hydroquinone includes, but is not limited to, arbutin.
  • AU percentages and ratios used herein are by weight of the total composition and all measurements made are at 25°C unless otherwise noted. All percentages, parts and ratios are based upon the total weight of the compositions of the present invention, unless otherwise specified. AU such weights as they pertain to listed ingredients are based on the active level and, therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise specified.
  • Active and other ingredients useful herein may be categorized or described herein by their cosmetic and/or therapeutic benefit or their postulated mode of action. However, it is to be understood that the active and other ingredients useful herein can in some instances provide more than one cosmetic and/or therapeutic benefit or operate via more than one mode of action. Therefore, classifications herein are made for the sake of convenience and are not intended to limit an ingredient to the particularly stated application or applications listed.
  • the terms “a,” “an,” “the,” and “the” means one or more.
  • the words “a,” “an,” “the,” or “the” may mean one or more than one.
  • another may mean at least a second or more.
  • the term "about" modifying the quantity of an ingredient in the compositions of the invention or employed in the methods of the invention refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use compositions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the compositions or carry out the methods; and the like. Whether or not modified by the term "about”, it is intended that the claims include equivalents to the quantities.
  • the term “benefit agent” includes any active ingredient that is to be delivered into and/or onto the skin, hair or nail at a desired location, such as a cosmetic agent or a pharmaceutical agent.
  • cosmetic agent it is meant any ingredient that is appropriate for cosmetically treating, providing nutrients to, and/or conditioning the hair, nail, and/or skin via topical application.
  • pharmaceutical agent it is mean any drug that is either hydrophobic or hydrophilic in nature and appropriate for topical use.
  • immediatecament agents include those agents capable of promoting recovery from injury and illness.
  • cosmetics includes make-up, foundation, and skin care products.
  • make-up refers to products that leave color on the face, including foundation, blacks and browns, i.e., mascara, concealers, eye liners, brow colors, eye shadows, blushers, lip colors, powders, solid emulsion compact, and so forth.
  • skin care products are those used to treat or care for, or somehow moisturize, improve, or clean the skin.
  • skin care products include, but are not limited to, adhesives, bandages, toothpaste, anhydrous occlusive moisturizers, antiperspirants, deodorants, personal cleansing products, powder laundry detergent, fabric softener towels, occlusive drug delivery patches, nail polish, powders, tissues, wipes, hair conditioners-anhydrous, shaving creams and the like.
  • foundation refers to liquid, cream, mousse, pancake, compact, concealer or like product created or reintroduced by cosmetic companies to even out the overall coloring of the skin.
  • tissue-acceptable or “cosmetically-acceptable” as used herein, means that the compounds or composition(s) which the term describes are suitable for use in contact with tissues (e.g., the skin) without undue toxicity, incompatibility, instability, irritation, allergic response and the like. This term is not intended to limit the compound/composition to which it describes for use solely as a cosmetic (i.e., the ingredient/product may be used as a pharmaceutical).
  • relief of symptoms refers to decrease in severity over that expected in the absence of treatment and does not necessarily indicate a total elimination or cure of the disease. Relief of symptoms is also intended to include prophylaxis.
  • topically applying means directly laying on or spreading on outer skin, e.g., by use of hands or an applicator such as a wipe, puff, roller or spray.
  • safe and effective amount means an amount of compound(s) or composition(s) sufficient to treat acne or other skin conditions described herein, but low enough to avoid serious side effects, i.e., to provide a reasonable benefit-to-risk ratio, within the scope of sound medical judgment.
  • treating means the treatment (e.g., alleviation or elimination of symptoms and/or cure) and/or prevention or inhibition of the condition (e.g. a skin condition) or relief of symptoms.
  • the present invention relates to compositions and their use for the treatment skin, particularly facial skin, or the scalp.
  • the present invention is directed to a conditioning composition comprising (a) one or more metasilicate; (b) one or more carbonate; (c) one or more glyconate; and (d) one or more sulfate.
  • the composition may also contain (e) salts, e.g., sea salts, and other additives.
  • the composition may also include other active ingredients.
  • the present invention also relates to compositions and their use for the treatment of the oral cavity.
  • the present invention also relates to compositions and their use for the treatment of contact lenses.
  • compositions comprising:
  • the composition further comprises (e) an inorganic salt.
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition additionally comprising:
  • Metasilicate may include one or more metasilicate which may be an alkali metal silicate selected from the group consisting of sodium or potassium metasilicate, sodium or potassium orthosilicate and mixtures thereof.
  • the metasilicate is incorporated in the final composition in an amount of 0.01%-5.0%, or 0.1-4.0%, based on the total amount of the composition.
  • the carbonate used in the present invention is one or more carbonates selected from the group consisting of sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, and sodium sesquicarbonate.
  • the carbonate used in the present invention is sodium carbonate and sodium bicarbonate.
  • the carbonates is incorporated in the final composition in an amount of 0.01%-4.0%, or 0.1-3.0%, based on the total amount of the composition.
  • Typical carbonates include sodium carbonate (Na 2 CO 3 ), potassium carbonate
  • Such carbonates can contain as an impurity some proportion of bicarbonate (HCO 3 " ).
  • the composition further comprises peroxygen compound.
  • the peroxygen compound is preferably a perborate or a percarbonate and more preferably a percarbonate.
  • the perborate or percarbonate preferably is complexed with a metal such as sodium, lithium, calcium, potassium or boron.
  • the percent by weight of the peroxygen compound in the final composition ranges from about 0.01%-4.0%, or 0.1-3.0%, based on the total amount of the composition.
  • the carbonate is a builder wherein the builder is at least one of the following compounds: a sodium carbonate (e.g., soda ash), sodium sesquicarbonate, sodium sulfate or sodium bicarbonate.
  • a builder is also known as a sequestrant.
  • a "sequestrant” is a molecule capable of coordinating (i.e., binding) metal ions to prevent the metal ions from interfering with the action of the other ingredients of the composition. Some chelating/sequestering agents can also function as a threshold agent when included in an effective amount.
  • the builders can be added, e.g., water soluble inorganic salt builders, preferably sodium salts, such as sodium polyphosphates, e.g. sodium tripolyphosphate and sodium pyrophosphate, sodium carbonate, sodium bicarbonate, sodium sesquicarbonate, sodium silicate, sodium disilicate, sodium metasilicate and sodium borate.
  • water insoluble builders may also be useful, including the ion exchanging zeolites, such as Zeolite 4A.
  • Organic builders may also be employed. Among suitable organic builders are polyacetal carboxylates, as described in U.S. Pat. No. 4,725,455, and water- soluble salts of lower hydroxycarboxylic acids, such as an alkali metal gluconate.
  • the carbonate is a hydrated carbonate such as trona.
  • the percent by weight of the builder is from about 0.01%-4.0%, or 0.1-3.0%, based on the total amount of the composition, hi another embodiment, the peroxygen compound, metasilicate and chelate are all salts having the same cation, hi one embodiment, the cation is sodium or potassium.
  • the glyconate is selected from the group consisting of ammonium glyconate, lithium glyconate, sodium glyconate, sodium starch glyconate, potassium glyconate, ammonium acid glyconate, sodium acid glyconate, lithium acid glyconate, potassium acid glyconate, ammonium D- glyconate, lithium D-glyconate, sodium D-glyconate, potassium D-glyconate, glyconic acid, glyconic D acid, glyconic L acid, ammonium L-glyconate, lithium L-glyconate, sodium L-glyconate, potassium L-glyconate, magnesium glyconate, magnesium acid glyconate, magnesium D-glyconate, magnesium L- glyconate, calcium glyconate, calcium acid glyconate, calcium D-glyconate, calcium L-glyconate and mixtures thereof.
  • the percent by weight of the builder is from about
  • aluminum salts suitable for use in the present invention include inorganic aluminum salts such as potassium aluminum sulfate, ammonium aluminum sulfate and aluminum chloride; and soluble aluminum carboxylates such as aluminum lactate, aluminum citrate and aluminum maleate.
  • inorganic aluminum salts such as potassium aluminum sulfate, ammonium aluminum sulfate and aluminum chloride
  • soluble aluminum carboxylates such as aluminum lactate, aluminum citrate and aluminum maleate.
  • % or more of their particles have diameters of 200 micrometers or less.
  • at least 90% or more of the particles which make up the composition have diameters of 200 micrometers or less, and, in one embodiment, the average particle diameter falls within a range of 20-150. Ideally, the average particle diameter should be between 20 and 100 micrometers.
  • the composition contains a salt.
  • the salt should not interfere with the biological activity of the composition. When other materials are present, the salt should not degrade those materials or interfere with their properties or biological activity, hi other words, the salt should be inert with respect to the other components.
  • the salt may be a single salt material or a mixture of two or more salts alone.
  • the carrier matrix contains a mixture of salts
  • those salts are preferably present in equal amounts, e.g., a mixture of two salts in a 1 :1 ratio.
  • suitable salts include various alkali metal and/or alkaline earth metal sulfates, chlorides, borates, bromides, citrates, acetates, lactates, etc.
  • Specific examples of suitable salts include, but are not limited to, sodium acetate, sodium bicarbonate, sodium borate, sodium bromide, sodium carbonate, sodium chloride, sodium citrate, sodium fluoride, sodium gluconate, sodium sulfate, calcium chloride, calcium lactate, calcium sulfate, potassium sulfate, tripotassium phosphate, potassium chloride, potassium bromide, potassium fluoride, magnesium chloride, magnesium sulfate and lithium chloride.
  • the preferred salts are the inorganic salts, such as the Group 1 or 2 metal sulfates and chlorides. Particularly preferred salts, because of their low cost, are sodium sulfate, and sodium chloride. Sodium chloride may be substantially pure or in the form of rock salt, sea salt, or dendrite salt.
  • composition prior to final use, is prepared as a composition comprising:
  • composition prior to final use, is prepared as a composition comprising:
  • composition prior to final use, is prepared as a composition comprising:
  • composition prior to final use, is prepared as a composition comprising:
  • composition prior to final use, is prepared as a composition comprising:
  • composition is prepared as a composition comprising:
  • the present invention provides for a composition
  • a composition comprising: [00114] (a) at least 0.0001 % wt of one or more metasilicates;
  • one or more sulfate selected from the group consisting of potassium aluminum sulfate, sulfuric acid, sodium sulfate, potassium sulfate, lithium sulfate, ammonium sulfate, magnesium sulfate, strontium sulfate, and aluminum sulfate; wherein the concentrations are the concentration in final composition.
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition comprising:
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition
  • a composition comprising: [00128] (a) at least 0.0003 % wt of one or more alkali metal silicate selected from the group consisting of sodium or potassium metasilicate, orthosilicate or other water-soluble silicate;
  • one or more sulfate selected from the group consisting of potassium aluminum sulfate, sulfuric acid, sodium sulfate, potassium sulfate, lithium sulfate, ammonium sulfate, magnesium sulfate, strontium sulfate, and aluminum sulfate; wherein the concentrations are the concentration in final composition.
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition comprising:
  • concentrations are the concentration in the final composition.
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition comprising:
  • concentrations are the concentration in final composition.
  • the present invention provides for a composition additionally comprising:
  • the present invention provides for a composition comprising:
  • concentrations are the concentration in final composition.
  • the present invention provides for a composition additionally comprising:
  • compositions of the present invention from about 0.0001 to about 0.0010 % wt of one or more salts.
  • the substances to be used in the compositions of the present invention are generally utilized within the following ranges:
  • the topical formulations of the invention contain the metasilicate, carbonate, glyconate, and sulfate ingredients in a concentration effective to prevent or reduce (hereafter, "inhibit") the skin irritation (such as itching, dry skin, inflammation) symptoms that are sought to be eliminated.
  • the formulation contains the ingredients in a suitable topical vehicle at a total concentration of about 10 to about 5000 mM.
  • the formulation contains the ingredients in a suitable topical vehicle at a total concentration of about 25 to about 3000 mM.
  • the formulation contains the ingredients in a suitable topical vehicle at a total concentration of about 50 to about 2000 mM.
  • the formulation contains the ingredients in a suitable topical vehicle at a total concentration of about 100 to about 1000 mM. In another embodiment, the formulation contains the ingredients in a suitable topical vehicle at a total concentration of about 200 to about 500 mM. In another embodiment, the formulation of the invention includes additional ingredients such as an exfoliant ingredient.
  • compositions and methods of the present invention are useful for treating follicular diseases such as acne, rosacea, hyperlipidemia, seborrhea, sebaceous hyperplasia, follicular rash, demodex folliculorum follicular infections such as folliculitis, staphylococcal impetigoacne necrotica, and pseudofollicuitis barbe, follicular ketarosis, keratosis pilaris, phrynoderma, ichthyosis follicularis, alopecia, follicular dysplasia, hirsutism, oily skin and hypertrichosis, hi one embodiment, the present invention relates to topical compositions that may also include an anti-acne agent.
  • follicular diseases such as acne, rosacea, hyperlipidemia, seborrhea, sebaceous hyperplasia, follicular rash, demodex folliculorum follicular infections
  • anti-acne agents include, but are not limited to, salicylic acid, benzoyl peroxide, sulphur, retinoic acid, Candida bombicola/glucose/methyl rapeseedate ferment, peat water, resorcinol, silt, peat, permethin, azelaic acid, clindamycin, adapalene, erythromycin, sodium sulfacetamide, and combinations thereof, hi one embodiment, the amount of anti-acne agent in the composition is from about 0.01% to about 10%, for example from about 0.1% to about 5% or from about 0.5% to about 2% by weight, based on the total weight of the composition.
  • compositions and methods of the present invention are also useful for evening skin tone (such as lightening dark areas of skin) in need of such treatment, smoothing the skin (such as reducing texture on the skin), reducing the production of sebum, and reducing the appearance of oil, shine, and/or pores on skin in need of such treatment.
  • skin in need of such treatment include, but are not limited to, skin having excessive pigmentation (such as freckles, post-inflammatory hyperpigmentation (PIH), or pigmentsed scars), rough skin, oily skin or skin having large, visible pores, hi another embodiment, the present invention relates to topical compositions that may also include other active ingredients known to improve skin condition or appearance.
  • compositions and methods of the present invention are also useful for the treatment of skin conditions such as eczema.
  • the present invention relates to topical compositions that may also include other active ingredients known to improve or treat eczema.
  • the present invention may be used for th treatment of rosacea, hi yet another embodiment, the present invention may also include one or more anti-rosacea agents.
  • the composition is heated prior to application, hi one embodiment, the temperature of the composition should not exceed a temperature of 100° F.
  • the present invention is directed to a cosmetic composition and corresponding methods of applying the composition directly to the skin or scalp, wherein the composition comprises from about 0.1% to about 50% by weight of the conditioning composition and from about 50% to about 99.9% by weight of a suitable carrier.
  • the present invention is directed to a cosmetic composition and corresponding methods of applying the composition directly to the skin or scalp, wherein the composition comprises from about 0.1% to about 40% by weight of the conditioning composition, from about 0.005% to about 20% by weight of a salt, and from about 40% to about 99% by weight of a suitable carrier.
  • the present invention is directed to a cosmetic composition and corresponding methods of applying the composition directly to the skin or scalp, wherein the composition comprises from about 0.1% to about 20% by weight of the conditioning composition, from about 0.005% to about 20% by weight of a benefit agent, and from about 60% to about 99% by weight of a suitable carrier.
  • the composition is a leave-on cosmetic composition and corresponding methods of applying the composition directly to the scalp, wherein the composition comprises from about 0.1% to about 20% by weight of the conditioning composition, from about 0.005% to about 20% by weight of a moisterizing agent or carrier, and from about 40% to about 99% by weight of a volatile liquid.
  • the composition further comprises a thickening polymer in an amount of 0.01 to 20 wt % based on the weight of the conditioning composition.
  • the composition further comprises one or more of at least one amphoteric surfactant; at least one nonionic surfactant or at least one phospholipid; and at least one wax; wherein the ingredients are present in a combined amount sufficient to allow the conditioning composition to be incorporated into an aqueous solution
  • the composition further comprises a fatty alcohol present in an amount of from about 2.5% to about 4% by weight of the composition.
  • the composition further comprises water present in an amount of from about 60% to about 96% by weight of the composition.
  • the composition further comprises at least one of the following additives: a thickener, a dye, a fragrance, and/or a preservative.
  • compositions of the present invention may be used as a skin conditioning system.
  • the skin conditioning system may further contain one or more benefit agents or pharmaceutically-acceptable salts thereof.
  • the benefit agents useful herein may be categorized by their therapeutic benefit or their postulated mode of action. However, it is to be understood that the benefit agents useful herein may, in some circumstances, provide more than one thereapeutic benefit or operate via greater than one mode of action. Therefore, the particular classifications provided herein are made for the sake of convenience and are not intended to limit the benefit agents to the particular application(s) listed, hi addition, the compounds, which are identified below as being suitable for use as benefit agents, may be used in an amount over and above the amount that they may be used for other purposes in the conditioning system.
  • Suitable benefit agents include, but are not limited to, depigmentation agents; reflectants; detangling/wet combing agents; film forming polymers; humectants; amino acids and their derivatives; antimicrobial agents; allergy inhibitors; anti-acne agents; anti-aging agents; anti-wrinkling agents antiseptics; analgesics; antitussives; antipruritics; local anesthetics; anti-hair loss agents; hair growth promoting agents; hair growth inhibitor agents, antihistamines such as Mandragora Vernalis, Tanacetum Parthenium and the like; antiinfectives such as Acacia Catechu, Aloe Barbadensis, Convallaria Majalis, Echinacea, Eucalyptus, Mentha Piperita, Rosa Canina, Sassafras Albidum, and the like; inflammation inhibitors; antiemetics; anticholinergics; vasoconstrictors; vasodilators; wound healing
  • anti-edema agents examples include bisabolol natural, synthetic bisabolol, and mixtures thereof.
  • vasoconstrictors nonexclusively include horse chestnut extract, prickly ash, and mixtures thereof.
  • Suitable anti-inflammatory agents nonexclusively include benoxaprofen, centella asiatica, bisabolol, feverfew (whole), feverfew (parthenolide free), green tea extract, green tea concentrate, hydrogen peroxide, lycopene, oat oil, chamomile, and mixtures thereof.
  • collagen enhancers nonexclusively include vitamin A, vitamin C, and mixtures thereof.
  • Suitable skin firming agent nonexclusively include dimethylaminoethanol (“DMAE").
  • Suitable antipruritics and skin protectants nonexclusively include oatmeal, betaglucan, feverfew, soy and derivatives thereof, bicarbonate of soda, colloidal oatmeal, surfactant based colloidal oatmeal cleanser, Anagallis Arvensis, Oenothera Biennis, Verbena Officinalis, and the like.
  • These antipruritics may be used in an amount, based upon the total weight of the skin conditioning composition, from about 0.01 percent to about 40 percent, and preferably from about 1 percent to about 5 percent.
  • colloidal oatmeal means the powder resulting from the grinding and further processing of whole oat grain meeting United States Standards for Number 1 or Number 2 oats.
  • the colloidal oatmeal has a particle size distribution as follows: not more than 3 percent of the total particles exceed 150 micrometers in size and not more than 20 percent of the total particles exceed 75 micrometers in size.
  • Suitable reflectants nonexclusively include mica, alumina, calcium silicate, glycol dioleate, glycol distearate, silica, sodium magnesium fluorosilicate, and mixtures thereof.
  • Suitable detangling/wet combing agents nonexclusively include polyquaternium-10, hydroxypropyltrimonium guar, dioleoylamidoethyl hydroxyethylmonium methosulfate, di-(soyoylethyl) hydroxyethylmonium methosulfate, hydroxyethyl behenamidopropyl dimonium chloride, olealkonium chloride, ⁇ olyquaternium-47, stearalkonium chloride, tricetylmonium chloride, and mixtures thereof.
  • Suitable film forming polymers include those that, upon drying, produce a substantially continuous coating or film on the heir, skin, or nails.
  • suitable film forming polymers include acrylamidopropyl trimonium chloride/acrylamide copolymer; corn starch/acrylamide/sodium acrylate copolymer, polyquaternium-10; polyquaternium-47; polyvinylmethylether/maleic anhydride copolymer; styrene/acrylates copolymers; and mixtures thereof.
  • humectants which are capable of providing moisturization and conditioning properties to the skin conditioning composition are suitable for use in the present invention.
  • the humectant is preferably present in an amount of from about 0 percent to about 10 percent, more preferably from about 0.5 percent to about 5 percent, and most preferably from about 0.5 percent to about 3 percent, based on the overall weight of the composition.
  • humectants nonexclusively include: 1) water soluble liquid polyols selected from the group comprising glycerine, propylene glycol, hexylene glycol, butylene glycol, pentylene glycol, dipropylene glycol, and mixtures thereof; 2) polyalkylene glycol of the formula L: HO ⁇ (R"O) b ⁇ H I. wherein R" is an alkylene group having from about 2 to about 4 carbon atoms and b is an integer of from about 1 to about 10, such as PEG 4; 3) polyethylene glycol ether of methyl glucose of formula IL: CH 3 -- C 6 H 1O O 5 -(OCH 2 CH 2 ) C -OH II.
  • Suitable amino acid agents include amino acids derived from the hydrolysis of various proteins as well as the salts, esters, and acyl derivatives thereof. Examples of such amino acid agents nonexclusively include amphoteric amino acids such as alkylamido alkylamines, i.e.
  • stearyl acetyl glutamate capryloyl silk amino acid, capryloyl collagen amino acids; capryloyl keratin amino acids; capryloyl pea amino acids; cocodimonium hydroxypropyl silk amino acids; corn gluten amino acids; cysteine; glutamic acid; glycine; hair keratin amino acids; amino acids such as aspartic acid, threonine, serine, glutamic acid, proline, glycine, alanine, cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, cysteic acid, lysine, histidine, arginine, cysteine, tryptophan, citrulline; lysine; silk amino acids, wheat amino acids; and mixtures thereof
  • Suitable proteins include those polymers that have a long chain, i.e. at least about 10 carbon atoms, and a high molecular weight, i.e. at least about 1000, and are formed by self-condensation of amino acids.
  • Nonexclusive examples of such proteins include collagen, deoxyribonuclease, iodized corn protein; milk protein; protease; serum protein; silk; sweet almond protein; wheat germ protein; wheat protein; alpha and beta helix of keratin proteins; hair proteins, such as intermediate filament proteins, high-sulfur proteins, ultrahigh-sulfur proteins, intermediate filament-associated proteins, high-tyrosine proteins, high-glycine tyrosine proteins, tricohyalin, and mixtures thereof.
  • the composition further comprises a nutrient.
  • a nutrient is an organic substance occurring in foods that is not synthesized by the body and is necessary in trace amounts for the normal metabolic functioning of the body, such as vitamins, essential amino acids, and essential fatty acids.
  • vitamins nonexclusively include vitamin B complex; including thiamine, nicotinic acid, biotin, pantothenic acid, choline, riboflavin, vitamin B6, vitamin B 12, pyridoxine, inositol, carnitine; vitamins A 5 C 3 D 5 E 5 K and their derivatives such as vitamin A palmitate and pro-vitamins, e.g. (i.e. panthenol (pro vitamin B5) and panthenol triacetate) and mixtures thereof.
  • vitamin B complex including thiamine, nicotinic acid, biotin, pantothenic acid, choline, riboflavin, vitamin B6, vitamin B 12, pyridoxine, inositol, carnitine; vitamins A 5 C 3 D 5 E 5 K and their derivatives such as vitamin A palmitate and pro-vitamins, e.g. (i.e. panthenol (pro vitamin B5) and panthenol triacetate) and mixtures thereof.
  • Examples of such essential amino acids include, but are not limited to, arginine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.
  • Examples of essential fatty acids include, but are not limited to, linoleate and linolenate.
  • Suitable antibacterial agents nonexclusively include bacitracin, erythromycin, neomycin, tetracycline, chlortetracycline, benzethonium chloride, phenol, and mixtures thereof.
  • Suitable skin emollients and skin moisturizers nonexclusively include mineral oil, lanolin, vegetable oils, isostearyl isostearate, glyceryl laurate, methyl gluceth-10, methyl gluceth-20 chitosan, and mixtures thereof.
  • Suitable hair conditioners nonexclusively include quaternized compounds such as behenamidopropyl PG-dimonium chloride, tricetylmonium chloride, dihydrogenated tallowamidoethyl hydroxyethyhnonium methosulfate, and mixtures thereof as well as lipophilic compounds like cetyl alcohol, stearyl alcohol, hydrogenated polydecene, and mixtures thereof.
  • An example of a suitable hair softener nonexclusively includes silicone compounds, such as those that are either non- volatile or volatile and those that are water soluble or water insoluble.
  • suitable silicones include organo-substituted polysiloxanes, which are either linear or cyclic polymers of monomelic silicone/oxygen monomers and which nonexclusively include cetyl dimethicone; cetyl triethylammonium dimethicone copolyol phthalate; cyclomethicone; dimethicone copolyol; dimethicone copolyol lactate; hydrolyzed soy protein/dimethicone copolyol acetate; silicone quaternium 13; stearalkonium dimethicone copolyol phthalate; stearamidopropyl dimethicone; and mixtures thereof.
  • Examples of suitable hair moisturizers nonexclusively include panthenyl ethyl ether, phytantriol, and mixtures thereof.
  • Examples of sunscreen agents nonexclusively include benzophenones, bornelone, butyl paba, cinnamidopropyl trimethyl ammonium chloride, disodium distyrylbiphenyl disulfonate, paba, potassium methoxycinnamate, butyl methoxydibenzoylmethane, octyl methoxycinnamate, oxybenzone, octocrylene, octyl salicylate, phenylbenzimidazole sulfonic acid, ethyl hydroxypropyl aminobenzoate, menthyl anthranilate, aminobenzoic acid, cinoxate, diethanolamine methoxycinnamate, glyceryl aminobenzoate, titanium dioxide, zinc oxide, oxybenzone, Pad
  • An example of a suitable tanning agent nonexclusively includes dihydroxyacetone.
  • Examples of skin lightening agents nonexclusively include hydroquinone, catechol and its derivatives, ascorbic acid and its derivatives, and mixtures thereof.
  • suitable insecticides nonexclusively include permethrm, pyrethrin, piperonyl butoxide, imidacloprid, N,N-diethyl toluamide, which refers to the material containing predominantly the meta isomer, i.e., N,N-diethyl-m-toluamide, which is also known as DEET; compounds of the formula III.
  • R 5 is a branched or unbranched alkyl group having about 1 to about 6 carbon atoms
  • R 6 is H, methyl or ethyl
  • R 7 is a branched or unbranched alkyl or alkoxy group having from about 1 to about 8 carbon atoms
  • K is a --CN or a -COOR 6 group, wherein R 6 is a branched or unbranched alkyl group having from about 1 to about 6 carbon atoms, natural or synthetic pyrethroids, whereby the natural pyrethroids are contained in pyrethrum, the extract of the ground flowers of Chrysanthemum cinerariaefolium or C coccineum; and mixtures thereof.
  • ethyl 3-(N- butylacetamido)propionate wherein R 7 is a CH 3 group, R 5 is an n-butyl group, R 6 is H, K is COOR 8 and R 8 is ethyl, which is available commercially from Merck KGaA of Darmstadt, Germany under the name, "Insect Repellent 3535.”
  • An example of an anti fungal for foot preparations nonexclusively includes tolnaftate.
  • Suitable depilating agents nonexclusively include calcium thioglycolate, magnesium thioglycolate, potassium thioglycolate, strontium thioglycolate, and mixtures thereof.
  • Suitable external analgesics and local anesthetics nonexclusively include benzocaine, dibucaine, benzyl alcohol, camphor, capsaicin, capsicum, capsicum oleoresin, juniper tar, menthol, methyl nicotinate, methyl salicylate, phenol, resorcinol, turpentine oil, and mixtures thereof.
  • suitable antiperspirants and deodorants nonexclusively include aluminium chlorohydrates, aluminium zirconium chlorohydrates, and mixtures thereof.
  • Suitable counterirritants nonexclusively include camphor, menthol, methyl salicylate, peppermint and clove oils, ichtammol, and mixtures thereof.
  • An example of a suitable inflammation inhibitor nonexclusively includes hydrocortisone, Fragaria Vesca, Matricaria Charnomilla, and Salvia Officinalis.
  • Suitable hemorrhoidal products nonexclusively include the anesthetics such as benzocaine, pramoxine hydrochloride, and mixtures thereof; antseptics such as benzethonium chloride; astringents such as zinc oxide, bismuth subgallate, balsam Peru, and mixtures thereof; skin protectants such as cod liver oil, vegetable oil, and mixtures thereof.
  • anesthetics such as benzocaine, pramoxine hydrochloride, and mixtures thereof
  • antseptics such as benzethonium chloride
  • astringents such as zinc oxide, bismuth subgallate, balsam Peru, and mixtures thereof
  • skin protectants such as cod liver oil, vegetable oil, and mixtures thereof.
  • Most preferred benefit agents nonexclusively include DMAE, soy and derivatives thereof, colloidal oatmeal, sulfonated shale oil, olive leaf, elubiol, 6-(l-piperidinyl)2,4-pyrimidinediamine-3-oxide, finasteride, ketoconazole, salicylic acid, zinc pyrithione, coal tar, benzoyl peroxide, selenium sulfide, hydrocortisone, sulfur, menthol, pramoxine hydrochloride, tricetylmonium chloride, polyquaternium 10, panthenol, panthenol triacetate, vitamin A and derivatives thereof, vitamin B and derivatives thereof, vitamin C and derivatives thereof, vitamin D and derivatves thereof, vitamin E and derivatives thereof, vitamin K and derivatives thereof, keratin, lysine, arginine, hydrolyzed wheat proteins, hydrolyzed silk proteins, ocryl methoxycinnamate
  • One preferred type of benefit agent includes those therapeutic components that are effective in the treatment of dandruff, seborrheic dermatitis, and psoriasis as well as the symptoms associated therewith.
  • suitable benefits agents nonexclusively include zinc pyrithione, anthralin, shale oil and derivatives thereof such as sulfonated shale oil, selenium sulfide, sulfur; salicylic acid; coal tar; povidone-iodine, imidazoles such as ketoconazole, dichlorophenyl imidazolodioxalan, which is commercially available from Janssen Pharmaceutica, N.
  • the amount of benefit agent to be combined with the skin conditioning composition or the emulsion may vary depending upon, for example, the ability of the benefit agent to penetrate through the skin, hair or nail, the specific benefit agent chosen, the particular benefit desired, the sensitivity of the user to the benefit agent, the health condition, age, and skin, hair, and/or nail condition of the user, and the like.
  • the benefit agent is used in a "safe and effective amount," which is an amount that is high enough to deliver a desired skin, hair or nail benefit or to modify a certain condition to be treated, but is low enough to avoid serious side effects, at a reasonable risk to benefit ratio within the scope of sound medical judgment.
  • the benefit agent is present in the skin conditioning system in an amount, based upon the total weight of the system, from about 0.01 percent to about 20.0 percent, and preferably from about 0.01 percent to about 5.0 percent, and more preferably from about 0.01 percent to about 2.0 percent.
  • detergent thickeners that are capable of imparting the appropriate viscosity to conditioning shampoo compositions are suitable for use in this invention. If used, the detergent thickeners should be present in the shampoo compositions in an amount sufficient to raise the Brookfield viscosity of the composition to a value of between about 500 to about 10,000 centipoise.
  • suitable detergent thickeners nonexclusively include: mono or diesters of polyethylene glycol of formula IV. HO-(CH 2 CH 2 O) 2 H IV.
  • z is an integer from about 3 to about 200; fatty acids containing from about 16 to about 22 carbon atoms; fatty acid esters of ethoxylated polyols; ethoxylated derivatives of mono and diesters of fatty acids and glycerine; hydroxyalkyl cellulose; alkyl cellulose; hydroxyalkyl alkyl cellulose; and mixtures thereof.
  • suitable detergent thickeners nonexclusively include behenalkonium chloride; cetyl alcohol, quaternium-46, hydroxyethyl cellulose, cocodimonium chloride, polyquaternium-6, polyquaternium-7, quaternium-18, PEG-18 glycerol oleate/cocoate, a mixture of acrylates/steareth-50 acrylate copolymer, laureth-3 and propylene glycol, which is commercially available from Goldschmidt under the tradename "Antil 208,” a mixture of cocamidopropylbetaine and glyceryl laurate which is commercially available from Goldschmidt under the tradename, "Antil HS60,” a mixture of propylene glycol, PEG 55, and propylene glycol oleate, which is commercially available from Goldschmidt under the tradename, "Antil 414 liquid,” and mixtures thereof.
  • behenalkonium chloride cetyl alcohol, quaternium-46, hydroxyethy
  • Preferred detergent thickeners include polyethylene glycol ester, and more preferably PEG-150 distearate which is available from the Stepan Company of Northfield, 111. or from Coniiel, S. p. A. of Bologna, Italy under the tradename, "PEG 6000 DS”.
  • compositions of the present invention are useful as a cleansing system and cleansing composition
  • the cleansing system and cleansing composition may also optionally contain a foaming surfactant.
  • the foaming surfactant may be non- ionic, cationic, amphoteric, or anionic; nonionic surfactants are preferred.
  • foaming it is meant that the surfactant, when used with the composition of the present invention, has a column height of foam greater than about 20 mm as determined by the Ross-Miles Test.
  • amphoteric shall mean: 1) molecules that contain both acidic and basic sites such as, for example, an amino acid containing both amino (basic) and acid (e.g., carboxylic acid, acidic) functional groups; or 2) zwitterionic molecules which possess both positive and negative charges within the same molecule.
  • the charges of the latter may be either dependent on or independent of the pH of the composition.
  • the above described skin conditioning composition and cleaning system may be prepared by combining the desired components in a suitable container and mixing them under ambient conditions in any conventional mixing means well known in the art, such as a mechanically stirred propeller, paddle, and the like.
  • Another embodiment of the present invention is directed to a method for depositing a benefit agent onto the skin, hair and/or nails comprised of applying either the above-described skin conditioning system or cleansing composition with an effective amount of a benefit agent to a desired location on a human or animal. While the frequency and amount of the benefit agent- containing cleaning system to be applied will depend upon, for example, the type and amount of benefit agent available, the intended usage of the final composition, i.e. therapeutic versus maintenance regimen, the amount and type of detergent present, and the sensitivity of the individual user to the composition/emulsion, typically the benefit agent-containing cleaning system of the present invention should be topically applied to affected body parts at regular intervals, and preferably from about 2 to about 14 times per week.
  • composition/emulsion is applied more frequently during the initial stages of treatment, e.g. from about 5 to about 7 times per week until the desired effect is achieved, then less frequently when maintenance is desired, e.g. from about 2 to about 5 times per week.
  • the above-described skin conditioning composition and cleansing system are capable of efficiently mediating the deposition and permeation of various benefit agents, such as antidandruff agents, onto and into the skin following topical administration thereto.
  • An alternative preferred embodiment of the present invention is directed to a method for treating hair loss, such as hair loss resulting from alopecia, comprising topically applying the above-described cleaning system and the hair loss benefit agent to a desired location on an animal or human, wherein the benefit agent is comprised of an effective amount of a hair loss treatment agent such as minoxidil or mixture thereof.
  • hair loss treatment agents shall include agents capable of growing hair and/or agents capable of preventing the loss of hair.
  • effective amount it is meant an amount effective for treating hair loss and preferably may range from, based upon the total weight of the skin conditioning system, from about 0.001 percent to about 20 percent, and preferably from about 1 percent to about 5 percent.
  • benefit agents suitable for treating hair loss include, but are not limited to potassium channel openers or peripheral vasodilators such as minoxidil, diazoxide, and compounds such as N*-cyano-N-(tert-pentyl)-N' ⁇ 3 ⁇ yridinyl-guanidine ("P-1075") as disclosed in U.S. Pat.
  • vitamins such as vitamin E and vitamin C, and derivatives thereof such as vitamin E acetate and vitamin C palmitate; hormones, such as erythropoietin, prostaglandins, such as prostaglandin El and prostaglandin F2-alpha; fatty acids, such as oleic acid; diruretics such as spironolactone; heat shock proteins ("HSP"), such as HSP 27 and HSP 72; calcium channel blockers, such as verapamil HCL, nifedipine, and diltiazemamiloride; immunosuppressant drugs, such as cyclosporin and Fk-506; 5 alpha-reductase inhibitors such as finasteride; growth factors such as, EGF, IGF and FGF; transforming growth factor beta; tumor necrosis factor; non-steroidal anti-inflammatory agents such as benoxaprofen; retinoids such as tretinoin; cytok
  • Preferred hair loss treatment agents include minoxidil, 6-(I-piperdinyl)-2,4- pyrimidinediarnine-3 -oxide, N'-cyano-N- ⁇ ert-pentyty-N'-S-pyridinyl- guanidine, finasteride, retinoids and derivatives thereof, ketoconazole, elubiol or mixtures thereof.
  • Another embodiment of the present invention is directed to a method for inhibiting hair growth comprising topically applying the above-described composition/system combined with a benefit agent to a desired area on an animal or human for inhibiting hair growth, wherein the benefit agent is comprised of an effective amount of a hair growth inhibiting agent, hi a preferred embodiment, the cleaning system contains, based upon the total weight of the cleaning system, from about 0.001 percent to about 20 percent, and preferably from about 0.01 percent to about 5 percent hair growth inhibiting agent.
  • benefit agents suitable for use in inhibiting hair growth include: serine proteases such as trypsin; vitamins such as alpha-tocophenol (vitamin E) and derivatives thereof such as tocophenol acetate and tocophenol palmitate; antineoplastic agents, such as doxorubicin, cyclophosphamide, chlormethine, methotrexate, fluorouracil, vincristine, daunorubicin, bleomycin and hydroxycarbamide; anticoagulants, such as heparin, heparinoids, coumaerins, detran and indandiones; antithyroid drugs, such as iodine, thiouracils and carbimazole; lithium and lithium carbonate; interferons, such as interferon alpha, interferon alpha-2a and interferon alpha-2b; retinoids, such as retinol (vitamin A), isotretinoin: glucocorticoids such as betamethasone
  • Another preferred embodiment of the present invention is directed to a method for treating acne and for reducing the signs of aging, i.e. wrinkles, fine lines, and other manifestations of photodamage, comprising topically applying the above-described cleaning system and the relevant benefit agent to the skin of an animal or human at a desired area, wherein the benefit agent is comprised of an effective amount of an anti-acne agent or an anti-aging agent, respectively.
  • Suitable anti-aging agents include, but are not limited to inorganic sunscreens such as titanium dioxide and zinc oxide; organic sunscreens such as octyl-methoxy cinnamates and derivatives thereof; retinoids; vitamins such as vitamin E, vitamin A, vitamin C, vitamin B, and derivatives thereof such as vitamin E acetate, vitamin C palmitate, and the like; antioxidants including beta carotene, alpha hydroxy acids such as glycolic acid, citric acid, lactic acid, malic acid, mandelic acid, ascorbic acid, alpha-hydroxybutyric acid, alpha- hydroxyisobutyric acid, alpha-hydroxyisocaprolc acid, atrrolactic acid, alpha- hydroxyisovaleric acid, ethyl pyruvate, galacturonic acid, glucoheptonic acid, glucoheptono 1,4-lactone, gluconic acid, gluconolactone, glucuronic acid, glucuronolactone, glyco
  • Preferred anti-aging agents include retinoids, anti-oxidants, alpha-hydroxy acids and beta-hydroxy acid with retinol and tretinoin being most preferred.
  • Suitable amounts of anti-aging agents include, based upon the total weight of the described cleaning system, from about 0.01 percent to about 20 percent, and preferably from about 0.04 percent to about 5 percent.
  • Suitable anti-acne agents include, but are not limited to topical retinoids (tretinoin, isotretinoin, motretinide, adapalene, tazarotene, azelaic acid, retinol); salicylic acid; benzoyl peroxide; resorcinol; antibiotics such as tetracycline and isomers thereof, erythromycin, and the anti-inflammatory agents such as ibuprofen, naproxen, hetprofen; botanical extracts such as alnus, arnica, artemisia capillaris, asiasarum root, birrh, calendula, chamomile, cnidium, comfrey, fennel, galla rhois, hawthorn, houttuynia, hypericum, jujube, kiwi, licorice, magnolia, olive, peppermint, philoden
  • Preferred anti-acne agents include benzoyl peroxide, retinol, elubiol, antibiotics, and salicylic acid, with retinol and tretinoin being most preferred.
  • Suitable amount of anti-acne agents include, based upon the total weight of the described cleaning system, from about 0.01 percent to about 10 percent, and preferably from about 0.04 percent to about 5 percent.
  • Another preferred embodiment of the present invention is directed to a method for depigmenting the skin, comprising topically applying to skin at a desired area the above-described cleaning system and an effective amount of the depigmentation benefit agent.
  • Suitable effective amounts of depigmentation agents include, based upon the total weight of the described cleaning system, from about 0.01 percent to about 10 percent, and preferably from about 0.04 percent to about 5 percent.
  • Suitable depigmentation agents include, but are not limited to soy and derivatives thereof, retinoids such as retinol; Kojic acid and its derivatives such as, for example, kojic dipalmitate; hydroquinone and it derivatives such as arbutin; transexamic acid; vitamins such as niacin, vitamin C and its derivatives; azelaic acid; placertia; licorice; extracts such as chamomile and green tea, and mixtures thereof, with retinol, Kojic acid, and hydroquinone, being preferred.
  • retinoids such as retinol
  • Kojic acid and its derivatives such as, for example, kojic dipalmitate
  • hydroquinone and it derivatives such as arbutin
  • transexamic acid vitamins such as niacin, vitamin C and its derivatives
  • vitamins such as niacin, vitamin C and its derivatives
  • azelaic acid placertia
  • An alternative preferred embodiment of the present invention is directed to a method for treating the symptoms and/or the diseases of dandruff, seborrheic dermatitis and/or psoriasis, comprising topically applying the above-described cleaning system and the relevant benefit agent to a location desired wherein the benefit agent is comprised of an effective amount of a dandruff treatment agent, a seborrheic dermatitis treatment agent, or a psoriasis treatment agent, respectively.
  • dandruff treatment agent As used herein, “dandruff treatment agent,” “seborrheic dermatitis treatment agent,” or a “psoriasis treatment agent,” respectively, shall include agents capable of treating the symptoms and/or the diseases of dandruff, seborrheic dermatitis, and psoriasis, respectively.
  • effective amount it is meant an amount effective for treating the disease and/or the symptoms associated therewith and preferably may range from, based upon the total weight of the cleaning system, from about 0.001 percent to about 10 percent, and preferably from about 0.01 percent to about 5 percent.
  • compositions of the present invention may be directed applied to the skin or may be applied onto other delivery implements such as wipes, sponges, brushes, and the like.
  • the compositions may be used in products designed to be left on the skin, wiped from the skin, or rinsed off of the skin.
  • compositions of the present invention comprise a safe and effective amount of a dermatologically-acceptable carrier, suitable for topical application to the skin within which the essential materials and optional other materials are incorporated to enable the essential materials and optional components to be delivered to the skin at an appropriate concentration.
  • the carrier can thus act as a diluent, dispersant, solvent, or the like for the active ingredients of the composition.
  • the carrier ensures that the active ingredients of the composition can be applied to and distributed evenly over the selected target at an appropriate concentration.
  • the carrier can be solid, semi-solid or liquid.
  • the carriers may be liquid or semi-solid, such as creams, lotions and gels.
  • the carrier can itself be inert or it can possess dermatological benefits of its own.
  • the carrier should also be physically and, chemically compatible with the essential components described herein, and should not unduly impair stability, efficacy or other use benefits associated with the compositions of the present invention.
  • the type of carrier utilized in the present invention depends on the type of product form desired for the composition.
  • the topical compositions useful in the subject invention may be made into a wide variety of product forms such as are known in the art. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, and mousses. These product forms may comprise several types of carriers including, but not limited to, solutions, aerosols, emulsions, gels, solids, and liposomes.
  • the compounds which are active in the compositions and methods of this invention may be delivered topically be any means known to those of skill in the art. If the delivery parameters of the topically active pharmaceutical or cosmetic agent so require, the topically active composition may be further composed of a pharmaceutically or cosmetically acceptable vehicle capable of functioning as a delivery system to enable the penetration of the topically active agent into the skin.
  • the composition described herein can be prepared in the form of a cosmetic composition.
  • the composition can be prepared in the form of basic cosmetic compositions (facial cleansers, such as toilet water, cream, essence, cleansing foam and cleansing water, pack and body oil), color cosmetic compositions (foundation, lipstick, mascara, and make-up base), hair product compositions (shampoo, rinse, hair conditioner and hair gel) and soap etc., which comprise the composition described herein as an active ingredient, together with a dermatologically acceptable carrier.
  • the cosmetic composition can be easily prepared in any method known in the art, using the composition described herein together with at least one carrier and additives, which are commonly used in the field of preparing cosmetic compositions.
  • cosmetic agents include emollients, humectants, colorants, pigments, fragrances, moisturizers, viscosity modifiers and any other cosmetic forming agent.
  • One or more cosmetic agents can be included in the cosmetic composition.
  • the form of the cosmetic composition can be a powder, lotion, gel, spray, stick cream, ointment, liquid, emulsion, foam or aerosol.
  • additional active ingredients as known in the art and described herein may also be used.
  • the carriers may include, but are not limited to, a skin softener, a skin permeation enhancer, a colorant, an aromatic, an emulsifier, a thickener, and a solvent.
  • the cosmetic composition may further comprise a perfumery, a pigment, a bactericidal agent, an antioxidant, a preservative and a moisturizer, and also a thickener, inorganic salts and synthetic polymer substances, for the purpose of improving physical properties.
  • a perfumery e.g., a perfumery, a pigment, a bactericidal agent, an antioxidant, a preservative and a moisturizer, and also a thickener, inorganic salts and synthetic polymer substances, for the purpose of improving physical properties.
  • the facial cleanser and soap which comprise the composition described herein, can be easily prepared by adding composition to the facial cleanser base and soap base.
  • the cream can be prepared by adding the composition to a general oil-in-water (OAV) cream base.
  • the cleanser, soap and cream may farther comprise a perfumery, a chelating agent, a pigment, an antioxidant and a preservative, and also synthetic or natural materials, proteins, minerals and vitamins, for the purpose of improving physical properties.
  • a perfumery a chelating agent
  • synthetic or natural materials e.g., synthetic or natural materials, proteins, minerals and vitamins
  • One acceptable vehicle for topical delivery of some of the compositions of this invention may contain liposomes.
  • the liposomes may be present in an amount, based upon the total volume of the composition, from about 10 mg/mL to about 100 mg/mL, or from about 20 mg/mL to about 50 mg/mL.
  • the liposome may have a ratio of about 37.5:12.5:33.3:16.7.
  • Suitable liposomes may be prepared in accordance with the protocol set forth in application U.S. Serial No. 09/110,409, though other methods commonly used in the art are also acceptable.
  • compositions of this invention maybe prepared by combining the desired components in a suitable container and mixing them under ambient conditions in any conventional high shear mixing means well known in the art for non-ionic liposomes preparations, such as those disclosed in Niemiec et al., "Influence of Nonionic Liposomal Composition On Topical Delivery of Peptide Drugs Into Pilosebacious Units: An In Vivo Study Using the Hamster Ear Model," 12 Pharm. Res. 1184-88 (1995) (“Niemiec”), which is incorporated by reference herein in its entirety.
  • Niemiec incorporated by reference herein in its entirety.
  • compositions useful in the present invention can be formulated as solutions.
  • Solutions typically include an aqueous solvent (e.g., from about 50% to about 99.99% or from about 90% to about 99% of a cosmetically acceptable aqueous solvent).
  • the composition may also be delivered topically via a lotion.
  • Lotions typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from about 50% to about 90% (e.g., from about 60% to about 80%) of water.
  • Another type of product that may be formulated from a solution is a cream.
  • a cream typically comprises from about 5% to about 50% (e.g., from about 10% to about 20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50% to about 75%) of water.
  • Single emulsion skin care preparations such as lotions and creams, of the oil-in- water type and water-in-oil type are well-known in the cosmetic art and are useful in the subject invention.
  • Multiphase emulsion compositions such as the water-in- oil-in- water type are also useful in the subject invention.
  • such single or multiphase emulsions contain water, emollients, and emulsifiers as essential ingredients.
  • Creams can be made with a support that is a soap-based or fatty alcohol-based formula in the presence of an emulsifier.
  • the soaps can be any known in the cosmetic formulation art, and include natural fatty or synthetic acids having from 12 to 20 carbon atoms (such as lauric acid, myristic acid, palmitic acid, oleic acid, stearic acid and their mixtures) in concentrations of from 10 to 30% neutralized with cosmetically acceptable salts including sodium, potassium, ammonia, monoethanolamine, triethanolamine and their mixtures.
  • Topical compositions useful in the subject invention may be formulated as a solution comprising an emollient.
  • compositions may contain from about 2% to about 50% of an emollient(s).
  • emollients refer to materials used for the prevention or relief of dryness, as well as for the protection of the skin.
  • the conditioning agent is an emollient it may be selected from hydrocarbons, fatty acids, fatty alcohols and esters. Isononyl isononanoate is a hydrocarbon type of emollient conditioning agent.
  • Other hydrocarbons that may be employed include mineral oil, polyolefms such as polydecene, and paraffins such as isohexadecane (e.g. Permethyl 99® and Permethyl 101®), Other examples of such materials are described in WO 96/16636, incorporated by reference herein.
  • One material that may be used is known by the INCI name sucrose polycottonseedate.
  • Organopolysiloxane oils may be volatile, nonvolatile, or a mixture of volatile and non- volatile silicones.
  • nonvolatile refers to those silicones that are liquid under ambient conditions and have a flash point (under one atmospheric of pressure) of or greater than about 100° C.
  • volatile refers to all other silicone oils.
  • Suitable organopolysiloxanes can be selected from a wide variety of silicones spanning a broad range of volatilities and viscosities. Non-volatile polysiloxanes are preferred. Suitable silicones are disclosed in U.S. Pat. No.
  • Organopolysiloxanes selected from the group consisting of polyalkylsiloxanes, alkyl substituted dimethicones, dimethiconols, polyalkylaryl siloxanes, and mixtures thereof may be used. Polyalkylsiloxanes, dimethicones and cyclomethicones may be used.
  • Vegetable oils and hydrogenated vegetable oils examples include safflower oil, castor oil, coconut oil, cottonseed oil, menhaden oil, palm kernel oil, palm oil, peanut oil, soybean oil, rapeseed oil, linseed oil, rice bran oil, pine oil, sesame oil, sunflower seed oil, partially and folly hydrogenated oils from the foregoing sources, and mixtures thereof.
  • Animal fats and oils e.g. cod liver oil, lanolin and derivatives thereof such as acetylated lanolin and isopropyl lanolate may be used.
  • compositions of the present invention may be substantially free of semi-solid hydrocarbons such as petrolatum, lanolin and lanolin derivatives, sterols (e.g., ethoxylated soya sterols), high molecular weight polybutenes and cocoa butter.
  • substantially free means that the concentration of the semi-solid hydrocarbons are less than 10%, or less than 5% or less than 2% or 0.
  • esters are derived from a sugar or polyol moiety and one or more carboxylic acid moieties. Depending on the constituent acid and sugar, these esters can be in either liquid or solid form at room temperature.
  • liquid esters include: glucose tetraoleate, the glucose tetraesters of soybean oil fatty acids (unsaturated), the mannose tetraesters of mixed soybean oil fatty acids, the galactose tetraesters of oleic acid, the arabinose tetraesters of linoleic acid, xylose tetralinoleate, galactose pentaoleate, sorbitol tetraoleate, the sorbitol hexaesters of unsaturated soybean oil fatty acids, xylitol pentaoleate, sucrose tetraoleate, sucrose pentaoletate, sucrose hexaoleate, sucrose hepatoleate, sucrose octaoleate, and mixtures thereof.
  • solid esters examples include: sorbitol hexaester in which the carboxylic acid ester moieties are palmitoleate and arachidate in a 1 :2 molar ratio; the octaester of raffmose in which the carboxylic acid ester moieties are linoleate and behenate in a 1 :3 molar ratio; the heptaester of maltose wherein the esterifying carboxylic acid moieties are sunflower seed oil fatty acids and lignocerate in a 3:4 molar ratio; the octaester of sucrose wherein the esterifying carboxylic acid moieties are oleate and behenate in a 1 :3 molar ratio; and the octaester of sucrose wherein the esterifying carboxylic acid moieties are laurate, linoleate and behenate in a 1 :3:4 molar ratio.
  • a solid material that may be used is sucrose polyester in which the degree of esterification is 7-8, and in which the fatty acid moieties , are Cl 8 mono- and/or di-unsaturated and behenic, in a molar ratio of unsaturates :behenic of 1 :7 to 3 :5.
  • a solid sugar polyester that may be used is the octaester of sucrose in which there are about 7 behenic fatty acid moieties and about 1 oleic acid moiety in the molecule.
  • Other materials include cottonseed oil or soybean oil fatty acid esters of sucrose. The ester materials are further described in, U.S. Pat. No. 2,831,854, U.S. Pat. No.
  • the topical compositions of the subject invention generally comprise from about 1% to about 50%, or about 3% to about 15% of a dermatologically acceptable emollient.
  • Emollients tend to lubricate the skin, increase the smoothness and suppleness of the skin, prevent or relieve dryness of the skin, and/or protect the skin.
  • Emollients are typically water-immiscible, oily or waxy materials.
  • suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of materials suitable as an emollient; See also International Cosmetic Ingredient Dictionary and Handbook, eds.
  • Emollients include stearyl alcohol, glyceryl monostearate, propane- 1,2-diol, butane- 1, 3 -diol, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, cetyl palmitate, polydimethylsiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, Methylene glycol, lanolin, sesame oil, coconut oil, arachis oil, acetylated lanolin alcohols, petroleum, mineral oil, butyl myristate, isostearic
  • An ointment may comprise a simple base of animal or vegetable oils or semi-solid hydrocarbons.
  • An ointment may comprise from about 2% to about 10% of an emollient(s) plus from about 0.1% to about 2% of a thickening agent(s).
  • thickening agents examples include cellulose derivatives (methyl cellulose and hydroxyl propylmethylcellulose), synthetic high molecular weight polymers (e.g., carboxyvinyl polymer and polyvinyl alcohol), plant hydrocolloids (e.g., karaya gum and tragacanth gum), clay thickeners (e.g., colloidal magnesium aluminum silicate and bentonite), and carboxyvinyl polymers (CARBOPOLS; sold by B.F. Goodrich Company, (such polymers are described in Brown, US Pat. NO. 2,798,053), carboxylic acid polymers, crosslinked polyacrylates, polyacrylamides, xanthan gum and mixtures thereof. See also Sagarin, Cosmetics, Science and Technology , 2 nd Ed. Vol.l or BSfCI Handbook pp. 1693-1697. for a more complete disclosure of thickening agents or viscosity increasing agents useful herein.
  • synthetic high molecular weight polymers e.g., carboxyvinyl polymer and poly
  • the topical compositions useful in the present invention may be formulated as emulsions.
  • the carrier is an emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the carrier comprises an emulsifier(s).
  • Emulsif ⁇ ers may be nonionic, anionic or cationic. Suitable emulsif ⁇ ers are disclosed in, for example, INCI Handbook, pp. 1673-1686.
  • Lotions and creams can be formulated as emulsions. Typically such lotions comprise from 0.5% to about 5% of an emulsifier(s).
  • Such creams would typically comprise from about 1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of an emulsifier(s).
  • compositions of this invention can also be formulated as a gel
  • Suitable gelling agents for aqueous gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g. , hydroxymethyl cellulose and hydroxypropyl cellulose).
  • Suitable gelling agents for oils include, but are not limited to, hydrogenated butylene/ethylene/styrene copolymer and hydrogenated ethylene/propylene/styrene copolymer. Such gels typically comprise between about 0.1% and 5%, by weight, of such gelling agents.
  • topical compositions of the present invention can also be formulated into a solid formulation (e.g., a wax-based stick, soap bar composition, powder, or a wipe containing liquid or powder).
  • a solid formulation e.g., a wax-based stick, soap bar composition, powder, or a wipe containing liquid or powder.
  • compositions useful in the subject invention may contain, in addition to the aforementioned components, a wide variety of additional oil- soluble materials and/or water-soluble materials conventionally used in compositions for use on skin, hair, and nails at their art-established levels.
  • Compositions can include at least one cosmetically acceptable vehicle other than water.
  • Vehicles other than water include solids or liquids such as emollients, solvents, humectants, thickeners and powders.
  • Suitable liquid vehicles include mineral oil, silicone oil, lipids (such as lecithin, vegetable oil, vitamin E, and derivatives of lanolin), low-molecular weight glycols such as PEG-4, PEG-6, propylene glycol, glycerine, and their lower alkyl conjugates, and ketones, such as acetone.
  • Solvents containing unconjugated hydroxyls may undergo slow exchange with the ester groups of the polyhydroxy acids; this may affect the bulk consistency of the preparation, but would still result in slow release of the hydroxy acid monomers.
  • Solvents include ethyl alcohol, isopropanol, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, and acetone.
  • Nonlimiting examples of these additional ingredients include additional skin care actives such as peptides (e.g., Matrixyl [pentapetide derivative]), farnesol, bisabolol, phytantriol, glycerol, urea, guanidine (e.g., amino guanidine); vitamins and derivatives thereof such ascorbic acid, vitamin A (e.g., retinoid derivatives such as retinyl palmitate or retinyl proprionate), vitamin E (e.g., tocopherol acetate), vitamin B 3 (e.g., niacinamide) and vitamin B 5 (e.g., panthenol) and the like and mixtures thereof; sunscreens; anti-acne medicaments (resorcinol, salicylic acid, and the like; antioxidants (e.g., phytosterols, lipoic acid); flavonoids (e.g., isoflavones, phytoestrogens); skin soothing
  • Nonlimiting examples of suitable carboxylic copolymers, emulsif ⁇ ers, emollients, and other additional ingredients are disclosed in U.S. Pat. No. 5,011,681, to Ciotti et al., issued Apr. 30, 1991 and U.S. Pat. No. 5,939,082, to Oblong et al., issued Aug. 17, 1999, both of which are herein incorporated by reference.
  • the above- mentioned vitamin B 3 compounds can be incorporated as re-crystallized crystals that remain in crystalized form in the composition or as partially solubilize crystals (i.e., some of the crystals are dissolved and some remain in crystalline form in the composition.).
  • Pigments are frequently added to cosmetic formulations to achieve a desired color for application to the skin. Such pigments are known and the concentrations required to achieve a desired coloring are readily determinable. Pigments may be inorganic or organic. Inorganic pigments include iron oxides (red, black, brown colors), manganese violet, ultramarines (green, blue, pink, red, or violet aluminum sulfosilicates), aquamarines, copper powder, mica, clays, silica, and titanium dioxide. Organic dyes that have been certified by the US FDA for cosmetic use generally have the prefix "D&C" and a suffix of a color and a number (for example, D&C Green #3).
  • D&C dyes there are at least 27 D&C dyes, each of which maybe present as a "lake", i.e., a salt of the dye with aluminum, zirconium, strontium, barium, calcium, potassium or other metallic cations, to produce increased adherence to a substrate.
  • CI colorants
  • CI 61570 is chemically the same as D&C Green #5.
  • Each of these pigments may further have several different trade names, or be present in mixed compositions.
  • Certain embodiments of the present invention contain from about 0% to about
  • a colorant on an anhydrous pigment weight basis.
  • These are usually aluminum, barium or calcium salts or lakes.
  • Dyes may be present at a concentration of from about 0% to about 3% and pearlizing agents and the like from 0% to about 10%.
  • Colorants useful herein are all inorganic and organic colors/pigments suitable for use in cosmetic compositions.
  • pigments When used, pigments are typically dispersed in emollients for the good dispersion of the pigments when incorporated into lip compositions of the present invention, thus providing an even distribution of color.
  • Lakes are either a pigment that is extended or reduced with a solid diluent or an organic pigment that is prepared by the precipitation of a water- soluble dye on an adsorptive surface, which usually is aluminum hydrate. There is uncertainty in some instances as to whether the soluble dye precipitates on the surface of the aluminum hydrate to yield a dyed inorganic pigment or whether it merely precipitates in the presence of the substrate.
  • a lake also forms from precipitation of an insoluble salt from an acid or basic dye. Calcium and barium lakes are also used herein.
  • Lakes suitable for use in the present invention include Red 3 Aluminum Lake,
  • Other colors can also be included in the lipsticks, such as dyes. Suitable examples include Red 6, Red 21, Brown, Russet and Sienna dyes and mixtures thereof.
  • the pigment, colorant or filler powders used in the composition are no specific limitations as to the pigment, colorant or filler powders used in the composition.
  • Each maybe a body pigment, inorganic white pigment, inorganic colored pigment, pearling agent, and the like.
  • Specific examples are talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, aluminum magnesium silicate, silica, titanium dioxide, zinc oxide, red iron oxide, yellow iron oxide, black iron oxide, ultramarine, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, crystalline cellulose, starch, titanated mica, iron oxide titanated mica, bismuth oxychloride, and the like.
  • Additional pigment/powder fillers include, but are not limited to, inorganic powders such as gums, chalk, Fuller's earth, kaolin, sericite, muscovite, phlogopite, synthetic mica, lepidolite, biotite, lithia mica, vermiculite, aluminum silicate, starch, smectite clays, alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed aluminum starch octenyl succinate barium silicate, calcium silicate, magnesium silicate, strontium silicate, metal tungstate, magnesium, silica alumina, zeolite, barium sulfate, calcined calcium sulfate (calcined gypsum), calcium phosphate, fluorine apatite, hydroxyapatite, ceramic powder, metallic soap (zin)
  • pigment and/or dye encapsulates such nanocolorants from BASF and multi-layer interference pigments such as Sicopearls from BASF.
  • the pigments/powders may be surface treated to provide added stability of color and ease of formulation. Hydrophobically-treated pigments may be more easily dispersed in the solvent/oil phase, hi addition, it may be useful to treat the pigments with a material that is compatible with a silicone phase. Particularly useful hydrophobic pigment treatments for use in water-in-silicone emulsions include polysiloxane treatments such as those disclosed in U.S. Pat. No. 5,143,722, incorporated herein by reference in its entirety. Pigment/powders having a primary average particle size of from about 10 ran to about 100,000 ran, or about 50 ran to about 5,000 ran, or about 100 ran to about 1000 ran maybe used.
  • Dispersants may also be used in conjunction with the colors and pigments of the present invention. Examples of suitable dispersants include, but are not limited to, those described in U.S. Pat. No. 5,688,493, herein incorporated by reference in its entirety.
  • Film forming agents may be optionally included in the compositions of the present invention to aid film substantivity and adhesion to the skin. Improving the long wear and non-transfer performance of the present compositions is quite desirable. Water-soluble, water insoluble, and water dispersible film forming agents can be used in the internal and external phases of the present compositions to give the desired end benefit.
  • compositions may comprise from about 0% to about 20%, or from about
  • Film forming agents that may be used with the present invention include: 1) organic silicone resins, fluorinated silicone resins, copolymers of organic silicone resins, e.g., trimethylsiloxysilicate from GE (SRlOOO), GE's copolymers of silicone resins, e.g., SF1318 (silicone resin and an organic ester of isostearic acid copolymer) and CFl 301 (silicone resin and alpha methyl styrene copolymer), Dow Coming's pressure sensitive adhesives—copolymers of silicone resins and various PDMS 's (BIO-PSA series); and 2) acrylic and methacrylic polymers and resins, silicone-acrylate type copolymers and fluorinated versions of, including—silicones plus polymer SA70 from 3M, KP545 from Shin-Etsu, alkyl-acrylate copolymers, e.g., KP 561 and 562 from Shin
  • compositions of the present invention may optionally also comprise a thickening agent from about 0.1% to about 5%, or from about 0.1% to about 3%, or from about 0.25% to about 2%, of a thickening agent.
  • Thickening agents that may be used with the present invention include cellulose and derivatives such as cellulose, carboxymethyl hydroxyethylcellulose, cellulose acetate propionate carboxylate, hydroxyethylcellulose, hydroxyethyl ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, methyl hydroxyethylcellulose, microcrystalline cellulose, sodium cellulose sulfate, and mixtures thereof.
  • alkyl substituted celluloses examples include those selected from the group consisting of stearyl, isostearyl, lauryl, myristyl, cetyl, isocetyl, cocoyl (i.e.
  • alkyl groups derived from the alcohols of coconut oil palmityl, oleyl, linoleyl, linolenyl, ricinoleyl, behenyl, and mixtures thereof.
  • the material sold under the tradename NatrosolTM. CS Plus from Aqualon Corporation may be used.
  • Other useful thickeners include acacia, agar, algin, alginic acid, ammonium alginate, amylopectin, calcium alginate, calcium carrageenan, carnitine, carrageenan, dextrin, gelatin, gellan gum, guar gum, guar hydroxypropyltrimonium chloride, hectorite, hyaluroinic acid, hydrated silica, hydroxypropyl chitosan, hydroxypropyl guar, karaya gum, kelp, locust bean gum, natto gum, potassium alginate, potassium carrageenan, propylene glycol alginate, sclerotium gum, sodium carboxymethyl dextran, sodium carrageenan, tragacanth gum, xanthan gum, and mixtures thereof.
  • acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold by the B.F. Goodrich Company under the trade mark of Carbopol resins. Suitable Carbopol resins are described in WO98/22085.
  • Shine control agents Cosmetic products that improve and/or regulate the condition of the shiny appearance of skin are increasingly popular with consumers and are referred to herein as "shine-control agents.” Shine control agents may be included in the compositions of the present invention.
  • a frequent, undesirable condition is "oily skin", which results from the excessive amount of sebum and sweat that is excreted onto the skin.
  • Sebum is an oily mixture, composed principally of squalene, triglycerides, fatty acids and wax esters. Sebum is produced in the sebaceous glands of the skin. Oily skin is associated with a shiny, undesirable appearance and disagreeable tactile sensation. Sweat is predominantly water with trace quantities of dissolved inorganic salts such as sodium chloride and potassium chloride.
  • shine-control agents are porous in nature. These agents, when applied to the skin provide a reservoir to absorb excess moisture into the pores, hence reducing the visible quantity of moisture on the skin.
  • Absorber and non-absorbing spherical particles may be combined to provide optimum shine control as well as providing a product with the best tactile sensory performance.
  • Suitable shine-control agents include, but are not limited to, silicas, magnesium aluminum silicates, talc, sericite and various organic copolymers.
  • Particularly effective shine control agents include silicates or carbonates that are formed by reaction of a carbonate or silicate with the alkali (IA) metals, alkaline earth (IIA) metals, or transition metals, and silicas (silicon dioxide).
  • Shine control agents that may be used include calcium silicates, amorphous silicas, calcium carbonates, magnesium carbonates, zinc carbonates, and combinations thereof.
  • Synthetic versions of the shine-control agents may be used.
  • Suitable synthetic carbonates are commercially available from Mallinckrodt or Whittaker, Clarke & Daniels.
  • Examples of synthetic silicates useful in the present invention are Hubersorb 250 . or Hubersorb 600 ., available from J.M. Huber.
  • Shine-control agents that primarily comprise silicas may be used instead of those materials comprising mainly silicates and/or carbonates when used for moisture and shine control.
  • Silicas may also be in the form of microspheres and/or ellipsoids, as they have been found to contribute good skin feel characteristics in addition to efficient moisture absorption.
  • Silica ellipsoids useful in the present invention are available from DuPont as ZELEC SiI and Kobo as Silica Shells.
  • Silica microspheres are available from Kobo as MSS- 500, MSS500/3, MSS-500H, MSS500/3N, MSS-500N and MSS 500/3N; Presperse as Spheron Ll 500, Spheron Pl 500. Fumed versions of silica can also be used with Aerosil from Degussa and Cab-O-Sil from Cabot both being useful.
  • magnesium aluminum silicates such as Sebumase, available from Miyoshi Kasei are useful.
  • the absorbent powder may comprise from about 1% to about 40%; or about 1% to about 25%, or about 2% to about 10%, by weight of the composition, of silicas.
  • Starch-based materials may also be used as shine control agents. Examples include Natrosorb W and Natrosorb HFW, DryFlo plus and DryFlo AF pure from National Starch and Chemical Company.
  • compositions of the present invention may further comprise a skin-conditioning agent.
  • skin-conditioning agent may be selected from humectants, exfoliants or emollients. Amounts of the skin-conditioning agent may range from about 0% to about 30%, or from about 1% to about 20%, or from about 1% to about 10% by weight.
  • Humectants are generally substances that can attract water, usually out of the air. Humectants are generally considered to be moisturizers. Suitable humectants that can be used with the present invention include but are not limited to glycerin, sorbitol, sodium 2-pyrrolidone-5-carboxylate, soluble collagen, dibutyl phthalate, gelatin, and poly(alkylene oxide)s, such as polyethylene glycol. Sodium carbonate is used in the art as a humectant
  • a safe and effective amount of a desquamation agent may be added to the compositions of the subject invention, or from about 0.1% to about 10%, or from about 0.2% to about 5%, or from about 0.5% to about 4% of the composition.
  • Desquamation agents enhance the skin appearance benefits of the present invention. For example, the desquamation agents tend to improve the texture of the skin (e.g., smoothness).
  • a variety of desquamation agents are known in the art and are suitable for use herein, including organic hydroxy acids such as salicylic acid, glycolic acid, lactic acid, 5-octanoyl salicylic acid, hydroxyoctanoic acid, hydroxycaprylic acid, and lanolin fatty acids.
  • One desquamation system that may be used comprises sulphydryl compounds and zwitterionic surfactants and is described in WO 96/01101, incorporated herein by reference.
  • Another desquamation system that may be used comprises salicylic acid and zwitterionic surfactants and is described in WO 95/13048, incorporated herein by reference.
  • Exfoliants that may be used with the present invention include but are not limited to C2-C30 alpha-hydroxycarboxylic acids, beta-hydroxycarboxylic acids and salts of these acids. Glycolic, lactic and salicylic acids and their ammonium salts may be used. Amounts of the exfoliants may range from about 1 to about 15%, or from 2 to 10% by weight.
  • Suitable examples of which include: alpha-hydroxyethanoic acid, alpha- hydroxypropanoic acid, alpha-hydroxyhexanoic acid, alpha-hydroxyoctanoic acid, alpha-hydroxydecanoic acid, alpha-hydroxydodecanoic acid, alpha- hydroxytetradecanoic acid, alpha-hydroxyhexadecanoic acid, alpha- hydroxyoctadecanoic acid, alpha-hydroxyeicosanoic acid, alpha- hydroxydocosanoic acid, alpha-hydroxyhexacosanoic acid, and alpha- hydroxyoctacosanoic acid.
  • Powders useful alone in dry compositions or as fillers in liquid compositions include chalk, talc, fullers earth, kaolin, starch, gums, colloidal silicon dioxide, sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, carboxyvinyl polymer, and sodium carboxymethyl cellulose.
  • Cosmetic gels may contain thickening or gelling agents such as sodium alginate or arabic gum or cellulose derivatives optionally in the presence of a solvent.
  • the thickening agent concentration may range from about 0.5 to about 30 weight percent or from about 0.5 to about 15 weight percent.
  • Solvents used can be aliphatic lower alcohols, glycols and their ethers with the concentration of the solvents ranging from about 2 to about 20%.
  • the cosmetic compositions of this invention may also contain one or more materials, herein singly or collectively referred to as a "solidifying agent,” that are effective to solidify the particular liquid base materials to be used in a cosmetic composition.
  • a solidifying agent refers to the physical and/or chemical alteration of the liquid base material so as to form a solid or semi-solid at ambient conditions, i.e., to form a final composition that has a stable physical structure and is deposited on the skin during normal use conditions.
  • the solidifying agent may be present at a concentration of from about 0 to about 90%, or from about 1 to about 50%, or from about 5% to about 40%, or from about 1% to about 15%.
  • Suitable solidifying agents may include waxy materials such as candelilla, carnauba, beeswax, spermaceti, carnauba, baysberry, montan, ozokerite, ceresin, paraffin, synthetic waxes such as Fisher-Tropsch waxes, silicone waxes (e.g., DC 2503 from Dow Coming), microcrystalline waxes and the like; soaps, such as the sodium and potassium salts of higher fatty acids, i.e., acids having from 12 to 22 carbon atoms; amides of higher fatty acids; higher fatty acid amides of alkylolamines; dibenzaldehyde-monosorbitol acetals; alkali metal and alkaline earth metal salts of the acetates, propionates and lactates; and mixtures thereof.
  • waxy materials such as candelilla, carnauba, beeswax, spermaceti, carnauba, baysberry, montan
  • polymeric materials such as, locust bean gum, sodium alginate, sodium casemate, egg albumin, gelatin agar, carrageenin gum sodium alginate, xanthan gum, quince seed extract, tragacanth gum, starch, chemically modified starches and the like, semisynthetic polymeric materials such as cellulose ethers (e.g.
  • hydroxyethyl cellulose methyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, hydroxy propylmethyl cellulose
  • polyvinylpyrrolidone polyvinylalcohol, guar gum, hydroxypropyl guar gum, soluble starch, cationic celluloses, cationic guars and the like and synthetic polymeric materials such as carboxyvinyl polymers, polyvinylpyrrolidone, polyvinyl alcohol polyacrylic acid polymers, polymethacrylic acid polymers, polyvinyl acetate polymers, polyvinyl chloride polymers, polyvinylidene chloride polymers and the like.
  • Inorganic thickeners may also be used such as aluminum silicates, such as, for example, bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • Aluminum silicates such as, for example, bentonites
  • a mixture of polyethylene glycol and polyethylene glycol stearate or distearate such as aluminum silicates, such as, for example, bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • Naturally occurring polymers or biopolymers and their use are further described in European Application No. 522624, to Dunphy et al. Additional examples of naturally occurring polymers or biopolymers can be found in the Cosmetic Bench Reference, pp. 1.40-1.42, herein incorporated by reference.
  • Spray compositions may require propellants, including propane, butane, isobutane, carbon dioxide, and nitrous oxide.
  • the composition can also include a perfume in an amount sufficient to make the composition acceptable to the consumer and pleasant to use.
  • the perfume will form from about 0.01% to about 10% by weight of the composition.
  • compositions herein may contain an emulsifier and/or surfactant, generally to help disperse and suspend the discontinuous phase within the continuous phase.
  • a surfactant may also be useful if the product is intended for skin cleansing.
  • emulsifiers will be referred to under the term “surfactants”, thus “surfactant(s)” will be used to refer to surface active agents whether used as emulsifiers or for other surfactant purposes such as skin cleansing.
  • surfactants can be used in the composition, provided that the selected agent is chemically and physically compatible with essential components of the composition, and provides the desired characteristics.
  • Suitable surfactants include silicone materials, non- silicone materials, and mixtures thereof.
  • compositions of the present invention may comprise from about 0.05% to about 15% of a surfactant or mixture of surfactants.
  • a surfactant or surfactant mixture chosen will depend upon the pH of the composition and the other components present.
  • Surface active agents (detergents) useful in cosmetic compositions include anionic surface active agents, such as salts of fatty acids (for example, sodium laurate and triethanolamine oleate), alkyl benzene sulfonates (such as triethanolamine dodecyl benzene sulfonate), alkyl sulfates such as sodium lauryl sulfate, alkyl ether sulfates, monoglyceride sulfates, isethionates, methyl taurides, acylsarcosinates, acyl peptides, acyl lactylates, polyalkoxylated ether glycollates, for example trideceth-7 carboxylic acid, and phosphates such as sodium
  • Amphoteric surface active agents include imidazole compounds, N-alkyl amino acids, (such as sodium cocaminopropionate and asparagine derivatives), and betaines.
  • Nonionic surface active agents such as fatty acid alkanolamides, for example, oleic ethanolamide; esters of polyalcohols, for example Span; polyglycerol esters; polyalkoxylated derivatives, for example TRITON X- 100 ., polyoxyethylene lauryl ether, and TWEEN .; and amine oxides, such as dodecyl dimethyl amine oxides.
  • Cationic surfactants may be of use in the composition. Mixtures of two or more of the above surface active agents can be employed in the composition. As noted above, many surfactants may also be used for their functionality as emollients, humectants or vehicles.
  • Nonionic surfactants include the condensation products of alkylene oxides with fatty acids (i.e. alkylene oxide esters of fatty acids). These materials have the general formula RCO(X) n OH wherein R is a C 10-3 O alkyl group, X is --OCH 2 CH 2 — (i.e. derived from ethylene glycol or oxide) or -OCH 2 CHCH 3 -- (i.e. derived from propylene glycol or oxide), and n is an integer from about 6 to about 200.
  • Other nonionic surfactants are the condensation products of alkylene oxides with 2 moles of fatty acids (i.e. alkylene oxide diesters of fatty acids).
  • RCO(X) famously OOCR
  • R is a C 10-30 alkyl group
  • X is -OCH 2 CH 2 - (i.e. derived from ethylene glycol or oxide) or -OCH 2 CHCH 3 ⁇ (i.e. derived from propylene glycol or oxide)
  • n is an integer from about 6 to about 100.
  • Other nonionic surfactants are the condensation products of alkylene oxides with fatty alcohols (i.e. alkylene oxide ethers of fatty alcohols).
  • R(X) n OR 1 wherein R is a C 10-30 alkyl group, X is -OCH 2 CH 2 ⁇ (i.e.
  • nonionic surfactants are the condensation products of alkylene oxides with both fatty acids and fatty alcohols [i.e. wherein the polyalkylene oxide portion is esterified on one end with a fatty acid and etherified (i.e. connected via an ether linkage) on the other end with a fatty alcohol].
  • RCO(X) n OR 1 wherein R and R are C 10-3O alkyl groups, X is --OCH 2 CH 2 (i.e.
  • n is an integer from about 6 to about 100, examples of which include ceteth-6, ceteth-10, ceteth-12, ceteareth-6, ceteareth-10, ceteareth-12, steareth-6, steareth-10, steareth-12, PEG-6 stearate, PEG-IO stearate, PEG-100 stearate, PEG- 12 stearate, PEG-20 glyceryl stearate, PEG-80 glyceryl tallowate, PEG-IO glyceryl stearate, PEG-30 glyceryl cocoate, PEG-80 glyceryl cocoate, PEG- 200 glyceryl tallowate, PEG- 8 dilaurate, PEG-10 distearate, and mixtures thereof.
  • Still other useful nonionic surfactants include polyhydroxy fatty acid amide surfactants, which are described in more detail in WO 98/04241.
  • nonionic surfactants suitable for use herein include sugar esters and polyesters, alkoxylated sugar esters and polyesters, C 1 -C 30 fatty acid esters of C 1 -C 30 fatty alcohols, alkoxylated derivatives OfC 1 -C 30 fatty acid esters Of C 1 - C 3 o fatty alcohols, alkoxylated ethers Of C 1 -C 30 fatty alcohols, polyglyceryl esters of C 1 -C 30 fatty acids, C 1 -C 30 esters of polyols, C 1 -C 30 ethers of polyols, alkyl phosphates, polyoxyalkylene fatty ether phosphates, fatty acid amides, acyl lactylates, and mixtures thereof.
  • non-silicon-containing surfactants include: polysorbate 20, polyethylene glycol 5 soya sterol, steareth- 20, ceteareth-20, PPG-2 methyl glucose ether distearate, ceteth-10, polysorbate 80, polysorbate 60, glyceryl stearate, sorbitan monolaurate, polyoxyethylene 4 lauryl ether sodium stearate, polyglyceryl-4 isostearate, hexyl laurate, PPG-2 methyl glucose ether distearate, PEG-100 stearate, and mixtures thereof.
  • the composition may include an effective amount of a sunscreen agent to provide protection from the harmful effects of excessive exposure to sunlight. This can be particularly important when the skin is partially debrided by the application of a hydroxy acid.
  • suitable organic sunscreens when required, include Benzophenone-3, DEA Methoxycinnamate, Ethyl dihydroxypropyl PABA, Glyceryl PABA, Octyl methoxycinnamate, Octyl salicylate, 2-phenyl-benzimidazole-5-sulfonic acid, and Butyl methoxy dibenzoylmethane.
  • An inorganic sunscreen such as titanium dioxide or zinc oxide, can also be used.
  • the sunscreen ingredients may be present free in the formulation.
  • the organic sunscreens may also be coupled to the conjugate block copolymer, as described above.
  • Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, ascorbyl esters of fatty acids, ascorbic acid derivatives (e.g., magnesium ascorbyl phosphate), beta-carotene, tocopherol (vitamin E), tocopherol sorbate, tocopherol acetate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, gallic acid and its alkyl esters, such as propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, amines (e.g., N 5 N- diethylhydroxylamine, amino-guanidine), sulfhydryl compounds (e.g., glutathione), dihydroxy fumaric acid and its salts, bioflavonoids, lysine, methionine, proline, superoxide dismutase, silymarin, tea
  • Anti- oxidants/radical scavengers that may be used include tocopherol acetate, tocopherol sorbate and other esters of tocopherol.
  • the tocopherol (vitamin E group) used as an additive or as an antioxidant for retinol, or a derivative, when present in the composition may include alpha- tocopherol, beta-tocopherol, gamma-tocopherol, and delta-tocopherol.
  • the amount of tocopherol, when present in the composition maybe from about 0.0001 to about 50%, or from about 0.001 to about 10% by weight of the composition.
  • composition may also further comprises biof ⁇ lm dislodging enhancer agents such as chaotropic agents or calcium chelators.
  • UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage.
  • a suitable amount is from about 0.01% to about 1%, or from about 0.05% to about 0.5%, of the composition.
  • Exemplary chelators that are useful herein are disclosed in U.S. Pat. No. 5,487,884, incorporated herein by reference. Chelators that maybe useful in compositions of the subject invention are ethylenediamine tetraacetic acid (EDTA), furildioxime and derivatives thereof.
  • EDTA ethylenediamine tetraacetic acid
  • a calcium chelator such as EDTA may also be in a salt form, in a concentration of at least about 0.25%, or any calcium chelator having a chelating potency substantially equivalent thereto may be added.
  • compositions of the present invention can also comprise a skin lightening agent.
  • the compositions may comprise from about 0.1% to about 10%, or from about 0.2% to about 5%, or from about 0.5% to about 2%, of a skin lightening agent.
  • Suitable skin lightening agents include those known in the art, including kojic acid, arbutin, ascorbic acid and derivatives thereof, e.g., magnesium ascorbyl phosphate.
  • Further skin lightening agents suitable for use herein also include those described in WO 95/34280 and WO 95/23780; each incorporated herein by reference.
  • the composition can also include an additional anti-aging active such as retinol (Vitamin A) and/or derivative thereof, to enhance repair of photodamage to skin following exposure to ultra-violet light, hi addition to retinol itself, examples of derivatives of retinol include: Retinyl acetate, Retinyl butyrate, Retinyl propionate, Retinyl octanoate, Retinyl laurate, Retinyl palmitate, Retinyl oleate, and Retinyl linoleate.
  • an additional anti-aging active such as retinol (Vitamin A) and/or derivative thereof, to enhance repair of photodamage to skin following exposure to ultra-violet light, hi addition to retinol itself
  • derivatives of retinol include: Retinyl acetate, Retinyl butyrate, Retinyl propionate, Retinyl o
  • the amount of retinol, or a cosmetically acceptable derivative thereof, when present in the composition is from about 0.01 to about 10% or from about 0.1 to about 5% by weight of the composition.
  • the retinols or derivatives maybe coupled to the conjugate.
  • Estradiol, estriol, hyyaluronic acid, and green tea extract may be incorporated into anti-wrinkle skin cleaning or moisturizing compositions. These formulations may also have ascorbic acid, date palm extract or combinations thereof.
  • compositions within the scope of the present invention may include particulate materials according to methods and materials described in U.S. Pat. No. 4,892,726, issued to Toshiba Silicone Co. Ltd. Compositions including particulate materials such as polymethylsilsesquioxane powders in makeup and cosmetic compositions are smooth upon application and impart natural colour.
  • Particulate materials may have a neat primary particle size of from about 2 to about 15 ⁇ m, or from about 2 to about 10 ⁇ m, or from about 3 to about 7.5 ⁇ m.
  • Median particle size can be determined by any suitable method known in the art, such as by using coulter-counter equipment or the ASTM Designation E20-85 "Standard Practice for Particle Size Analysis of Particulate Substances in the Range of 0.2 to 75 Micrometers by Optical Microscopy," ASTM Volume 14.02, 1993, incorporated herein by reference.
  • the particulate materials can be inorganic or organic, such as organosilicone, or organosilicone polymers. Particles may be free-flowing, solid, materials. By “solid” is meant that the particles are not hollow. The void at the centre of hollow particles can have an adverse effect on refractive index and therefore the visual effects of the particles on either skin or the composition.
  • Tospearl®145 which has a median particle size of about 4.5 ⁇ m.
  • a further representative commercially available example is Orgasol®2002 D NAT COS available from Elf Atochem SA, Paris, France, which is an example of a polyamide organic particulate material.
  • a representative commercially available example of the second particulate material is EA-209® from Kobo which is an ethylene/acrylic acid copolymer having a median particle size of about 10 ⁇ m.
  • particulate materials that may be used are those made of polymethylsilsesquioxane, referenced above, polyamide, polythene, polyacrylonitrile, polyacrylic acid, polymethacrylic acid, polystyrene, polytetrafluoroethylene (PTFE) and poly(vinylidene chloride). Copolymers derived from monomers of the aforementioned materials can also be used.
  • Inorganic materials include silica and boron nitride.
  • compositions of the present invention may comprise one or more particulate materials in a concentration of from about 0.5% to about 25%, or from about 1% to about 20%, or from about 2% to about 12%.
  • the composition can also contain adjuncts conventionally used in skin-treating compositions other than those already mentioned, depending on the form of the intended product. It is, for example, possible to include antiseptics, preservatives, and coloring agents, which can improve the stability and consumer appeal of the composition. Examples of other materials include antimicrobials including bactericides and fungicides, acne medication, and wart removers including salicylic acid. Agents known in the art for treatments of conditions such as blisters, insect bites, diaper rash and canker sores may be included; these may be include local anesthetics, emollients, and other known materials.
  • pH-adjusting agents including minor amounts of mineral acids, basic compositions, and organic acids
  • An exemplary composition includes citric acid, such as is available in an anhydrous salt form of an alkali metal citric acid.
  • citric acid such as is available in an anhydrous salt form of an alkali metal citric acid.
  • the addition of an effective amount of such a pH-adjusting agent is useful in establishing a targeted pH range for compositions according to the invention.
  • the addition of an effective amount of a pH buffering composition so as to maintain the pH of the inventive compositions may also be added.
  • the pH of the final composition is about 4 to about 8, or about 5 to about 7.
  • pH buffer compounds and/or pH buffering systems or compositions are alkali metal phosphates, polyphosphates, pyrophosphates, triphosphates, tetraphosphates, silicates, metasilicates, polysilicates, carbonates, hydroxides, and mixtures of the same.
  • Certain salts such as the alkaline earth phosphates, carbonates, hydroxides, can also function as buffers. It may also be suitable to use as buffers such materials as aluminosilicates (zeolites), borates, aluminates and certain organic materials such as gluconates, succinates, maleates, citrates, and their alkali metal salts.
  • Such buffers keep the pH ranges of the compositions of the present invention within acceptable limits. Others, not particularly elucidated here may also be used. Citric acid, such as is available in an anhydrous salt form of an alkali metal citric acid may be added as it is readily commercially available, and effective. The addition of such a buffering agent is desirable in certain cases wherein long term, i.e., prolonged storage, is to be anticipated for a composition, as well as insuring the safe handling of the aqueous composition.
  • Suitable traditional preservatives for compositions of this invention are alkyl esters of parahydroxybenzoic acid.
  • Other preservatives that have more recently come into use include hydantoin derivatives such as l,3-bis(hydroxymethyl)- 5,5-dimthylhydantoin, propionate salts, and a variety of quaternary ammonium compounds such as benzalkonium chloride, quaternium 15 (Dowicil 200), benzethonium chloride, and methylbenzethonium chloride.
  • Cosmetic chemists are familiar with appropriate preservatives and routinely choose them to satisfy the preservative challenge test and to provide product stability.
  • Disodium EDTA, phenoxyethanol, methyl paraben, propyl paraben, imidazolidinyl urea (commercially available as Germall 1157), sodium dehydroacetate or benzyl alcohol may be used with the present invention.
  • the preservatives should be selected having regard for the use of the composition and possible incompatibilities between the preservatives and other ingredients in the emulsion. Preservatives are employed in amounts ranging from about 0% to about 5%, or from about 0.01% to about 2.5%, or from about 0.01% to about 1%, by weight of the composition.
  • compositions further include water sufficient to provide the remaining weight of the composition.
  • Deionized or distilled water may be employed.
  • the present invention may also include active agents that alleviate psoriasis.
  • antipsoriatic agents include, but are not limited to, corticosteroids (e.g., betamethasone dipropionate, betamethasone valerate, clobetasol propionate, diflorasone diacetate, halobetasol propionate, triamcinonide, dexamethasone, fmocinonide, fluocinolone acetonide, halcinonide, triamcinolone acetate, hydrocortisone, hydrocortisone verlerate, hydrocortisone butyrate, aclometasone dipropionte, flurandrenolide, mometasone furoate, and methylprednisolone acetate), methotrexate, cyclosporine, calcipotriene, anthraline, shale oil, elubiol, ketocon
  • corticosteroids e.g., betamethasone dipropionate, betamethasone
  • compositions of the present invention include an anti-viral agent.
  • anti-viral agents include, but are not limited to, imiquimod, podof ⁇ lox, podophyllin, interferon alpha, acyclovir, famcyclovir, valcyclovir, reticulos and cidofovir.
  • compositions of the present invention include an antimicrobial agent.
  • Antimicrobial agent as used herein is a compound that kills microorganisms or prevents or inhibits their growth or reproduction.
  • antimicrobial agents include, but are not limited to ethanol, propanol, betains, benzalkonium chloride, ben-zethonium chloride, lauric arginayte, sugarquat, methyl benzethonium chloride, cetypyridiunium chloride, 2,4,4', -trichloro-2- hydroxydiphenyl ether (Triclosan), parachlorometa xylenol (PCMX), lodopropynyl butylcarbamate, diazolidinyl urea, chlorhexidene digluconate, chlorhexidene acetate, chlorhexidene isethionate, chlorhexidene hydro-chloride, hexetidine, Qua
  • Bactericidal agents used in the present invention may include enzymatic enzymes. These may include any member from the class of oxido-reductases, EC 1 that generate active oxygen; Monosasccharide oxidases, Peroxidases, Lactoperoxidases, Salivary peroxidases, Myeloperoxidases, Phenol oxidase, Cytochrome oxidase, Dioxygenases, Monooxygenases.
  • the enzymes also include bacterial cell lytic enzymes, e.g., Lysozyme, Lactoferrin.
  • agents include antimicrobials e.g., chlorhexidine, amine fluoride compounds, fluoride ions, hypochlorite, quaternary ammonium compounds e.g. cetylpyridinium chloride, hydrogen peroxide, monochloramine, providone iodine, any recognized sanitizing agent or oxidative agent and biocides.
  • antimicrobials e.g., chlorhexidine, amine fluoride compounds, fluoride ions, hypochlorite, quaternary ammonium compounds e.g. cetylpyridinium chloride, hydrogen peroxide, monochloramine, providone iodine, any recognized sanitizing agent or oxidative agent and biocides.
  • compositions of the present invention may also include antibiotics including, but not limited to the following classes and members within a class: Aminoglycosides: Gentamicin, Tobramycin, Netilmicin, Amikacin, Kanamycin, Streptomycin, Neomycin; Quinolones/Fluoroquinolones: Nalidixic Acid, Cinoxacin, Norfloxacin, Ciprofloxacin, Perfloxacin, Ofloxacin, Enoxacin, Fleroxacin, Levofloxacin; Antipseudomonal: Carbenicillin, Carbenicillin Indanyl, Ticarcillin, Azlocillin, Mezlocillin, Piperacillin; Cephalosporins: Cephalothin, Cephaprin, Cephalexin, Cephradine, Cefadroxil, Cefazolin, Cefamandole, Cefoxitin, Cefaclor, Cefuroxime, Cefotetan, Ce
  • the amount of antimicrobial agent in the compositions is from about 0.001% to about 10%, such as from about 0.01% to about 5%, such as from about 0.05% to about 2% by weight, based on the total weight of the composition.
  • the antimicrobial agent is an anti-fungal agent such as an azole.
  • an anti-fungal agent such as an azole.
  • examples include, but are not limited to, miconazole, ketoconazole, econazole, itraconazole, sertaconazole, fluconazole, voriconazole, clioquinol, bifoconazole, terconazole, butoconazole, tioconazole, oxiconazole, sulconazole, saperconazole, clotrimazole, unde-cylenic acid, haloprogin, butenafme, tolnaftate, nystatin, ciclopirox olamine, terbinaf ⁇ ne, amorolfme, naftifine, elubiol, griseofulvin, their cosmetically acceptable salts, and combinations thereof.
  • the antimicrobial agent is an antibiotic or an antiseptic.
  • examples include, but are not limited to, mupirocin, neomycin sulfate bacitracin, polymyxin B, 1 -ofloxacin, tetracyclines such as chlortetracycline hydrochloride, oxytetracycline - 10 hydrochloride and tetrachcy-cline hydrochoride, clindamycin phosphate, gentamicin sulfate, metronidazole, hexylresorcinol, methylbenzethonium chloride, phenol, quaternary ammonium compounds, tea tree oil, and combinations thereof.
  • tetracyclines such as chlortetracycline hydrochloride, oxytetracycline - 10 hydrochloride and tetrachcy-cline hydrochoride
  • clindamycin phosphate gentamicin sulfate
  • metronidazole
  • compositions of the present invention may include an anti-inflammatory agent.
  • a safe and effective amount of an anti- inflammatory agent may be added to the compositions of the subject invention, from about 0.1% to about 5%, or from about 0.1% to about 2%, of the composition.
  • the anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone or colour.
  • the exact amount of antiinflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.
  • Anti-inflammatory agents useful herein include steroids such as hydrocortisone; panthenol and ether and ester derivatives thereof e.g. panthenol ethyl ether, panthenyl triacetate; pantothenic acid and salt and ester derivatives thereof, such as calcium pantothenate; aloe vera, bisabolol, allantoin and compounds of the liquorice (the plant genus/species Glycyrrhiza glabra) family, including glycyrrhetic acid, glycyrrhizic acid, and derivatives thereof e.g.
  • steroids such as hydrocortisone
  • panthenol and ether and ester derivatives thereof e.g. panthenol ethyl ether, panthenyl triacetate
  • pantothenic acid and salt and ester derivatives thereof such as calcium pantothenate
  • aloe vera bisabolol, allantoin and compounds of
  • Additional anti-inflammatory agents include, but are not limited to, corticosteroids such as hydrocortisone, hydroxyltriamcinolone alphamethyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobe-tasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone di- acetate, diflucortolone valerate, fluadrenolone, fluclarolone acetonide, fludrocortisone, flumethasone pivalate, fluosi-nolone acetonide, fluocinonide, flucortine butylester
  • corticosteroids such as hydrocortisone, hydroxyltriamcinolone alphamethyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobe-tasol va
  • wound healing enhancing agents such as calcium alginate, collagen, recombinant human platelet-derived growth factor (PDGF) and other growth factors, ketanserin, iloprost, prostaglandin El and hyaluronic acid; scar reducing agents such as mannose-6-phosphate; analgesic agents; debriding agents such as papain, and enzymatic debriding agents; and anesthetics such as lidocaine and benzocaine.
  • wound healing enhancing agents such as calcium alginate, collagen, recombinant human platelet-derived growth factor (PDGF) and other growth factors, ketanserin, iloprost, prostaglandin El and hyaluronic acid
  • scar reducing agents such as mannose-6-phosphate
  • analgesic agents debriding agents such as papain, and enzymatic debriding agents
  • anesthetics such as lidocaine and benzocaine.
  • the composition comprises one or more of menthol, camphor, an antihistamine, or a local anesthetic such as tetracaine, lidocaine, prilocaine, benzocaine, bupivacaine, mepivacaine, dibucaine, etidocaine, butacaine, cyclomethycaine, hexylcaine, proparacaine, and lopivacaine, capsaicin, or oatmeal.
  • a local anesthetic such as tetracaine, lidocaine, prilocaine, benzocaine, bupivacaine, mepivacaine, dibucaine, etidocaine, butacaine, cyclomethycaine, hexylcaine, proparacaine, and lopivacaine, capsaicin, or oatmeal.
  • the amount of anti-inflammatory agent, anti- viral agent, anti-psoriatic agent and/or other active agent in the compositions is from about 0.001% to about 10%, such as from about 0.01% to about 5% such as from about 0.05% to about 2% by weight, based on the total weight of the composition.
  • compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum, and the like.
  • compositions of the present invention are useful for regulating mammalian skin condition, for example human skin, including the face, scalp, and hands or other non-facial parts of the body, including regulating visible and/or tactile discontinuities in skin, e.g., visible and/or tactile discontinuities in skin texture, such as discontinuities associated with skin ageing.
  • Regulating skin condition involves topically applying to the skin a safe and effective amount of a composition of the present invention.
  • the amount of the composition which is applied, the frequency of application and the period of use will vary widely depending upon the active levels of a given composition and the level of regulation desired, e.g., in light of the level of skin ageing present in the subject and the rate of further skin ageing.
  • compositions of the present invention can be employed to provide a skin appearance and/or feel benefit.
  • Quantities of the present compositions which are typically applied per application are, in mg composition/cm 2 skin, from about 0.1 mg/cm 2 to about 10 mg/cm 2 .
  • a particularly useful application amount is about 2 mg/cm 2 .
  • applications would be on the order of about once per day, however application rates can vary from about once per week up to about three times per day or more.
  • the compositions of this invention provide a visible improvement in skin condition essentially immediately following application of the composition to the skin. Such immediate improvement involves coverage or masking of skin imperfections such as textural discontinuities (including those associated with skin ageing,, such as enlarged pores), and/or providing a more even skin tone or color.
  • compositions of the invention also provide visible improvements in skin condition following chronic topical application of the composition.
  • Chronic topical application involves continued topical application of the composition over an extended period during the subject's lifetime, for a period of at least about one week, or for a period of at least about one month, or for at least about three months, or for at least about six months, or for at least about one year.
  • Chronic regulation of skin condition involves improvement of skin condition following multiple topical applications of the composition to the skin. Typically applications would be on the order of about once per day over such extended periods, however application rates can vary from about once per week up to about three times per day or more.
  • Regulating skin condition may be practiced by applying a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for an extended period for some aesthetic, prophylactic, therapeutic or other benefit (i.e., a "leave-on" composition).
  • a composition in the form of a skin lotion, cream, cosmetic, or the like which is intended to be left on the skin for an extended period for some aesthetic, prophylactic, therapeutic or other benefit
  • “leave-on” compositions exclude rinse-off skin cleansing products.
  • the leave-on composition is may be left on the skin for a period of at least about 15 minutes, or at least about 30 minutes, or at least about 1 hour, or for at least several hours, e.g., up to about 12 hours.
  • compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, cooling, application of vacuum and the like.
  • the following emulsion is prepared using conventional formulating techniques.
  • the meta silicate, sodium carbonate, sodium glyconate, potassium Al sulfate are mixed with the niacinamide and water until homogeneous.
  • the glycerin, ethylene/acrylic acid copolymers microspheres and methylparaben are then added.
  • the Mixture is then combined with the cyclomethicone and mixed using conventional mixing methods until homogenous.
  • the mixture is then poured into suitable continers.
  • the moisturizing cosmetic lotion is applied to the face and/or body to provide softening, moisturization and conditioning.
  • the present invention relates to hair care compositions, particularly those that contact the scalp.
  • the present invention maybe used to allieviate or improve dandruff or other conditions of the scalp, hi yet another embodiment, the composition may also include active ingredients known to improve dandruff or similar conditions of the scalp.
  • the composition of the present invention may be incorporated into hair care products, such as shampoos, conditioners, styling products and hair coloring products, as known and described in the art.
  • the present composition is particularly useful for the treatment of dandruff or other conditions that affect the scalp.
  • the composition comprises meta silicate, carbonate glyconate, and aluminum sulfate in a suitable carrier for treatment of the hair and scalp.
  • the composition may comprise a) from about 0.04% to about 1.6% of ameta silicate, b) from about 0.03% to about 1.2% of a carbonate, c) from about 0.01% to about 0.04% of a glyconate, and d) from about 0.01% to about 0.04% of a sulfate.
  • composition may be delivered to the scalp and hair in the form of a shampoo, conditioner, styling product or other liquid or cream formulation that maybe formulated as known in the art. See, for example, U.S. 5,883,058, Wells, et al.; U.S. 5,837,661, Evans, et al.
  • the present composition can be used to produce sprayable, pumpable, and foamable, non-aerosol gels and foams, such as sprayable hair gels and foamable sun protection products with optimized spray pattern and optimized droplet size distribution.
  • These compositions may be directly applied to the scalp to treat dandruff or similar conditions, or the compositions may be applied to the scalp and hair simultaneously.
  • Non-limiting examples of optional components for use in the shampoo composition include particles, cationic polymers, conditioning agents (hydrocarbon oils, fatty esters, silicones), anti-dandruff agents, suspending agents, viscosity modifiers, dyes, nonvolatile solvents or diluents (water soluble and insoluble), pearlescent aids, foam boosters, additional surfactants or nonionic co-surfactants, pediculocides, pH adjusting agents, perfumes, preservatives, chelants, proteins, skin active agents, sunscreens, UV absorbers, and vitamins.
  • conditioning agents hydrocarbon oils, fatty esters, silicones
  • anti-dandruff agents suspending agents
  • viscosity modifiers dyes
  • nonvolatile solvents or diluents water soluble and insoluble
  • pearlescent aids foam boosters
  • additional surfactants or nonionic co-surfactants pediculocides
  • pH adjusting agents perfumes, preservatives, chelants, proteins, skin active agents,
  • Pigments or coloring agents, opacif ⁇ ers, pearlescent agents, feel modifiers, oil absorbers, skin protectants, matting agents, friction enhancers, slip agents, conditioning agents, exfoliants, odor absorbers, or cleaning enhancers may be added to the hair care formulation.
  • Other active ingredients useful as treatment agents for various disorders or conditions may also be added to the hair care composition, including antiperspirant agents, anti-dandruff agents, antimicrobials, antibiotics, and sunscreens.
  • the shampoo compositions may further comprise one or more optional components known for use in hair care or personal care products, provided that the optional components are physically and chemically compatible with the essential components described herein, or do not otherwise unduly impair product stability, aesthetics or performance. Individual concentrations of such optional components may range from about 0.001% to about 10% by weight of the shampoo compositions.
  • compositions of the present invention may optionally include a silicone conditioning component.
  • the silicone conditioning component may comprise volatile silicone, nonvolatile silicone, or mixtures thereof.
  • nonvolatile refers to silicone material with little or no significant vapour pressure under ambient conditions, as is understood by those in the art.
  • compositions of the invention can contain emulsified droplets of a silicone conditioning agent, for enhancing conditioning performance.
  • Suitable silicones include polydiorganosiloxanes, in particular polydimethylsiloxanes that have the CTFA designation dimethicone. Also suitable for use compositions of the invention (particularly shampoos and conditioners) are polydimethyl siloxanes having hydroxyl end groups, which have the CTFA designation dimethiconol. Also suitable for use in compositions of the invention are silicone gums having a slight degree of cross-linking, as are described for example in WO 96/31188.
  • the viscosity of the emulsified silicone itself (not the emulsion or the final hair conditioning composition) maybe at least 10,000 cst at 25° C.
  • the viscosity of the silicone itself is preferably at least 60,000 cst, most preferably at least 500,000 cst, ideally at least 1,000,000 cst.
  • Emulsified silicones for use in the shampoo compositions of the invention may have an average silicone droplet size in the composition of less than 30, preferably less than 20, more preferably less than 10 ⁇ m, ideally from 0.01 to 1 ⁇ m. Silicone emulsions having an average silicone droplet size of ⁇ 0.15 ⁇ m are generally termed microemulsions.
  • Examples of pre-formed emulsions include emulsions DC2-1766, DC2-1784,
  • DC- 1785 DC- 1786 and microemulsions DC2-1865 and DC2-1870 all available from Dow Corning. These are all emulsions/microemulsions of dimethiconol.
  • Cross-linked silicone gums are also available in a pre-emulsified form, which can be advantageous for ease of formulation.
  • DC X2-1787 which is an emulsion of cross-linked dimethiconol gum or DC X2-1391, which is a microemulsion of cross-linked dimethiconol gum, may both be used with the present invention and are available from Dow Corning.
  • a further class of silicones that may be included in embodiments of the present invention are amino functional silicones.
  • amino functional silicone is meant a silicone containing at least one primary, secondary or tertiary amine group, or a quaternary ammonium group.
  • suitable amino functional silicones include: polysiloxanes having the CTFA designation "amodimethicone",
  • amino functional silicones suitable for use in the invention are the aminosilicone oils DC2-8220, DC2-8166, DC2-8466, and DC2-8950-114 (all ex Dow Corning), and GE 1149-75.
  • Suitable quaternary silicone polymers are described in EP-A-O 530 974.
  • An example of a quaternary silicone polymer is K3474.
  • emulsions of amino functional silicone oils with non-ionic and/or cationic surfactant are also suitable from suppliers of silicone oils such as Dow Corning and General Electric. Specific examples include DC929 Cationic Emulsion, DC939 Cationic Emulsion, and the non-ionic emulsions DC2-7224, DC2- 8467, DC2-8177 and DC2-8154 (all ex Dow Corning). With some shampoos a combination of amino and non amino functional silicones maybe used.
  • the total amount of silicone may be from about 0.01 to about 10% wt of the total composition or from about 0.3 to about 5; or from about 0.5 to about 3-wt % is a suitable level.
  • compositions of the present invention can also comprise one or more additional cationic polymeric conditioning agents such as those known with their CTFA category name of Polyquaternium. Typical examples are Polyquaternium 6, Polyquaternium 7, Polyquaternium 10, Polyquaternium 11, Polyquaternium 16, Polyquaternium 22 and Polyquaternium 28. Quaternium polymers may also be used.
  • Quaternium-8 Quaternium- 14, Quaternium- 15, Quaternium- 18, Quaternium-22, Quaternium-24, Quaternium- 26, Quaternium-27, Quaternium-30, Quaternium-33, Quaternium-53, Quaternium-60, Quaternium-61, Quaternium-72, Quaternium-78, Quaternium- 80, Quaternium-81, Quaternium-81, Quaternium-82, Quaternium-83 and Quaternium-84.
  • Cationic cellulose type polymers known as Polymer JR type from Amerchol such as Polyquaternium 10 or cationic guar gum known with trade name Jaguar from Rhone-Poulenc and chemically for example Guar hydroxypropyl trimonium chloride, may also be used.
  • Chitosan and chitin can also be included in the compositions as cationic natural polymers.
  • the cationic polymers may also include the quaternized products of graft polymers from organopolysiloxanes and polyethyl oxazolines. Formulations using these polymers are described in US Application 20060140887, Molenda, et al. It is also possible to use mixtures of various cationic polymers.
  • the cationic polymer conditioning agents may be water soluble.
  • the total level of cationic polymers in the compositions of the present invention maybe from about 0.001% to about 20%, or from about 0.005% to about 10%, or from about 0.01 % to about 2%, by weight.
  • compositions according to the present invention may also comprise a dispersed, non-volatile, water-insoluble oily conditioning agent.
  • insoluble is meant that the material is not soluble in water (distilled or equivalent) at a concentration of 0.1% (w/w), at 25° C.
  • Suitable oily or fatty materials are selected from hydrocarbon oils, fatty esters and mixtures thereof.
  • Straight chain hydrocarbon oils may contain from about 12 to about 30 carbon atoms.
  • polymeric hydrocarbons of alkenyl monomers such as C 2 -C 6 alkenyl monomers.
  • hydrocarbon oils include paraffin oil, mineral oil, saturated and unsaturated dodecane, saturated and unsaturated tridecane, saturated and unsaturated tetradecane, saturated and unsaturated pentadecane, saturated and unsaturated hexadecane, and mixtures thereof.
  • Branched-chain isomers of these compounds, as well as of higher chain length hydrocarbons, can also be used.
  • Suitable fatty esters are characterised by having at least 10 carbon atoms, and include esters with hydrocarbyl chains derived from fatty acids or alcohols, Monocarboxylic acid esters include esters of alcohols and/or acids of the formula R'COOR in which R' and R independently denote alkyl or alkenyl radicals and the sum of carbon atoms in R 1 and R is at least 10, or at least 20. Di- and trialkyl and alkenyl esters of carboxylic acids can also be used.
  • Fatty esters that may be used with the present invention may be mono-, di- and triglycerides, more specifically the mono-, di-, and tri-esters of glycerol and long chain carboxylic acids such as C 1 -C 22 carboxylic acids.
  • Materials that may be used include cocoa butter, palm stearin, sunflower oil, soyabean oil and coconut oil.
  • the oily or fatty material is suitably present at a level of from about 0.05 to about 10, or from about 0.2 to about 5, or from about 0.5 to about 3 wt %.
  • a cationic polymer may also be present.
  • the hair care compositions of the present invention may also comprise a sensate.
  • sensate means a substance that, when applied to the skin, causes a perceived sensation of a change in conditions, for example, but not limited to, heating, cooling, refreshing and the like.
  • Any sensate suitable for use in hair care compositions may be used herein.
  • sensates are described in U.S. Application 20010043912, Michael et al. incorporated by reference herein.
  • Examples of sensates that can be used in the compositions herein are camphor, menthol, I-isopulegol, ethyl menthane carboxamide and trimethyl isopropyl butanamide.
  • Sensates maybe utilized at levels of from about 0.001% to about 10%, or from about 0.005% to about 5%, or from about 0.01% to about 1%, by weight, of the total composition.
  • compositions of the present invention can also comprise viscosity modifiers as described by US. 6,627,183, Young et al. and incorporated herein by reference. Any viscosity modifier suitable for use in hair care compositions may be used herein. Generally, if present, the viscosity modifier may comprise from about 0.01% to about 10%, or from about 0.05% to about 5%, or from about 0.1% to about 3%, by weight, of the total composition.
  • suitable viscosity modifiers can be found in the CTFA International Cosmetic Ingredient Dictionary and Handbook, 7th edition, edited by Wenninger and McEwen, (The Cosmetic, Toiletry, and Fragrance Association, Inc., Washington, D. C, 1997), herein incorporated by reference.
  • compositions whose viscosity is also sensitive to the electrolyte concentration in the aqueous phase known hereafter as "salt sensitive viscosity modifiers".
  • Salt sensitive viscosity modifiers Background material on the properties of salt sensitive viscosity modifiers can be found in American Chemical Society Symposium Series (1991), Vol. 462, pplOl-120, incorporated herein by reference. Any salt sensitive viscosity modifier suitable for use in hair care compositions may be used herein.
  • Suitable viscosity modifiers include, but are not limited to, synthetic hectorites, carboxylic anionic polymers/copolymers and carboxylic anionic cross-linked polymers/copolymers.
  • Suitable polyethylene glycol derivatives of glycerides include any polyethylene glycol derivative of glycerides which are water-soluble and which are suitable for use in a hair care composition can be used as described by U.S. 6,709,648, Sako et al., incorporated herein by reference.
  • Polyethylene glycol derivatives of glycerides that maybe used include PEG-20 hydrogenated castor oil, PEG- 30 hydrogenated castor oil, PEG-40 hydrogenated castor oil, PEG-45 hydrogenated castor oil, PEG-50 hydrogenated castor oil, PEG-54 hydrogenated castor oil, PEG-55 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-80 hydrogenated castor oil, and PEG-100 hydrogenated castor oil.
  • polyethylene glycol derivatives of glycerides can be polyethylene glycol derivatives of stearic acid.
  • PEG-30 stearate, PEG40 stearate, PEG-50 stearate, PEG-75 stearate, PEG-90 stearate, PEG-100 stearate, PEG-120 stearate, and PEG-150 stearate examples of polyethylene glycol derivatives of stearic acid.
  • PEG-30 stearate, PEG40 stearate, PEG-50 stearate, PEG-75 stearate, PEG-90 stearate, PEG-100 stearate, PEG-120 stearate, and PEG-150 stearate PEG-30 stearate, PEG40 stearate, PEG-50 stearate, PEG-75 stearate, PEG-90 stearate, PEG-100 stearate, PEG-120 stearate, and PEG-150 stearate.
  • compositions of the present invention can comprise a surfactant or mixture of surfactants.
  • the surfactant system may be present in the compositions herein at an active level of from about 0.001% to about 30%, or from about 0.01% to about 25%, or from about 0.1% to about 20%. It should be recognized, however, that the concentration of the surfactant system may vary with the purpose the surfactants are intended to serve, the cleaning or lather performance desired, the surfactants incorporated into the surfactant system, the desired product concentration, the presence of other components in the composition, and other factors well known in the art.
  • Surfactant systems useful herein can comprise one or more surfactants selected from anionic surfactants, amphoteric surfactants, nonionic surfactants, cationic surfactants and mixtures thereof.
  • Amphoteric surfactant components useful in the present composition include those known to be useful in personal cleansing compositions, and which may contain a group that is anionic at the pH of the compositions of the present invention.
  • the active concentration of such surfactant components in the surfactant system of the present invention ranges from about 0.001% to about 20%, or from about 0.01% to about 15%, or from about 0.1% to about 10% by weight of the surfactant system.
  • amphoteric surfactants suitable for use in the composition herein are described in U.S. Pat. No. 5,104,646, Bolich Jr. et al. and U.S. Pat. No. 5,106,609, Bolich Jr. et al.
  • amphoteric detersive surfactants which can be used in the compositions of the present invention are those which are broadly described as derivatives of aliphatic secondary and tertiary amines in which the aliphatic radical can be straight or branched chain and wherein one of the aliphatic substituents contains from about 8 to about 18 carbon atoms and one contains an anionic water solubilizing group, e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • an anionic water solubilizing group e.g., carboxy, sulfonate, sulfate, phosphate, or phosphonate.
  • Examples of compounds falling within this definition are sodium 3-dodecyl-aminopropionate, sodium 3-dodecylamino-propane sulfonate, sodium lauroamphoacetate, N-alkyltaurines such as the one prepared by reacting dodecylamine with sodium isethionate according to the teaching of U.S. Pat. No. 2,658,072, N-higher alkyl aspartic acids such as those produced according to the teaching of U.S. Pat. No. 2,438,091, and the products sold under the trade name "MIRANOLTM.” and described in U.S. Pat. No. 2,528,378.
  • amphoterics sometimes classified as zwitterionics, such as betaines can also be used in the present invention.
  • zwitterionics are considered as amphoterics in the present invention where the zwitterionic has an attached group that is anionic at the pH of the composition.
  • betaines useful herein include the high alkyl betaines, such as coco dimethyl carboxymethyl betaine, cocoamidopropyl betaine, cocobetaine, lauryl amidopropyl betaine, oleyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl alpha- carboxyethyl betaine, cetyl dimethyl carboxymethyl betaine, lauryl bis-(2- hydroxyethyl)carboxymethyl betaine, stearyl bis-(2- hydroxypropyl)carboxymethyl betaine, oleyl dimethyl gamma-carboxypropyl betaine, and lauryl bis-(2-hydroxypropyl)alpha-carboxyethyl betaine.
  • high alkyl betaines such as coco dimethyl carboxymethyl betaine, cocoamidopropyl betaine, cocobetaine, lauryl amidopropyl betaine, oleyl betaine, lauryl dimethyl carboxymethyl betaine, lauryl dimethyl
  • the sulfobetaines may be represented by coco dimethyl sulfopropyl betaine, stearyl dimethyl sulfopropyl betaine, lauryl dimethyl sulfoethyl betaine, lauryl bis-(2- hydroxyethyl) sulfopropyl betaine and the like; amidobetaines and amidosulfobetaines, wherein the RCONH(CH 2 ) 3 radical is attached to the nitrogen atom of the betaine are also useful in this invention.
  • Anionic surfactants suitable for use in the present invention include alkyl sulfate, alkyl ethoxylated sulfate, or a mixture thereof. These materials have the respective formulae (I) ROSO 3 M and (II) RO(C 2 H 4 O) x SO 3 M, wherein R is alkyl or alkenyl of from about 8 to about 30 carbon atoms, x is 1 to 10, and M is H or a salt-forming cation such as ammonium, alkanolamine containing C 1 -C 3 alkyl groups such as triethanolamine, and monovalent and polyvalent metals such as the alkaline and alkaline earth metals. Metals that may be used include sodium, potassium, magnesium, and calcium.
  • the cation M, of the anionic surfactant may be chosen such that the anionic surfactant component is water soluble. Solubility of anionic surfactants, in general, will depend upon the particular anionic surfactants and cations chosen. As an aid to determining appropriate mixtures of anionic surfactants, the anionic surfactants should be chosen such that the Krafft temperature is about 15° C. or less, or about 10° C. or less, or about 0° C. or less. The anionic surfactant may also be soluble in the composition hereof. [00426] R may have from about 10 to about 18 carbon atoms in both the alkyl and alkyl ethoxylated sulfates.
  • the alkyl ethoxylated sulfates may be made as condensation products of ethylene oxide and monohydric alcohols having from about 8 to about 24 carbon atoms.
  • the alcohols can be derived from fats, e.g., coconut oil, palm kernel oil, or tallow, or can be synthetic. Such alcohols are may be reacted with about 1 to about 10, or from about 1 to about 4, or from about 2 to about 3.5, molar proportions of ethylene oxide and the resulting mixture of molecular species having, for example, an average of 3 moles of ethylene oxide per mole of alcohol, is sulfated and neutralized.
  • alkyl ether sulfates which may be used in the present invention are sodium and ammonium salts of coconut alkyl Methylene glycol ether sulfate; tallow alkyl Methylene glycol ether sulfate, and tallow alkyl hexaoxyethylene sulfate.
  • Alkyl ether sulfates may comprise a mixture of individual compounds, said mixture having an average alkyl chain length of from about 12 to about 16 carbon atoms and an average degree of ethoxylation of from about 1 to about 4 moles of ethylene oxide.
  • the sulfate surfactant may be comprised of a combination of ethoxylated and nonethoxylated sulfates.
  • Alkyl sulfates can provide excellent cleaning and lather performance.
  • Alkyl ethoxylated sulfates can provide excellent cleaning performance.
  • Suitable anionic detersive surfactants include, but are not limited to water-soluble salts of organic, sulfuric acid reaction products of the general formula [R 1 -SO 3 -M] where R 1 is selected from the group consisting of a straight or branched chain, saturated aliphatic hydrocarbon radical having from about 8 to about 24, or about 10 to about 18, carbon atoms; and M is a cation such as ammonium, alkanolamines, such as triethanolamine, monovalent metals, such as sodium and potassium, and polyvalent metal cations, such as magnesium, and calcium.
  • the cation M, of the anionic detersive surfactant should be chosen such that the detersive surfactant component is water soluble.
  • Solubility will depend upon the particular anionic detersive surfactants and cations chosen.
  • detersive surfactants are the salts of an organic sulfuric acid reaction product of a hydrocarbon of the methane series, including iso-, neo-, and n-paraffms, having about 8 to about 24 carbon atoms, or about 10 to about 18 carbon atoms and a sulfonating agent, e.g., SO 3 , H 2 SO 4 , obtained according to known sulfonation methods, including bleaching and hydrolysis.
  • Alkali metal and ammonium sulfonated C 10-18 n-paraffins may be used.
  • anionic surfactants suitable for use in the present invention are the reaction products of fatty acids esterified with isethionic acid and neutralized with sodium hydroxide where, for example, the fatty acids are derived from coconut oil or palm kernal oil; sodium, ammonium, tetraethylammonium or potassium salts of fatty acid amides of methyl tauride in which the fatty acids, for example, are derived from coconut oil or palm kernal oil.
  • Other similar anionic surfactants are described in U.S. Pat. No. 2,486,921; U.S. Pat. No. 2,486,922; and U.S. Pat. No. 2,396,278.
  • Other anionic detersive surfactants suitable for use in the present invention are the succinnates, examples of which include disodium N- octadecylsulfosuccinnate; disodium lauryl sulfosuccinate; diammonium lauryl sulfosuccinate; tetrasodium N-(l,2-dicarboxyethyl)-N- octadecylsulfosuccinnate; diamyl ester of sodium sulfosuccinic acid; dihexyl ester of sodium sulfosuccinic acid; dioctyl esters of sodium sulfosuccinic acid.
  • succinnates examples of which include disodium N- octadecylsulfosuccinnate; disodium lauryl sulfosuccinate; diammonium lauryl sulfosuccinate; tetrasodium N-(l
  • alkyl glyceryl ether sulfonate surfactants also referred to herein as an "AGS" surfactant
  • AGS surfactants are derived from an alkyl glyceryl ether containing a sulfonate or sulfonate salt group.
  • These compounds generally can be described as an alkyl monoether of glycerol that also contains a sulfonate group.
  • Cationic surfactants useful in compositions of the present invention may contain amino or quaternary ammonium moieties.
  • the cationic surfactant may be insoluble in the compositions hereof.
  • Cationic surfactants among those useful herein are disclosed in the following documents, all incorporated by reference herein: M.C. Publishing Co., McCutcheon's, Detercients & Emulsifiers, (North American edition 1979); Schwartz, et al.; Surface Active Agents, Their Chemistry and Technoloqy, New York: Interscience Publishers, 1949; U.S. Pat. No. 3,155,591, Spotifyr, issued Nov. 3, 1964; U.S. Pat. No.
  • the hair care compositions of the present invention may also comprise fatty alcohols. Any fatty alcohol suitable for use in hair care may be used herein.
  • Fatty alcohols may be utilized at levels of from about 0.1 % to about 20%, or from about 0.25% to about 10%, or from about 0.5% to about 5%, by weight of the composition.
  • the ratio of alcohol: surfactant may be in the range of from about 3 : 1 to about 6: 1 , or about 4: 1.
  • the hair treatment composition for example if it is a shampoo composition, further comprises from 0.1 to 5.0 wt % of a suspending agent.
  • Suitable suspending agents are selected from polyacrylic acids, cross- linked polymers of acrylic acid, copolymers of acrylic acid with a hydrophobic monomer, copolymers of carboxylic acid-containing monomers and acrylic esters, cross-linked copolymers of acrylic acid and acrylate esters, heteropolysaccharide gums and crystalline long chain acyl derivatives.
  • the long chain acyl derivative is desirably selected from ethylene glycol stearate, alkanolamides of fatty acids having from 16 to 22 carbon atoms and mixtures thereof.
  • Ethylene glycol distearate and polyethylene glycol 3 distearate may be used.
  • Polyacrylic acid is available commercially as Carbopol 420, Carbopol 488 or Carbopol 493.
  • Polymers of acrylic acid cross-linked with a polyfunctional agent may also be used; they are available commercially as Carbopol 910, Carbopol 934, Carbopol 941 and Carbopol 980.
  • An example of a suitable copolymer of a carboxylic acid containing monomer and acrylic acid esters is Carbopol 1342. All Carbopol TM materials are available from Goodrich.
  • Suitable cross-linked polymers of acrylic acid and acrylate esters are Pemulen
  • TRl or Pemulen TR2.
  • a suitable heteropolysaccharide gum is xanthan gum.
  • the product is a styling product a styling polymer may be present
  • the hair styling polymer if present is in the compositions of the invention in an amount of from about 0.001% to about 10% by weight, or from about 0.1% to about 10% by weight, or from about 1% to about 8% by weight.
  • Hair styling polymers are well known. Suitable hair styling polymers include commercially available polymers that contain moieties that render the polymers cationic, anionic, amphoteric or nonionic in nature. Suitable hair styling polymers include, for example, block and graft copolymers. The polymers may be synthetic or naturally derived.
  • Hair care compositions of the present invention can comprise a carrier, or a mixture of such carriers, which are suitable for application to the hair.
  • the carriers are present at from about 0.5% to about 99.5%, or from about 5.0% to about 99.5%, or from about 10.0% to about 98.0%, of the composition.
  • suitable for application to hair means that the carrier does not damage or negatively affect the aesthetics of hair or cause irritation to the underlying skin.
  • compositions according to the invention comprise a buffer or pH adjuster.
  • Buffers or pH adjusters that may be used include weak acids and bases such glycine/sodium hydroxide, citric acid, lactic acid, succinic acid, acetic salt and salts thereof. Frequently a mixture of buffering system is used such as sodium citrate and citric acid.
  • Carriers suitable for use with hair care compositions of the present invention include, for example, those used in the formulation of hair sprays, mousses, tonics, gels, shampoos, conditioners, and rinses.
  • the choice of appropriate carrier will depend on the particular product to be formulated.
  • the carriers used herein can include a wide range of components conventionally used in hair care compositions.
  • the carriers can contain a solvent to dissolve or disperse the styling compound being used, with water, the C 1 -C 6 alcohols, lower alkyl acetate and mixtures thereof.
  • the carriers can also contain a wide variety of additional materials such as acetone, hydrocarbons (such as isobutane, hexane, decene), halogenated hydrocarbons (such as Freons) and volatile silicones such as cyclomethicone.
  • hydrocarbons such as isobutane, hexane, decene
  • halogenated hydrocarbons such as Freons
  • volatile silicones such as cyclomethicone.
  • the hair care composition is a hair spray
  • tonic, gel, or mousse possible solvents include water, ethanol, volatile silicone derivatives, and mixtures thereof.
  • the solvents used in such mixtures may be miscible or immiscible with each other.
  • Mousses and aerosol hair sprays can also utilize any of the conventional propellants to deliver the material as a foam (in the case of a mousse) or as a fine, uniform spray (in the case of an aerosol hair spray).
  • suitable propellants include materials such as trichlorofluoromethane, dichlorodiimoromethane, difluoroethane, dimethylether, propane, n-butane or isobutane.
  • a tonic or hair spray product having a low viscosity may also utilize an emulsifying agent.
  • suitable emulsifying agents include nonionic, cationic, anionic surfactants, or mixtures thereof. If such an emulsifying agent is used, it maybe present at a level of from about 0.01 % to about 7.5% by weight based on total weight of the composition.
  • the level of propellant can be adjusted as desired but is generally from about 3% to about 30% by weight based on total weight for mousse compositions and from about 15% to about 50% by weight based on total weight for aerosol hair spray compositions.
  • Hair styling creams or gels also typically contain a structurant or thickener, typically in an amount of from about 0.01% to about 10% by weight.
  • Suitable spray containers are well known in the art and include conventional, non-aerosol pump sprays i.e., "atomizers," aerosol containers or cans having propellant, as described above, and also pump aerosol containers utilizing compressed air as the propellant.
  • the carrier can include a wide variety of conditioning materials such as cationic conditioners suitable for hair, quaternary silicone polymers, silicone based conditioners and their emulsions, and amino functional silicones and their emulsions.
  • the carrier can include, for example, anionic surfactants, nonionic surfactants, amphoteric surfactants, ' suspending agents, and thickeners
  • compositions of the invention include sun- screening agents, anti-dandruff actives, carboxylic acid polymer thickeners for hair shampoo and conditioner compositions and emulsifiers for emulsifying the various carrier components of the compositions of the invention.
  • compositions of the present invention may also contain adjuvants suitable for hair care.
  • adjuvants suitable for hair care include amino acids and ceramides.
  • compositions of the present invention will also generally contain water.
  • compositions herein can contain a variety of other optional components suitable for rendering such compositions more cosmetically or aesthetically acceptable or to provide them with additional usage benefits.
  • Such conventional optional ingredients are well-known to those skilled in the art.
  • a wide variety of additional ingredients can be formulated into the present composition. These include: other hair conditioning ingredients such as panthenol, panthetine, pantotheine, panthenyl ethyl ether, and combinations thereof; other solvents such as hexylene glycol; hair-hold polymers such as those described in WO-A-94/08557, herein incorporated by reference; detersive surfactants such as anionic, nonionic, amphoteric, and zwitterionic surfactants; additional viscosity modifiers and suspending agents such as xanthan gum, guar gum, hydroxyethyl cellulose, triethanolamine, methyl cellulose, starch and starch derivatives; viscosity modifiers such as methanolamides of long chain fatty acids such as cocomonoethanol amide; crystalline suspending agents; pearlescent aids such as ethylene glycol distearate; opacifiers such as polystyrene; preservatives such as phenoxyethanol
  • compositions of the present invention can be formulated in a wide variety of product forms, including but not limited to creams, gels, aerosol or non-aerosol foams, mousses and sprays.
  • Mousses, foams and sprays can be formulated with propellants such as propane, butane, pentane, dimethylether, hydrofluorocarbon, or without specifically added propellants (using air as the propellant in a pump spray or pump foamer package).
  • the hair care compositions of the present invention may be used in a conventional manner for care of human hair.
  • An effective amount of the composition typically from about 1 gram to about 50 grams, or from about 1 gram to about 20 grams, is applied to the hair.
  • Application of the composition typically includes working the composition through the hair, generally with the hands and fingers, or with a suitable implement such as a comb or brush, to ensure good coverage.
  • the composition is then left on the hair, generally until the consumer next washes their hair.
  • the hair may be treated using a method comprising the steps of: (a) applying an effective amount of the hair care composition to wet, damp or dry hair, (b) working the hair care composition into the hair with hands and fingers or with a suitable implement.
  • the method can, optionally, comprise a further step of rinsing the hair with water.
  • compositions of the invention are in the form of hair colorants, hair bleaches and/or hair tinting compositions and comprise one or more substances selected from direct dyes, oxidation dye precursors, and bleaching agents, hi these compositions the composition is used in the usual pH ranges.
  • Suitable direct dyes include nitroaniline derivatives, such as l-[(2- hydroxyethyl)amino]-2-nitrobenzene (Velsol® Yellow 2), 4- hydroxypropylamino-3-nitrophenol (Velsol® Red BN), 3-nitro-p- hydroxyethylaminophenol (Velsol® Red 54), 4-hydroxyethylamino-3- nitroaniline (Velsol® Red 3), N,N'-bis(hydroxyethyl)-2-nitro-p- phenylenediamine (Velsol® Violet BS), N,N',N'-tris(hydroxyethyl)-2-nitro-p- phenylenediamine (Velsol® Blue 2), 4-(2'-hydroxyethyl)amino-3-nitrotoluene, 4-(2' ⁇ hydroxyethyl)amino-3-nitrobenzyl alcohol, 4-(2'-hydroxyethyl)amino-3
  • azo dyes such as Acid Brown 4 (CI. 14805), anthraquinone dyes, such as Disperse Blue 23 (CI. 61545), Disperse Violet 4 (CI. 61105), 1,4,5,8-tetraaminoanthraquinone and 1,4- diaminoanthraquinone and further direct dyes.
  • Oxidation dye precursors available are p-phenylenediamines and p- aminophenols or derivatives thereof such as p-tolylenediamine, p- phenylenediamine, and p-aminophenol, for example, which for the purpose of shading the dyeing are combined with modifiers or couplers, such as m- phenylenediamine, resorcinol, m-aminophenol and derivatives thereof.
  • Suitable oxidizing agents for developing the hair dyeings, or as bleaching agents are, for example, hydrogen peroxide and its addition compounds.
  • the composition may also be in the form of a hair bleach and comprise one or more oxidizing agents, for example, hydrogen peroxide.
  • compositions of the invention may comprise the carriers which are customary in cosmetic systems, such as benzyl alcohol, vanillin (4-hydroxy-3-methoxybenzaldehyde), iso vanillin, p- hydroxyanisole, 3-hydroxy-4-methoxybenzaldehyde, 2-phenoxyethanol, salicylaldehyde, 3,5-dihydroxy-benzaldehyde, 3,4-dihydroxybenzaldehyde, 4- hydroxyphenylacetamide, methyl p-hydroxybenzoate, p-hydroxybenzaldehyde, m-cresol, hydroquinone monomethyl ether, o-fluorophenol, m-fluorophenol, p- fluorophenol, 2-(2-hydroxyphenoxy)ethanol, 3 ,4-methylenedioxyphenol, resorcinol monomethyl ether, 3,4-dimethoxyphenol, 3-trifluoromethylphenol, resorcinol monoacetate, ethyl
  • the hair colorants of the invention may comprise compounds which impart pearlescence, examples being fatty acid monoalkanolamides, fatty acid dialkanolamides, monoesters or diesters of alkylene glycol, ethylene glycol and/or propylene glycol or its oligomers with higher fatty acids, e.g., palmitic acid, stearic acid or behenic acid or mixtures thereof, monoesters or diesters of alkylene glycols with fatty acids, fatty acids and their metal salts, monoesters or polyesters of glycerol with carboxylic acids, and keto sulfones of various kind, such as ethylene glycol distearate and polyethylene glycol distearate with about 3 glycol units.
  • the liquid formulation for contact lenses of the present invention comprises one or more metasilicate; one or more carbonate; one or more glyconate; and one or more sulfate.
  • the composition comprises Meta Silicate from about 0.08% to about 3.2%, sodium carbonate from about 0.03% to about 1.2 %, sodium glyconate from about 0.02% to about 0.08% and potassium Al sulfate from about 0.02% to about 0.08%.
  • the composition comprises Meta Silicate from about 0.16% to about 6.4%, sodium carbonate from about 0.06% to about 2.4%, sodium glyconate from about 0.04% to about 0.16% and potassium Al sulfate from about 0.04% to about 0.16%.
  • nitrogen-containing organic anti-microbial agents may be combined with the present invention when used as a contact lens treatment.
  • the nitrogen-containing organic anti-microbial agent include polyhexamethylene biguanide, polyhexamethylene biguanide salt and quaternary ammonium salt.
  • these nitrogen- containing organic anti-microbial agents may be used alone or in combination of two or more.
  • the liquid formulation for contact lenses of the present invention may further contain water and at least one component selected from the group consisting of buffer, surfactant, viscosity inducing agent and isotonic agent.
  • the buffer which can be contained in the liquid formulation for contact lenses of the present invention is not particularly limited if it is a buffer which is generally used as the formulation for contact lenses.
  • the buffer include boric acid-based buffers and phosphoric acid-based buffers.
  • the surfactant that can be contained in the contact lens solutions of the present invention can be ampholytic surfactant, cationic surfactant, anionic surfactant and nonionic surfactant.
  • the nonionic surfactant include polyoxyethylene-polyoxypropylene block copolymer, polyoxyethylene alkyl ethers, polyoxyethylene alkylphenylethers, polyoxyethylene sorbitan alkylate, polyoxyethylene hydrogenated castor oil, monoglyceryl esters of fatty acids, propylene glycol esters of fatty acids, sucrose esters of fatty acids, polyoxyethylene-polyoxypropylene ethylenediamine condensates and the like.
  • cationic surfactant examples include tri(polyoxyethylene)stearylammonium chloride (5E.O.), oleylbis(2- hydroxyethyl)methylammonium chloride, N(N'-lanolin fatty acid amide propyl)N-ethyl-N,N-dimethylammonium ethyl sulfate, N-cocoyl-L- arginineethyl ester-DL-pyrrolidonecarboxylates and the like.
  • 5E.O. tri(polyoxyethylene)stearylammonium chloride
  • oleylbis(2- hydroxyethyl)methylammonium chloride examples include N(N'-lanolin fatty acid amide propyl)N-ethyl-N,N-dimethylammonium ethyl sulfate, N-cocoyl-L- arginineethyl ester-DL-pyrrolidonecarboxylates and the
  • ampholytic surfactant examples include sodium lauryl diaminoethyl glycinate, 2-alkyl- N-carboxymethyl-N-hydroxyethyl imidazolinium betain, alkyldimethylamine oxide and the like.
  • anionic surfactant examples include .alpha.
  • the surfactant may be used alone or in combination of two or more.
  • nonionic surfactant When nonionic surfactant is used from among the above surfactant, it is contained in the formulation in an amount of IxIO "4105 (w/v) %, or IxIO '3102 (w/v) %, or 1x10 "3 to l(w/v)%.
  • another surfactant when another surfactant is used, after an effect obtained when it is used in combination with polylysine and nitrogen- containing organic anti-microbial agent is confirmed in advance, it may be suitably used in limits that do not affect the effect.
  • the viscosity-inducing agent that can be contained in the liquid formulation for contact lenses of the present invention is not particularly limited if it is generally used as the formulation for ophthalmology.
  • the viscosity inducing agent include hyaluronic acid and/or salt thereof, cellulose typified by hydroxypropylmethyl cellulose, and/or derivatives thereof, chitosan and/or derivatives thereof, polyvinylpyrrolidone, polyvinyl alcohols, chondroitin sulfuric acid and salt thereof and the like, hi the present invention, the above viscosity inducing agents may be used alone or in combination of two or more.
  • the viscosity inducing agent is contained in the formulation in an amount of IxIO '3 105 (w/v) %, or 3xlO "3 to 2.5 (w/v) %, or 5xlO '3 10 * (w/v) %.
  • the isotonic agent that can be contained in the liquid formulation for contact lenses of the present invention is not particularly limited if it is generally used as the formulation for contact lenses.
  • the isotonic agent include sodium chloride, potassium chloride, potassium iodide, glycerin, propylene glycol, polyethylene glycol, mannitol, sorbitol, dextrin, dextran and the like.
  • the above isotonic agents may be used alone or in combination of two or more.
  • the liquid formulation for contact lenses of the present invention may optionally contain metal chelating agent such as ethylenediamine tetraacetic acid (EDTA), citric acid, gluconic acid, tartaric acid, diethylenediamine pentaacetic acid, sodium or potassium salt thereof, and sodium nitrilotriacetate, a proteolytic enzyme derived from an animal, plant, or microorganism, and a pH adjusting agent such as hydrochloric acid and sodium hydroxide besides the above components.
  • the liquid formulation for contact lenses of the present invention may contain at least one metal chelating agent, at least one proteolytic enzyme and at least one pH adjuster.
  • the pH of the liquid formulation for contact lenses of the present invention is adjusted to a range of about 5.5 to about 8.0, or about 6.8 to about 7.8 by using the appropriate pH adjusting agents.
  • the osmotic pressure of the liquid formulation is suitably selected from a range of 180 to 460 mOsm., or 260 to 360 mOsm.
  • the liquid formulation for contact lenses of the present invention is a liquid formulation obtained by dissolving the above components in a solvent that is harmless to eyes, such as purified water.
  • the liquid formulation for contact lenses of the present invention can be advantageously produced on an industrial scale, for example, by dissolving the above components excluding viscosity inducing agent in water, adjusting the pH of the obtained solution with acid or alkali, adding viscosity inducing agent, dissolving it under stirring and adjusting the pH of the obtained solution with acid or alkali.
  • the contact lenses taken off from eyes are soaked in the liquid formulation without cleaning by digital rubbing and left as they are for about 5 minutes to about 24 hours, or about 30 minutes to about 8 hours. Thereafter, the thus treated contact lenses can be worn in eyes without being rinsed with the liquid formulation.
  • the contact lenses to be cleaned, disinfected and stored may be hard contact lenses and soft contact lenses.
  • the present invention also relates to an oral care composition.
  • the present composition is useful for inhibiting the growth of microbials that are correlated to the formation of biofilm in the oral cavity. It is believed that plaque and eventually tartar and calculus result from a biofilm reaching a more advanced and complex stage of development, trapping additional material and eventually hardening. Therefore, by inhibiting the development of the biofilm, the development of plaque tartar and/or calculus may also be prevented.
  • the composition comprises meta silicate, carbonate glyconate, and aluminum sulfate in a suitable carrier for the treatment of oral cavities and teeth.
  • the composition may comprise a) from about 0.08% to about 3.2% of a meta silicate, b) from about 0.06% to about 2.4% of a carbonate, c) from about 0.02% to about 0.08% of a glyconate, and d) from about 0.02% to about 0.08% of a sulfate.
  • the concentration used for oral care products is about 1.5 to about 2 times that of the concentration used for skincare products or shampoos due to the less sensitive inner mouth skin composition and the needed direct effect of the toothpaste and mouth water.
  • the composition is delivered to the oral cavity or teeth using a suitable carrier as described below.
  • compositions may include additional active ingredients that improve oral hygiene or the appearance of the teeth.
  • agents that improve asthetics or efficacy of the product may also be used and are described herein.
  • the present invention can incorporate essential oils demonstrating antimicrobial properties as described in U.S. Application 20060045851, Oral care composition comprising essential oils, Fitzgerald et al., published March 2, 2006.
  • the oral care composition comprising the combination of Group A and B essential oils can also comprise a variety of oral care carriers including dentifrice, rinse, gel, gum, candy, confectionary or lozenge, edible film, and/or a quick dissolving wafer such as described in U.S. Pat. No. 6,221,392. Additionally, the oral care composition can be disposed on a dental wipe such as described in U.S. Pat. No. 6,721,987 and WO Application No. 02/069753.
  • a carrier to be used is determined by the way the composition is to be introduced into the oral cavity. If a tooth paste (including tooth gels, chewable tablets etc.) is to be used, then a “toothpaste carrier” is chosen as disclosed in, e.g., U.S. Pat. No. 3,988,433, (e.g., abrasive materials, sudsing agents, binders, humectants, flavoring and sweetening agents, etc.). If a mouth rinse is to be used, then a "mouth rinse carrier” is chosen, as disclosed in, e.g., U.S. Pat. No. 3,988,433 (e.g., water, flavoring and sweetening agents, etc.).
  • a mouth spray carrier e.g., a "mouth spray carrier” is chosen. If a sachet is to be used, then a "sachet carrier” is chosen (e.g., sachet bags flavoring and sweetening agents). If a subgingival gel is to be used (for delivery of actives into the periodontal pockets or around the periodontal pockets), then a "subgingival gel carrier” is chosen as disclosed in, e.g. U.S. Pat. Nos. 5,198,220; and 5,242,910. Carriers suitable for the preparation of compositions of the present invention are well known in the art. Their selection will depend on secondary considerations like taste, cost, and shelf stability, etc.
  • the compositions are in the form of dentifrices, such as toothpastes, tooth gels and tooth powders.
  • Components of such toothpaste and tooth gels may include one or more of a dental abrasive (from about 10% to about 50%), a surfactant (from about 0.5% to about 10%), a thickening agent (from about 0.1% to about 5%), a humectant (from about 10% to about 55%), an essential oil component (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), a coloring agent (from about 0.01% to about 0.5%) and water (from about 2% to about 4 5%).
  • a dental abrasive from about 10% to about 50%
  • a surfactant from about 0.5% to about 10%
  • a thickening agent from about 0.1% to about 5%
  • a humectant from about 10% to about 55%)
  • an essential oil component from about 0.04% to about 2%
  • a sweetening agent from about 0.
  • Such toothpaste or tooth gel may also include one or more of an additional anticaries agent (from about 0.05% to about 10% additional anticaries agent), and an anticalculus agent (from about 0.1% to about 13%).
  • additional anticaries agent from about 0.05% to about 10% additional anticaries agent
  • anticalculus agent from about 0.1% to about 13%).
  • the tooth powders of course, contain substantially all non-liquid components.
  • compositions of the subject invention are mouthwashes, including mouth sprays.
  • Components of such mouthwashes and mouth sprays typically include one or more of water (from about 45% to about 95%), ethanol (from about 0% to about 25%), a humectant (from about 0% to about 50%), a surfactant (from about 0.01% to about 7%), a flavoring agent (from about 0.04% to about 2%), a sweetening agent (from about 0.1% to about 3%), and a coloring agent (from about 0.001% to about 0.5%).
  • Such mouthwashes and mouth sprays may also include one or more of an of - Ill -
  • additional anticaries agent from about 0.05% to about of additional anticaries agent
  • an anticalculus agent from about 0.1% to about 13%).
  • compositions of the subject invention are dental solutions.
  • Components of such dental solutions generally include one or more of water (from about 90% to about 99%), preservative (from about 0.01% to about 0.5%), thickening agent (from 0% to about 5%), flavoring agent (from about 0.04% to about 2%), sweetening agent (from about 0.1% to about 3%), and surfactant (from 0% to about 5%).
  • Another embodiment of the present invention includes a candy, confection and/or lozenge.
  • the carrier material for the candy, confection and/or lozenge can be chosen from chewable or non chewable materials.
  • the chewable material can be selected from gums including, but not limited to, agar gum, and gelatine; low boiled sugar candy base and gum base materials.
  • Hard and low boiled candy carrier, pressed tablets and the like can comprise greater than about 70% bulk sweetener including suitable sugar and sugar syrups including cariogenic and non-cariogenic materials.
  • Low boiled candies can also comprise butter to form chewable toffee.
  • the carrier can comprise greater than about 25% bulk sweetener and additionally comprise gums including gum arabic, gelatine, agar powder and the like.
  • the candy, confections and/or lozenge can additionally comprise other oral and/or therapeutic actives.
  • compositions include chewing gum compositions.
  • Such compositions may be in the form of a conventional chewing gum or any other product form which is suitable for chewing. Suitable physical forms include sticks, dragees, chiclets, and batons.
  • a chewing gum is typically retained in the oral cavity for a time sufficient to allow ingredients released to contact substantially all of the dental surfaces and/or oral tissues for purposes of oral activity.
  • Chewing gums can comprise abrasive polishing materials, elastomers, resins, plasticizers, fats, solvents, bulking agents, sweeteners, absorbents, orally active metallic ions, cationic material, fluoride ion sources, additional anticalculus agents, antimicrobiali agents, buffers, whitening agents, alkali metal bicarbonate salts, thickening materials, humectants, water, surfactants, titanium dioxide, flavoring agents, xylitol, coloring agents, and mixtures thereof.
  • the essential oil composition is present in an edible film that is physiologically acceptable and particularly well adapted to adhere to and dissolve in the oral cavity of a consumer.
  • suitable edible film and methods for making such films are described in U.S. Pat. Nos. 6,596,298; 5,733,584; 5,948,430; 6,177,096;, and W.O. Application No. 00/18365.
  • An edible film comprising pullulan can be used.
  • the edible films of the present invention can be used to deliver or release the essential oil composition and/or other oral care active.
  • the edible films can include a variety of other suitable ingredients such as softeners, colorants, flavoring agents, emulsifiers, surfactants, thickening agents, binding agents, sweeteners, fragrances, and combinations thereof.
  • compositions of the present invention can further comprise abrasives, surfactants, thickening agents, humectants and flavorants previously disclosed it the art.
  • a dental abrasive may be included.
  • the material selected is to be compatible within the composition of interest and does not excessively abrade dentin.
  • Suitable abrasives include, for example silicas including gels and precipitates, insoluble sodium polymetaphosphate, hydrated alumina, calcium carbonate, dicalcium orthophosphate dihydrate, calcium pyrophosphate, tricalcium phosphate, calcium polymetaphosphate, and resinous abrasive materials such as particulate condensation products of urea and formaldehyde.
  • abrasives for use in the present compositions is the particulate thermo-setting polymerized resins as described in U.S. Pat. No. 3,070,510.
  • Suitable resins include, for example, melamines, phenolics, ureas, melamine- ureas, melamine-formaldehydes, urea-formaldehyde, melamine-urea- formaldehydes, cross-linked epoxides, and cross-linked polyesters. Mixtures of abrasives may also be used.
  • Silica dental abrasives of various types can be used because of their unique benefits of exceptional dental cleaning and polishing performance without unduly abrading tooth enamel or dentine.
  • the silica abrasive polishing materials can have an average particle size ranging between about 0.1 to about 30 microns, and in another embodiment from about 5 to about 15 microns.
  • the abrasive can be precipitated silica or silica gels such as the silica xerogels described in U.S. Pat. No. 3,538,230, and U.S. Pat. No. 3,862,307.
  • Suitable silica xerogels are the silica xerogels marketed under the trade name "Syloid" by the W.R. Grace & Company, Davison Chemical Division.
  • precipitated silica materials such as those marketed by the J. M.
  • Huber Corporation under the trade name, ZeodentRTM. can be used; in one embodiment the silica carrying the designation Zeodent 119.RTM. can be used.
  • the types of silica dental abrasives useful in the toothpastes of the present invention are described in more detail in U.S. Pat. No. 4,340,583.
  • the abrasive in the toothpaste compositions described herein is generally present at a level of from about 6% to about 70% by weight of the composition.
  • the toothpastes can contain from about 10% to about 50% of abrasive, by weight of the composition. Mixtures of the abrasives can be used.
  • suitable precipitated silica is the silica disclosed in U.S. Pat. Nos. 5,603,920; 5,589,160; 5,658,553; 5,651,958.
  • Suitable sudsing agents are those which are reasonably stable and form foam throughout a wide pH range. Sudsing agents include nonionic, anionic, amphoteric, cationic, zwitterionic, synthetic detergents, and mixtures-thereof Many suitable-nonionic and amphoteric surfactants are disclosed in U.S. Pat. Nos. 3,988,433; and 4,051,234, and many suitable nonionic surfactants are disclosed in U.S. Pat. No. 3,959,458.
  • Suitable thickening agents are carboxyvinyl polymers, carrageenan, hydroxyethyl cellulose, laponite and water soluble salts of cellulose ethers such as sodium carboxymethylcellulose and sodium carboxymethyl hydroxyethyl cellulose.
  • Natural gums such as gum karaya, xanthan gum, gum arabic, and gum tragacanth can also be used.
  • Colloidal magnesium aluminum silicate or finely divided silica can be used as part of the thickening agent to further improve texture.
  • Thickening agents can include however, except polymeric polyether compounds, e.g., polyethylene or polypropylene oxide (M. W. 300 to 1,000,000), capped with alkyl or acyl groups containing 1 to about 18 carbon atoms.
  • polymeric polyether compounds e.g., polyethylene or polypropylene oxide (M. W. 300 to 1,000,000)
  • alkyl or acyl groups containing 1 to about 18 carbon atoms.
  • a suitable class of thickening or gelling agents includes a class of homopolymers of acrylic acid crosslinked with an alkyl ether of pentaerythritol or an alkyl ether of sucrose, or carbomers.
  • Carbomers are commercially available from B. F. Goodrich as the Carbopol.RTM. series. Particularly the carbopols include Carbopol 934, 940, 941, 956, and mixtures thereof.
  • Copolymers of lactide and glycolide monomers are useful for delivery of actives into the periodontal pockets or around the periodontal pockets as a "subgingival gel carrier.” These polymers are described in U.S. Pat. Nos. 5,198,220; 5,242,910; and 4,443,430.
  • Thickening agents in an amount from about 0.1% to about 15%, or from about
  • humectant Another optional component of the topical, oral-carriers of the compositions of the subject invention is a humectant.
  • the humectant serves to keep toothpaste compositions from hardening upon exposure to air, to give compositions a moist feel to the mouth, and, for particular humectants, to impart desirable sweetness of flavor to toothpaste compositions.
  • the humectant, on a pure humectant basis, can comprise from about 0% to about 70%, and in another embodiment from about 5% to about 25%, by weight of the compositions herein.
  • Suitable humectants for use in compositions of the subject invention include edible polyhydric alcohols such as glycerin, sorbitol, xylitol, butylene glycol, polyethylene glycol, and propylene glycol, especially sorbitol and glycerin.
  • Sweetening agents which can be used include sucrose, glucose, saccharin, dextrose, levulose, lactose, mannitol, sorbitol, fructose, maltose, xylitol, saccharin salts, thaumatin, aspartame, D-tryptophan, dihydrochalcones, acesulfame and cyclamate salts, especially sodium cyclamate and sodium saccharin, and mixtures thereof.
  • a composition can contain from about 0.1% to about 10% of these agents, in another embodiment from about 0.1% to about 11%, by weight of the composition.
  • compositions of the present invention can be used as optional ingredients in compositions of the present invention. These agents are present in the compositions at a level of from about 0.001% to about 10%, in another embodiment from about 0.1% to about 1%, by weight of the composition.
  • the coolant can be any of a wide variety of materials. Included among such materials are carboxamides, menthol, ketals, diols, and mixtures thereof. Suitable coolants in the present compositions include the paramenthan carboxyamide agents such as N-ethyl-p-menthan-3-carboxamide, known commercially as "WS-3", N,2,3-trimethyl-2-isopropylbutanamide, known as "WS-23,” and mixtures thereof.
  • paramenthan carboxyamide agents such as N-ethyl-p-menthan-3-carboxamide, known commercially as "WS-3”
  • WS-23 N,2,3-trimethyl-2-isopropylbutanamide
  • Additional coolants are selected from the group consisting of menthol, 3-l-menthoxypropane-l,2-diol known as TK-IO manufactured by Takasago, menthone glycerol acetal known as MGA manufactured by Haarmann and Reimer, and menthyl lactate known as Frescolat.RTM. manufactured by Haarmann and Reimer.
  • menthol and menthyl as used herein include dextro and a levorotatory isomers of these compounds and racemic mixtures thereof.
  • TKlO is described in U.S. Pat. No. 4,459,425.
  • WS-3 and other agents are described in U.S. Pat. No. 4,136,163.
  • Suitable salivating agents of the present invention include Jambu® manufactured by Takasago.
  • Suitable warming agents include capsicum and nicotinate esters, such as benzyl nicotinate.
  • Suitable numbing agents include benzocaine, lidocaine, clove bud oil, and ethanol.
  • the oral care composition may also comprise suitable cosmetic and/or therapeutic actives.
  • actives include any material that is generally considered safe for use in the oral cavity and that provides changes to the overall appearance and/or health of the oral cavity, including, but not limited to, anti-calculus agents, fluoride ion sources, stannous ion sources, whitening agents, anti-microbial, anti-plaque agents, anti-inflammatory agents, nutrients, antioxidants, anti-viral agents, analgesic and anesthetic agents, H-2 antagonists, components which impart a clean feel to the teeth, pigments and colorants, fragrances and sensates, and mixture thereof.
  • the level of cosmetic and/or therapeutic active in the composition is, in one embodiment from about 0.001% to about 90%, in another embodiment from about 0.01% to about 50%, and in another embodiment from about 0. 1% to about 30%, by weight of the composition.
  • the following is a non-limiting list of actives that may be used in the present invention.
  • compositions of the present invention may also comprise an anti-calculus agent, which in one embodiment maybe present from about 0.05% to about 50%, by weight of the oral care composition, in another embodiment is from about 0.05% to about 25%, and in another embodiment is from about 0.1% to about 15%.
  • an anti-calculus agent which in one embodiment maybe present from about 0.05% to about 50%, by weight of the oral care composition, in another embodiment is from about 0.05% to about 25%, and in another embodiment is from about 0.1% to about 15%.
  • the anti-calculus agent maybe selected from the group consisting of polyphosphates (including pyrophosphates) and salts thereof; polyamino propane sulfonic acid (AMPS) and salts thereof; polyolefin sulfonates and salts thereof; polyvinyl phosphates and salts thereof; polyolefin phosphates and salts thereof; diphosphonates and salts thereof; phosphonoalkane carboxylic acid and salts thereof; polyphosphonates and salts thereof; polyvinyl phosphonates and salts thereof, polyolefin phosphonates and salts thereof; polypeptides; and mixtures thereof.
  • the salts are alkali metal salts.
  • Polyphosphates are generally employed as their wholly or partially neutralized water-soluble alkali metal salts such as potassium, sodium, ammonium salts, and mixtures thereof.
  • the inorganic polyphosphate salts include alkali metal (e.g. sodium) tripolyphosphate, tetrapolyphosphate, dialkyl metal (e.g. disodium) diacid, trialkyl metal (e.g. trisodium) monoacid, potassium hydrogen phosphate, sodium hydrogen phosphate, and alkali metal (e.g. sodium) hexametaphosphate, and mixtures thereof.
  • Polyphosphates larger than tetrapolyphosphate usually occur as amorphous glassy materials, hi one embodiment the polyphosphates are those manufactured by FMC Corporation, which are commercially known as Sodaphos (n ⁇ 6), Hexaphos (n ⁇ 13), and Glass H (n ⁇ 21, sodium hexametaphosphate), and mixtures thereof.
  • the pyrophosphate salts useful in the present invention include, alkali metal pyrophosphates, di-, tri-, and mono-potassium or sodium pyrophosphates, dialkali metal pyrophosphate salts, tetraalkali metal pyrophosphate salts, and mixtures thereof.
  • the pyrophosphate salt is selected from the group consisting of trisodium pyrophosphate, disodium dihydrogen pyrophosphate (Na 2 H 2 P 2 O 7 ), dipotassium pyrophosphate, tetrasodium pyrophosphate (Na 4 P 2 O 7 ), tetrapotassium pyrophosphate (K 4 P 2 O 7 ), and mixtures thereof.
  • Polyolefm sulfonates include those wherein the olefin group contains 2 or more carbon atoms, and salts thereof.
  • Polyolefm phosphonates include those wherein the olefin group contains 2 or more carbon atoms.
  • Polyvinylphosphonates include polyvinylphosphonic acid.
  • Diphosphonates and salts thereof include azocycloalkane-2,2-diphosphonic acids and salts thereof, ions of azocycloalkane-2,2-diphosphonic acids and salts thereof, azacyclohexane-2,2-diphosphonic acid, azacyclopentane-2,2-diphosphonic acid, N-methyl-azacyclopentane-2,3-diphosphonic acid, EHDP (ethane-1- hydroxy-l,l,-diphosphonic acid), AHP (azacycloheptane-2,2-diphosphonic acid), ethane- 1 -amino- 1 , 1 -diphosphonate, dichloromethane-diphosphonate, etc.
  • Phosphonoalkane carboxylic acid or their alkali metal salts include PPTA (phosphonopropane tricarboxylic acid), PBTA (phosphonobutane- 1,2,4- tricarboxylic acid), each as acid or alkali metal salts.
  • Polyolefm phosphates include those wherein the olefin group contains 2 or more carbon atoms.
  • Polypeptides include polyaspartic and polyglutamic acids.
  • the oral care compositions of the present invention may include a stannous ion source.
  • the stannous ions may be provided from stannous fluoride and/or other stannous salts.
  • Stannous fluoride has been found to help in the reduction of gingivitis, plaque, sensitivity, and in improved breath benefits.
  • the stannous ions provided in an oral composition will provide efficacy to a subject using the composition. Although efficacy could include benefits other than the reduction in gingivitis, efficacy is defined as a noticeable amount of reduction in in situ plaque metabolism.
  • Formulations providing such efficacy typically include stannous levels provided by stannous fluoride and/or other stannous salts ranging from about 3,000 ppm to about 15,000 ppm stannous ions in the total composition.
  • the stannous ion is present in an amount of from about 4,000 ppm to about 12,000 ppm, in one embodiment from about 5,000 ppm to about 10,000 ppm.
  • stannous salts include organic stannous carboxylates, such as stannous acetate, stannous gluconate, stannous oxalate, stannous malonate, stannous citrate, stannous ethylene glycoxide, stannous formate stannous sulfate, stannous lactate, stannous tartrate, and the like.
  • Other stannous ion sources include, stannous halides such as stannous chlorides, stannous bromide, stannous iodide and stannous chloride dihydride. In one embodiment the stannous ion source is stannous fluoride in another embodiment, stannous chloride dihydrate.
  • the combined stannous salts may be present in an amount of from about 0.001% to about 11%, by weight of the compositions.
  • the stannous salts may, in one embodiment, be present in an amount of from about 0.01% to about 7%, in another embodiment from about 0.1% to about 5%, and in another embodiment from about 1.5% to about 3%, by weight of the composition.
  • a whitening agent may also be included in the present compositions.
  • the actives suitable for whitening are selected from the group consisting of alkali metal and alkaline earth metal peroxides, metal chlorites, perborates inclusive of mono and tetrahydrates, perphoshates, percarbonates, peroxyacids, and persulfates, such as ammonium, potassium, sodium and lithium persulfates, and combinations thereof.
  • Suitable peroxide compounds include hydrogen peroxide, urea peroxide, calcium peroxide, carbamide peroxide, magnesium peroxide, zinc peroxide, strontium peroxide and mixtures thereof. In one embodiment the peroxide compound is carbamide peroxide.
  • Suitable metal chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.
  • Additional whitening actives may be hypochlorite and chlorine dioxide.
  • the chlorite is sodium chlorite
  • hi another embodiment the percarbonate is sodium percarbonate.
  • hi one embodiment the persulfates are oxones. The level of these substances is dependent on the available oxygen or chlorine, respectively, that the molecule is capable of providing to bleach the stain.
  • the whitening agents maybe present at levels from about 0.01% to about 40%, in another embodiment from about 0.1% to about 20%, in another embodiment form about 0.5% to about 10%, and in another embodiment from about 4% to about 7%, by weight of the composition.
  • Anti-microbial agents may be included in the compositions of the present invention.
  • Such agents may include, but are not limited to: 5-chloro ⁇ 2-(2,4- dichlorophenoxy)-phenol, comnuonly referred to as triclosan; 8- hydroxyquinoline and its salts; copper II compounds, including, but not limited to, copper(II) chloride, co ⁇ per(II) sulfate, copper(II) acetate, copper(II) fluoride and copper(II) hydroxide; phthalic acid and its salts including, but not limited to those disclosed in U.S. Pat. No.
  • 4,994,262 including magnesium monopotassium phthalate; chlorhexidine; alexidine; hexetidine; sanguinarine; benzalkonium chloride; salicylanilide; domiphen bromide; cetylpyridinium chloride (CPC); tetradecylpyridinium chloride (TPC); N-tetradecyl-4- ethylpyridinium chloride (TDEPC); octenidine; iodine; sulfonamides; bisbiguanides; phenolics; delmopinol, octapinol, and other piperidino derivatives; niacin preparations; zinc or stannous ion agents; nystatin; grapefruit extract; apple extract; thyme oil; thymol; antibiotics such as augmentin, amoxicillin, tetracycline, doxycycline, minocycline, metronidazole, neomycin, kan
  • compositions of the present invention may include an anti-plaque agent such as stannous salts, copper salts, strontium salts, magnesium salts or a dimethicone copolyol.
  • the dimethicone copolyol is selected from C12 to C20 alkyl dimethicone copolyols and mixtures thereof, hi one embodiment the dimethicone copolyol is cetyl dimethicone copolyol marketed under the Trade Name Abil EM90.
  • the dimethicone copolyol in one embodiment can be present in a level of from about 0.001% to about 25%, in another embodiment from about 0.01% to about 5%, and in another embodiment from about 0. 1% to about 1.5% by weight of the composition.
  • Anti-inflammatory agents can also be present in the oral care compositions of the present invention.
  • Such agents may include, but are not limited to, nonsteroidal anti-inflammatory (NSAID) agents oxicams, salicylates, propionic acids, acetic acids and fenamates.
  • NSAID nonsteroidal anti-inflammatory
  • NSAIDs include but are not limited to ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, ketoprofen, fenoprofen, piroxicam, nabumetone, aspirin, diflunisal, meclofenamate, mefenamic acid, oxyphenbutazone, phenylbutazone and acetaminophen.
  • ketorolac ketorolac
  • flurbiprofen ibuprofen
  • naproxen indomethacin
  • diclofenac diclofenac
  • etodolac indomethacin
  • sulindac tolmetin
  • ketoprofen fenoprofen
  • piroxicam nabumetone
  • aspirin diflunisal
  • Suitable steroidal anti-inflammatory agents include corticosteroids, such as fluccinolone, and hydrocortisone.
  • Nutrients may improve the condition of the oral cavity and can be included in the oral care compositions of the present invention.
  • Nutrients include minerals, vitamins, oral nutritional supplements,, enteral nutritional supplements, and mixtures thereof.
  • Useful minerals include calcium, phosphorus, zinc, manganese, potassium and mixtures thereof.
  • Vitamins can be included with minerals or used independently. Suitable vitamins include Vitamins C and D, thiamine, riboflavin, calcium pantothenate, niacin, folic acid, nicotinamide, pyridoxine, cyanocobalamin, para-aminobenzoic acid, bioflavonoids, and mixtures thereof.
  • Oral nutritional supplements include amino acids, lipotropics, fish oil, and mixtures thereof.
  • Amino acids include, but are not limited to L-Tryptophan, L-Lysine, Methionine, Threonine, Levocarnitine or L-camitine and mixtures thereof.
  • Lipotropics include, but are not limited to, choline, inositol, betaine, linoleic acid, linolenic acid, and mixtures thereof.
  • Fish oil contains large amounts of Omega-3 (N-3) polyunsaturated fatty acids, eicosapentaenoic acid and docosahexaenoic acid.
  • Enteral nutritional supplements include, but are not limited to, protein products, glucose polymers, corn oil, safflower oil, medium chain triglycerides. Minerals, vitamins, oral nutritional supplements and enteral nutritional supplements are described in more detail in Drug Facts and Comparisons (loose leaf drug information service), Wolters Kluer Company, St. Louis, Mo., ⁇ 1997, pps. 3- 17 and 54-57.
  • Antioxidants are generally recognized as useful in oral care compositions.
  • Antioxidants are disclosed in texts such as Cadenas and Packer, The Handbook of Antioxidants, ⁇ 1996 by Marcel Dekker, Lie.
  • Antioxidants useful in the present invention include, but are not limited to, Vitamin E, ascorbic acid, Uric acid, carotenoids, Vitamin A, flavonoids and polyphenols, herbal antioxidants, melatonin, aminoindoles, lipoic acids and mixtures thereof.
  • Anti-pain or desensitizing agents can also be present in the oral care compositions of the present invention.
  • Analgesics are agents that relieve pain by acting centrally to elevate pain threshold without disturbing consciousness or altering other sensory modalities.
  • agents may include, but are not limited to: strontium chloride, potassium nitrate; sodium fluoride; sodium nitrate; acetanilide; phenacetin; acertophan; thiorphan; spiradoline; aspirin; codeine; thebaine; levorphenol; hydroimorphone; oxymorphone; phenazocine; fentanyl; buprenorphine; butaphanol; nalbuphine; pentazocine; natural herbs, such as gall nut; Asarum; Cubebin; Galanga; Scutellaria; Liangmianzhen; and Baizhi.
  • Anesthetic agents such as acetaminophen, sodium salicylate, trolamine salicylate, lidocaine and benzocaine may also be present.
  • topical analgesics such as acetaminophen, sodium salicylate, trolamine salicylate, lidocaine and benzocaine may also be present.
  • the present invention may also optionally comprise selective H-I and H-2 antagonists as disclosed in U.S. Pat. No. 5,294,433.
  • Pigments may be added to the compositions herein to more precisely indicate the locations at which the composition has actually been in contact. Additionally, these substances maybe suitable for modifying the color of the teeth to satisfy the consumer. These substances comprise particles that when applied on the tooth surface modify that surface in terms of absorption and, or reflection of light. Such particles provide an appearance benefit when a film containing such particles is applied over the surfaces of a tooth or teeth. Where the pigment is for the satisfaction of the consumer, appropriate pigment levels are selected for the particular impact that is desirable to the consumer. The levels of pigments and colorants may be in the range of about 0.001% to about 20%, in one embodiment from about 0.01% to about 15% and in another embodiment from about 0.1% to about 10% by total weight of the chewing oral care composition.
  • Pigments and colorants include inorganic white pigments, inorganic colored pigments, pearling agents, filler powders and the like; see Japanese Published Patent Application Kokai No. 9 [1997]-100215, published Apr. 15, 1997. Specific examples are selected from the group consisting of talc, mica, magnesium carbonate, calcium carbonate, magnesium silicate, aluminum magnesium silicate, silica, titanium dioxide, zinc oxide, red iron oxide, brown iron oxide, yellow iron oxide, black iron oxide, ferric ammonium ferrocyanide, manganese violet, ultramarine, nylon powder, polyethylene powder, methacrylate powder, polystyrene powder, silk powder, crystalline cellulose, starch, titanated mica, iron oxide titanated mica, bismuth oxychloride, and mixtures thereof.
  • the pigments and colorants are those selected from the group consisting of titanium dioxide, bismuth oxychloride, zinc oxide, Opatint D&C Red 27, CI 16185:1 Acid 27 Lake E123, CI14720:l Carmosoisine Aluminum Lake E122, Red 7 Lake, or Red 30 Lake and mixtures thereof.
  • Additional active ingredients suitable for use in the present invention may include, but are not limited to, insulin, steroids, herbal and other plant derived remedies, and anti-neoplasties. Additionally, anti-gingivitis or gum care agents known in the art may also be included. Components which impart a clean feel to the teeth may optionally be included. These components may include, for example, baking soda or Glass-H. Also, it is recognized that in certain forms of therapy, combinations of these above-named agents may be useful in order to obtain an optimal effect. Thus, for example, an anti-microbial and an antiinflammatory agent may be combined in a single oral care composition to provide combined effectiveness.
  • Optional agents to be used include such known materials as synthetic anionic polymers, including polyacrylates and copolymers of maleic anhydride or acid and methyl vinyl ether (e.g., Gantrez), as described, for example, in U.S. Pat. No. 4,627,977, as well as, e.g., polyamino propoane sulfonic acid (AMPS), zinc citrate trihydrate, polyphosphates (e.g., tripolyphosphate; hexametaphosphate), diphosphonates (e.g., EHDP; AHP), polypeptides (such as polyaspartic and polyglutamic acids), and mixtures thereof.
  • the oral care composition can include a polymer carrier, such as those described in U.S. Pat. Nos. 6,682,722 and 6,589,512 and U.S. application Ser. Nos. 10/424,640 and 10/430,617.
  • Alkali Metal Bicarbonate Salt may also include an alkali metal bicarbonate salt.
  • Alkali metal bicarbonate salts are soluble in water and unless stabilized, tend to release carbon dioxide in an aqueous system.
  • sodium bicarbonate also known as baking soda, is the alkali metal bicarbonate salt.
  • the present composition may contain from about 0.5% to about 30%, in another embodiment from about 0.5% to about 1.5%, and in another embodiment from about 0.5% to about 5% of an alkali metal bicarbonate salt.
  • Water employed in the preparation of commercially suitable oral compositions should be of low ion content and free of organic impurities. Water generally comprises from about 5% to about 70%, and in another embodiment from about 20% to about 50%, by weight of the composition herein. These amounts of water include the free water which is added plus that which is introduced with other materials, such as with sorbitol.
  • Titanium dioxide may also be added to the present composition. Titanium dioxide is a white powder which adds opacity to the compositions. Titanium dioxide generally comprises from about 0.25% to about 5% by weight of the dentifrice compositions.
  • Antimicrobial antiplaque agents may also be optionally present in oral compositions.
  • Such agents may include, but are not limited to, triclosan, 5- chloro-2-(2,4-dichlorophenoxy)-phenol, as described in The Merck Index, 1 lth ed. (1989), pp. 1529 (entry no. 9573) in U.S. Pat. No. 3,506,720, and in European Patent Application No. 0,251,591 of Beecham Group, PLC, published Jan. 7, 1988; chlorhexidine (Merck Index, no. 2090), alexidine (Merck Index, no. 222; hexetidine (Merck Index, no. 4624); sanguinarine (Merck Index, no.
  • the antimicrobial antiplaque. agents generally comprise from about 0.1% to about -5% by-weight-of the-compositions of the present invention.
  • copolymers can be 1 :4 to 4: 1 copolymers of maleic anhydride or acid with another polymerizable ethylenically unsaturated monomer, in particular the methyl vinyl ether (methoxyethylene) can have a molecular weight (M. W.) of about 30,000 to about 1,000,000.
  • Gantrez AN 139 (M.W. 500,000), A.N. 119 (M.W. 250,000) and as S-97 Pharmaceutical Grade (M.W. 70,000), of GAF Corporation.
  • a safe and effective amount of the compositions of the present invention may be topically applied to the mucosal tissue of the oral cavity, to the gingival tissue of the oral cavity, and/or to the surface of the teeth, for the treatment or prevention of biofilms or bacterial growth, in several conventional ways.
  • the gingival or mucosal tissue may be rinsed with a solution (e.g., mouth rinse, mouth spray); or in a dentifrice (e.g., toothpaste, tooth gel, chewable tablet, tooth powder), the gingival/mucosal tissue and/or teeth are bathed in the liquid and/or lather generated by brushing the teeth.
  • a solution e.g., mouth rinse, mouth spray
  • a dentifrice e.g., toothpaste, tooth gel, chewable tablet, tooth powder
  • a chewable dentifrice tablet can be chewed thus delivering the tooth actives to the surfaces of the oral cavity such as described in U.S. patent application Publication Nos. 2004/0101493 and 2004/0101494.
  • the teeth can then be brushed after the tablet is chewed.
  • Other non-limiting examples include applying a non-abrasive gelpor paste, directly to the gingival/mucosal tissue or to the teeth with or without an oral care appliance described below.
  • a safe and effective amount of the oral care composition of the present invention can be administered to the oral cavity of a subject in need thereof.
  • the compositions of the present invention can be applied to the gingival/mucosal tissue and/or the teeth (for example, by rinsing with a mouthrinse, directly applying a non-abrasive gel with or without a device, applying a dentifrice or a tooth gel with a toothbrush, etc.) of a person in need thereof, for at least about 10 seconds, in another embodiment from about 20 seconds to about 10 minutes, in even another embodiment from about 30 seconds to about 60 seconds.
  • the method often involves expectoration of most of the composition following such contact.
  • the frequency of such contact can be from about once per week to about four times per day, in another embodiment from about thrice per week to about three times per day, and in another embodiment from about once per day to about twice per day.
  • the period of such treatment typically ranges from about one day to a lifetime.
  • the duration of treatment depends on the severity of the oral disease or condition being treated, the particular delivery form utilized and the patient's response to treatment.
  • a mouthrinse can be delivered to the periodontal pocket using a syringe or water injection device. These devices are known to one skilled in the art. Devices of this type include "Water Pik" by Teledyne Corporation.
  • the subject can swish the rinse in the mouth to also cover the dorsal tongue and other gingival and mucosal surfaces.
  • a toothpaste, non-abrasive gel, toothgel, etc. can be brushed onto the tongue surface and other gingival and mucosal tissues of the oral cavity.
  • the period of such treatment typically ranges from about one day to a lifetime.
  • the subject may repeat the application as needed.
  • the duration of treatment can be from about 3 weeks to about 3 months, but may be shorter or longer depending on the severity of the condition being treated, the particular delivery form utilized and the patient's response to treatment.
  • the oral cavity can be treated by using edible films, candy, confectionary, lozenges and/or gums. Such compositions are retained in the oral cavity for a substantial period of time during consumption, and therefore, provide an ideal product form for a portable oral care product.
  • compositions of this invention are useful for both human and other lower animal (e.g. pets, zoo, or domestic animals) applications.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne des compositions et leur utilisation pour le traitement de la peau humaine, plus particulièrement la peau du visage, pour atténuer les symptômes d'affections cosmétiques ou dermatologiques de la peau. L'invention concerne des compositions pour le traitement et l'amélioration d'affections de la peau comme l'acné, la couperose et les rides provoquées par photodégradation ou d'affections liées au vieillissement, aux déséquilibres hormonaux, à l'hyperpigmentation, à la mélanodermie, à la kératose ou similaire. L'invention peut également s'utiliser pour traiter des affections du cuir chevelu comme les pellicules. La présente invention concerne également des compositions que l'on peut utiliser pour retirer les biofilms des lentilles de contact. Plus particulièrement, la présente invention porte sur une composition comprenant (a) un ou plusieurs métasilicates ; (b) un ou plusieurs carbonates ; (c) un ou plusieurs glyconates ; et (d) un ou plusieurs sulfates. La composition peut également contenir (e) des sels, par exemple, des sels marins et autres additifs ou agents actifs.
PCT/IB2006/004122 2004-09-27 2006-08-04 procédés et compositions pour le traitement de la peau WO2007099398A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06849473.1A EP1948236B1 (fr) 2005-09-27 2006-08-04 Procedes et compositions pour le traitement de la peau
EP21160312.1A EP3871693A1 (fr) 2005-09-27 2006-08-04 Compositions pour l'hygiène buccale
US11/912,839 US9499419B2 (en) 2004-09-27 2006-08-04 Methods and compositions for treatment of skin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IB2005/003665 WO2006035320A2 (fr) 2004-09-27 2005-09-27 Procedes et compositions de matieres pour le traitement de l'eau
IBPCT/IB2005/003665 2005-09-27
US59609506A 2006-05-30 2006-05-30
US10/596,095 2006-05-30

Publications (2)

Publication Number Publication Date
WO2007099398A2 true WO2007099398A2 (fr) 2007-09-07
WO2007099398A3 WO2007099398A3 (fr) 2007-12-27

Family

ID=38459396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/004122 WO2007099398A2 (fr) 2004-09-27 2006-08-04 procédés et compositions pour le traitement de la peau

Country Status (2)

Country Link
EP (2) EP1948236B1 (fr)
WO (1) WO2007099398A2 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006049580A1 (de) * 2006-10-20 2008-04-24 Rochel, Michael, Dr. med. Topische Zusammensetzung zur Behandlung von Ekzemen
WO2009027823A2 (fr) * 2007-08-29 2009-03-05 Ramirez D'onofrio, Alvaro D. Composition pharmaceutique pour une stimulation sélective de procédés de cicatrisation de lésion, de procédés de tropisme tissulaire normal dermique-épidermique, sa préparation et son application
EP2152071A1 (fr) * 2007-06-07 2010-02-17 The Trustees of Columbia University in The City of New York Nettoyant désinfectant à effet prolongé
US20100076552A1 (en) * 2007-04-06 2010-03-25 Senju Pharmaceutical Co., Ltd. Suspension for visualization of transparent tissue in eye
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
WO2011147964A1 (fr) 2010-05-27 2011-12-01 Intendis Gmbh Formulation contenant de l'acide azélaïque avec ajout de pigment
US20120039823A1 (en) * 2008-03-20 2012-02-16 Beiersdorf Ag Preparations for reducing itching and other paraesthesias with (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethylcyclohexanecarboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexanecarboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2isopropyl-5-methylcyclohexanecarboxamide
US20120283226A1 (en) * 2009-09-11 2012-11-08 Reckitt Benckiser Healthcare International Limited Cosmetic Composition
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US20130210923A1 (en) * 2010-01-06 2013-08-15 Reckitt & Colman (Overseas) Limited Antimicrobial Hand Soap Composition
WO2013148064A1 (fr) * 2012-03-30 2013-10-03 Zotos International, Inc. Composition de traitement et de revitalisation de cheveux et procédés correspondants
WO2015038788A1 (fr) * 2013-09-11 2015-03-19 Glenn Abrahmsohn Compositions thérapeutiques antimicrobiennes hypertoniques
EP2857025A1 (fr) 2013-10-02 2015-04-08 Special Water Patents B.V. Composition de traitement des plaies
GB2520326A (en) * 2013-11-15 2015-05-20 Emma Neame Composition
US9149528B2 (en) 2011-10-13 2015-10-06 Premier Dental Products Company Topical vitamin D oral supplement compositions
US9463147B2 (en) 2012-03-30 2016-10-11 Zotos International, Inc. Hair treatment and revitalizing composition and methods
WO2017035665A1 (fr) * 2015-09-03 2017-03-09 Delivra, Inc. Formulations transdermiques pour l'administration de doxycycline et leur utilisation dans le traitement de maladies et de pathologies sensibles à la doxycycline
US9604078B2 (en) 2012-10-12 2017-03-28 Premier Dental Products Company Methods for protecting and reparing enamel
US9757320B2 (en) 2012-12-19 2017-09-12 Colgate-Palmolive Company Oral care composition
WO2017200476A1 (fr) 2016-05-19 2017-11-23 Biocool Ab Nouvelle utilisation d'un produit pour le traitement de la peau
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
DE102017210389A1 (de) * 2017-06-21 2018-12-27 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt an einer oder mehreren alpha-Hydroxycarbonsäuren und/oder einer oder mehreren beta-Hydroxycarbonsäuren und/oder einer oder mehreren Polyhydroxysäuren, einem oder mehreren Distearaten und Stärke
EP3733192A1 (fr) * 2008-08-04 2020-11-04 Polichem SA Formulations de finastéride pour la libération de médicaments dans les cheveux et le cuir chevelu
US20210275506A1 (en) * 2018-07-03 2021-09-09 Blueberry Therapeutics Limited Compositions and methods of treatment
WO2021183551A1 (fr) * 2020-03-10 2021-09-16 Soakness Llc Formulation de produit de bain à dissolution de percarbonate de sodium
WO2022146089A1 (fr) * 2020-12-31 2022-07-07 주식회사태준제약 Formulation orale solide pour le nettoyage du côlon

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110540305B (zh) * 2019-08-30 2021-01-29 福建闽泰交通工程有限公司 小流域河道修复方法
EP4230212A1 (fr) * 2022-02-16 2023-08-23 UNIVERSITÄTSmedizin der Johannes Gutenberg- Universität Mainz Composition et kits pour la prévention ou le traitement de maladies des gencives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441057A1 (fr) * 1990-02-07 1991-08-14 Diversey Corporation Procédé de préparation d'un dÀ©tergent en pâte et produit ainsi obtenu
JP2000063894A (ja) * 1998-08-21 2000-02-29 Daisan Kogyo Kk 自動食器洗浄機用洗浄剤組成物

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2798053A (en) 1952-09-03 1957-07-02 Goodrich Co B F Carboxylic polymers
US2831854A (en) 1955-05-24 1958-04-22 Procter & Gamble Method for preparing fatty esters of non-reducing oligosaccharides in the presence of an amide
US3070510A (en) 1959-11-03 1962-12-25 Procter & Gamble Dentifrice containing resinous cleaning agents
US3506720A (en) 1963-02-22 1970-04-14 Geigy Chem Corp Halogenated hydroxy-diphenyl ethers
US3538230A (en) 1966-12-05 1970-11-03 Lever Brothers Ltd Oral compositions containing silica xerogels as cleaning and polishing agents
US4136163A (en) 1971-02-04 1979-01-23 Wilkinson Sword Limited P-menthane carboxamides having a physiological cooling effect
BE794788A (fr) * 1972-01-31 1973-07-31 Berthelsen Ind Comm Nouvelle composition minerale d'addition
US3959458A (en) 1973-02-09 1976-05-25 The Procter & Gamble Company Oral compositions for calculus retardation
US3862307A (en) 1973-04-09 1975-01-21 Procter & Gamble Dentifrices containing a cationic therapeutic agent and improved silica abrasive
US3988433A (en) 1973-08-10 1976-10-26 The Procter & Gamble Company Oral compositions for preventing or removing stains from teeth
US3963699A (en) 1974-01-10 1976-06-15 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters
US3956480A (en) 1974-07-01 1976-05-11 Colgate-Palmolive Company Treatment of teeth
US4051234A (en) 1975-06-06 1977-09-27 The Procter & Gamble Company Oral compositions for plaque, caries, and calculus retardation with reduced staining tendencies
US4005196A (en) 1976-02-12 1977-01-25 The Procter & Gamble Company Vitaminized compositions for treating hypercholesterolemia
US4005195A (en) 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
US4138477A (en) 1976-05-28 1979-02-06 Colgate Palmolive Company Composition to control mouth odor
US4110429A (en) 1976-12-30 1978-08-29 Colgate-Palmolive Company Antibacterial oral composition
US4183914A (en) 1977-12-19 1980-01-15 Abdul Gaffar Magnesium polycarboxylate complexes and anticalculus agents
US4355028A (en) 1978-04-04 1982-10-19 Westwood Pharmaceuticals, Inc. Composition for treating acne vulgaris
US4340583A (en) 1979-05-23 1982-07-20 J. M. Huber Corporation High fluoride compatibility dentifrice abrasives and compositions
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
JPS5888334A (ja) 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4443430A (en) 1982-11-16 1984-04-17 Ethicon, Inc. Synthetic absorbable hemostatic agent
US4518772A (en) 1983-06-23 1985-05-21 The Proctor & Gamble Company Synthesis of higher polyol fatty acid polyesters using high soap:polyol ratios
US4517360A (en) 1983-06-23 1985-05-14 The Procter & Gamble Company Synthesis of higher polyol fatty acid polyesters using carbonate catalysts
US4725455A (en) 1984-06-01 1988-02-16 Colgate-Palmolive Company Process for manufacturing particulate built nonionic synthetic organic detergent composition comprising polyacetal carboxylate and polyphosphate builders
US4627977A (en) 1985-09-13 1986-12-09 Colgate-Palmolive Company Anticalculus oral composition
US4906456A (en) 1986-03-20 1990-03-06 Colgate-Palmolive Company Anticalculus oral composition
DE3584837D1 (de) * 1985-10-08 1992-01-16 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
GB8615534D0 (en) 1986-06-25 1986-07-30 Beecham Group Plc Composition
US4797300A (en) 1987-04-10 1989-01-10 The Procter & Gamble Company Compositions containing novel solid, nondigestible, fat-like compounds
JPH0651614B2 (ja) 1987-05-29 1994-07-06 東芝シリコ−ン株式会社 メ−クアップ化粧料
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
EP0496433B1 (fr) 1987-10-22 1999-03-24 The Procter & Gamble Company Compositions photoprotectrices contenant des agents chélatants
US4994262A (en) 1988-10-14 1991-02-19 The Procter & Gamble Company Oral compositions
US5011681A (en) 1989-10-11 1991-04-30 Richardson-Vicks, Inc. Facial cleansing compositions
US5198220A (en) 1989-11-17 1993-03-30 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5306516A (en) 1990-04-26 1994-04-26 The Procter & Gamble Company Shortening compositions containing polyol fatty acid polyesters
US5306515A (en) 1990-04-26 1994-04-26 The Procter & Gamble Company Reduced calorie pourable shortening, cooking oils, salad oils or like compositions
FR2673372B1 (fr) 1991-02-28 1993-10-01 Oreal Composition cosmetique capable d'estomper les defauts de la peau.
GB9114255D0 (en) 1991-07-02 1991-08-21 Unilever Plc Cosmetic composition
US5294433A (en) 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
DE69429822T2 (de) 1993-11-12 2002-11-28 The Procter & Gamble Company, Cincinnati Abschuppende zusammensetzung von salicylsäure und zwitterionischen verbindungen
DE9402027U1 (de) 1994-02-08 1995-06-14 Wilkinson Sword Gmbh, 42659 Solingen Vorrichtung zur Herstellung von Folien
CA2194158C (fr) 1994-07-01 2000-08-22 Donald Lynn Bissett Compositions de desquamation
US5603920A (en) 1994-09-26 1997-02-18 The Proctor & Gamble Company Dentifrice compositions
MX9703895A (es) 1994-11-28 1997-08-30 Procter & Gamble Composiciones topicas para el cuidado de la piel que contienen esteres de acido carboxilico de poliol espesado como agentes de acondicionamiento de la piel.
JP3534910B2 (ja) 1994-12-13 2004-06-07 三菱鉛筆株式会社 歯の塗布液
US5626838A (en) 1995-03-13 1997-05-06 The Procter & Gamble Company Use of ketorolac for treatment of squamous cell carcinomas of the oral cavity or oropharynx
US5658553A (en) 1995-05-02 1997-08-19 The Procter & Gamble Company Dentifrice compositions
US5589160A (en) 1995-05-02 1996-12-31 The Procter & Gamble Company Dentifrice compositions
US5651958A (en) 1995-05-02 1997-07-29 The Procter & Gamble Company Dentifrice compositions
US5939082A (en) 1995-11-06 1999-08-17 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
JP3227378B2 (ja) * 1996-03-29 2001-11-12 カネボウ株式会社 表皮角質化促進剤
GB9615631D0 (en) 1996-07-25 1996-09-04 Procter & Gamble Shampoo compositions
AU722452B2 (en) * 1996-10-22 2000-08-03 Procter & Gamble Company, The Oral compositions containing stannous gluconate
US6063397A (en) 1996-10-25 2000-05-16 The Procter & Gamble Company Disposable cleansing products for hair and skin
DE19646392A1 (de) 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CA2272306A1 (fr) 1996-11-22 1998-05-28 The Procter & Gamble Company Compositions cosmetiques
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6627183B1 (en) 1998-07-30 2003-09-30 The Procter & Gamble Company Hair care compositions
FR2783424B1 (fr) * 1998-09-03 2002-10-04 Labcatal Utilisation du gluconate de lithium dans la fabrication d'un medicament pour le traitement de l'herpes et de la dermite seborrheique
US6596298B2 (en) 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
US6589512B1 (en) 1999-07-02 2003-07-08 The Procter & Gamble Company Compositions comprising organosiloxane resins for delivering oral care substances
US6721987B2 (en) 2000-04-06 2004-04-20 Kimberly-Clark Worldwide, Inc. Dental wipe
US6709648B2 (en) 2000-05-30 2004-03-23 The Procter & Gamble Company Hair conditioning composition comprising silicones and frizz control agents
GB0105248D0 (en) 2001-03-02 2001-04-18 Hirschowitz Wayne K Cleaning device
US6682722B2 (en) 2001-09-19 2004-01-27 The Procter & Gamble Company Oral compositions providing enhanced overall cleaning
US6984377B2 (en) * 2002-05-29 2006-01-10 J. M. Huber Corporation Oral care products comprising calcium metasilicates
US6723755B2 (en) 2002-06-12 2004-04-20 Piotr Chomczynski Method of treating rosacea
US20040101493A1 (en) 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
US20040101494A1 (en) 2002-11-26 2004-05-27 Scott Douglas Craig Chewable solid unit dosage forms and methods for delivery of active agents into occlusal surfaces of teeth
RU2007106564A (ru) 2004-09-02 2008-10-10 Дзе Проктер Энд Гэмбл Компани (US) Композиция для ухода за полостью рта, включающая эфирные масла
SG11201707263XA (en) 2015-03-31 2017-10-30 Enanta Pharm Inc Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0441057A1 (fr) * 1990-02-07 1991-08-14 Diversey Corporation Procédé de préparation d'un dÀ©tergent en pâte et produit ainsi obtenu
JP2000063894A (ja) * 1998-08-21 2000-02-29 Daisan Kogyo Kk 自動食器洗浄機用洗浄剤組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PATENT ABSTRACTS OF JAPAN vol. 2000, no. 05, 14 September 2000 (2000-09-14) & JP 2000 063894 A (DAISAN KOGYO KK; SHOWA DENKO KK), 29 February 2000 (2000-02-29) *
See also references of EP1948236A2 *

Cited By (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006049580A1 (de) * 2006-10-20 2008-04-24 Rochel, Michael, Dr. med. Topische Zusammensetzung zur Behandlung von Ekzemen
US20100076552A1 (en) * 2007-04-06 2010-03-25 Senju Pharmaceutical Co., Ltd. Suspension for visualization of transparent tissue in eye
EP2152071A1 (fr) * 2007-06-07 2010-02-17 The Trustees of Columbia University in The City of New York Nettoyant désinfectant à effet prolongé
EP2152071A4 (fr) * 2007-06-07 2012-08-15 Univ Columbia Nettoyant désinfectant à effet prolongé
WO2009027823A2 (fr) * 2007-08-29 2009-03-05 Ramirez D'onofrio, Alvaro D. Composition pharmaceutique pour une stimulation sélective de procédés de cicatrisation de lésion, de procédés de tropisme tissulaire normal dermique-épidermique, sa préparation et son application
WO2009027823A3 (fr) * 2007-08-29 2009-04-23 Ramirez D Onofrio Alvaro D Composition pharmaceutique pour une stimulation sélective de procédés de cicatrisation de lésion, de procédés de tropisme tissulaire normal dermique-épidermique, sa préparation et son application
US20120039823A1 (en) * 2008-03-20 2012-02-16 Beiersdorf Ag Preparations for reducing itching and other paraesthesias with (1r,2s,5r)-2-isopropyl-5-methyl-n-(2-(pyridin-2-yl)ethylcyclohexanecarboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexanecarboxamide and/or (1r,2s,5r)-n-(4-(cyanomethyl)-phenyl)-2isopropyl-5-methylcyclohexanecarboxamide
EP3733192A1 (fr) * 2008-08-04 2020-11-04 Polichem SA Formulations de finastéride pour la libération de médicaments dans les cheveux et le cuir chevelu
JP2013504552A (ja) * 2009-09-11 2013-02-07 レキット ベンキサー ヘルスケア インターナショナル リミテッド 化粧用組成物
AU2010293967A8 (en) * 2009-09-11 2016-09-22 Karo Healthcare AB Cosmetic composition
AU2010293967B2 (en) * 2009-09-11 2016-09-15 Karo Healthcare AB Cosmetic composition
US20120283226A1 (en) * 2009-09-11 2012-11-08 Reckitt Benckiser Healthcare International Limited Cosmetic Composition
US8877762B2 (en) 2009-12-15 2014-11-04 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8871773B2 (en) 2009-12-15 2014-10-28 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8927554B2 (en) 2009-12-15 2015-01-06 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US10646429B2 (en) 2009-12-15 2020-05-12 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US10064811B2 (en) 2009-12-15 2018-09-04 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US9636296B2 (en) 2009-12-15 2017-05-02 Johnson & Johnson Consumer Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US20130210923A1 (en) * 2010-01-06 2013-08-15 Reckitt & Colman (Overseas) Limited Antimicrobial Hand Soap Composition
US20110195042A1 (en) * 2010-02-10 2011-08-11 Thomas Edward Huetter Compositions, Methods and Kits Useful for Treating a Respiratory Symptom
US20120027862A1 (en) * 2010-05-27 2012-02-02 Intendis Gmbh Azelaic acid-comprising formulation with added pigment
DE102010021671A1 (de) * 2010-05-27 2011-12-01 Intendis Gmbh Azelainsäurehaltige Formulierung mit Pigmentzusatz
WO2011147964A1 (fr) 2010-05-27 2011-12-01 Intendis Gmbh Formulation contenant de l'acide azélaïque avec ajout de pigment
US9149528B2 (en) 2011-10-13 2015-10-06 Premier Dental Products Company Topical vitamin D oral supplement compositions
US9877929B2 (en) * 2011-10-13 2018-01-30 Premier Dental Products Company Topical vitamin D and ubiquinol oral supplement compositions
US9463147B2 (en) 2012-03-30 2016-10-11 Zotos International, Inc. Hair treatment and revitalizing composition and methods
US9283157B2 (en) 2012-03-30 2016-03-15 Zotos International, Inc. Hair treatment and revitalizing composition and methods
WO2013148064A1 (fr) * 2012-03-30 2013-10-03 Zotos International, Inc. Composition de traitement et de revitalisation de cheveux et procédés correspondants
US9283156B2 (en) 2012-03-30 2016-03-15 Zotos International, Inc. Hair treatment and revitalizing composition and methods
US9724542B2 (en) 2012-10-12 2017-08-08 Premier Dental Products Company Remineralizing and desensitizing compositions, treatments and methods of manufacture
US9604078B2 (en) 2012-10-12 2017-03-28 Premier Dental Products Company Methods for protecting and reparing enamel
US9616004B2 (en) 2012-10-12 2017-04-11 Premier Dental Products Company Enamel protectant and repair toothpaste
US9877930B2 (en) 2012-10-12 2018-01-30 Premier Dental Products Company Topical ubiquinol oral supplement compositions with amorphous calcium phosphate
US9757320B2 (en) 2012-12-19 2017-09-12 Colgate-Palmolive Company Oral care composition
WO2015038788A1 (fr) * 2013-09-11 2015-03-19 Glenn Abrahmsohn Compositions thérapeutiques antimicrobiennes hypertoniques
US12059466B2 (en) 2013-09-11 2024-08-13 Aim Targeted Therapies, Inc. Hypertonic antimicrobial therapeutic compositions
WO2015049364A1 (fr) 2013-10-02 2015-04-09 Special Water Patents B.V. Composition de traitement de blessure
US20160243159A1 (en) * 2013-10-02 2016-08-25 Special Water Patents B.V. Wound treatment composition
EP2857025A1 (fr) 2013-10-02 2015-04-08 Special Water Patents B.V. Composition de traitement des plaies
GB2520326A (en) * 2013-11-15 2015-05-20 Emma Neame Composition
WO2017035665A1 (fr) * 2015-09-03 2017-03-09 Delivra, Inc. Formulations transdermiques pour l'administration de doxycycline et leur utilisation dans le traitement de maladies et de pathologies sensibles à la doxycycline
WO2017200476A1 (fr) 2016-05-19 2017-11-23 Biocool Ab Nouvelle utilisation d'un produit pour le traitement de la peau
DE102017210389A1 (de) * 2017-06-21 2018-12-27 Beiersdorf Ag Kosmetische Zubereitungen mit einem Gehalt an einer oder mehreren alpha-Hydroxycarbonsäuren und/oder einer oder mehreren beta-Hydroxycarbonsäuren und/oder einer oder mehreren Polyhydroxysäuren, einem oder mehreren Distearaten und Stärke
US20210275506A1 (en) * 2018-07-03 2021-09-09 Blueberry Therapeutics Limited Compositions and methods of treatment
WO2021183551A1 (fr) * 2020-03-10 2021-09-16 Soakness Llc Formulation de produit de bain à dissolution de percarbonate de sodium
US11684634B2 (en) 2020-03-10 2023-06-27 Soakness Llc Sodium percarbonate dissolving bath product formulation
WO2022146089A1 (fr) * 2020-12-31 2022-07-07 주식회사태준제약 Formulation orale solide pour le nettoyage du côlon

Also Published As

Publication number Publication date
WO2007099398A3 (fr) 2007-12-27
EP3871693A1 (fr) 2021-09-01
EP1948236B1 (fr) 2021-03-03
EP1948236A2 (fr) 2008-07-30

Similar Documents

Publication Publication Date Title
US9499419B2 (en) Methods and compositions for treatment of skin
WO2007099398A2 (fr) procédés et compositions pour le traitement de la peau
KR101247693B1 (ko) 피지 흡수 조성물
JP2009517429A (ja) グルカン組成物
US20060013845A1 (en) Oxygenated personal care products
CN101394898A (zh) 葡聚糖组合物
TW201429497A (zh) 含四鹼基鋅－胺基酸鹵化物錯合物及半胱胺酸之二成分組成物
TW200927183A (en) Dentifrice compositions for treating xerostomia
KR20220068226A (ko) 피부 결함을 예방, 감소 또는 제거하고 피부 장애를 치료하고 두피의 과지루성 상태를 예방, 치료 및 퇴치하기 위한 석신산을 포함하는 메이크업을 제거하고/하거나 클렌징하기 위한 화장용 또는 피부과용 조성물
ES2400284T3 (es) Mezclas con una acción estimulante de la síntesis de colágeno
JP2001348308A (ja) 菌代謝阻害剤
EP3562467B2 (fr) Composition antimicrobienne
EP3506874B1 (fr) Composition de soins personnels
JP7451564B2 (ja) ２（１ｈ）－ピリジノン類及び炎症状態を治療するためのそれらの使用
JP2003026528A (ja) 美白化粧料
WO2015043907A1 (fr) Composition pour la santé de la peau et du cuir chevelu
EP3727300B1 (fr) Composition antimicrobienne
CA3181110A1 (fr) Composition antimicrobienne pour lutter contre les mauvaises odeurs
JP2001199873A (ja) 外用組成物
WO2020263190A1 (fr) Xanthones permettant de diminuer la production de lipides dans les sébocytes
WO2020263189A1 (fr) Phénols qui diminuent la production de lipides dans des sébocytes
WO2018077958A1 (fr) Composition de soins personnels comprenant des curcuminoïdes
EP3532040B1 (fr) Composition de soins personnels
JP2005325091A (ja) 外用剤組成物
JP2020002118A (ja) ヘアケア用又は皮膚用外用剤組成物

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006849473

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11912839

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006849473

Country of ref document: EP